data_1pt4_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1pt4 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 121.135 0.493 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.26 34.63 90.42 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.511 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -145.34 136.83 25.18 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-O 120.934 0.397 . . . . 0.0 110.026 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.413 HG22 HG12 ' A' ' 21' ' ' ILE . 36.7 p -99.41 143.57 29.51 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.164 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.6 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -115.36 60.45 0.7 Allowed 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.412 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -55.97 -34.91 66.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.494 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.52 16.95 57.36 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.593 178.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.415 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 68.13 40.82 88.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.877 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.6 t -151.55 146.46 25.89 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 121.272 -0.171 . . . . 0.0 110.685 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.6 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 18.8 m -145.69 138.74 26.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.015 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -74.01 -42.58 60.15 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.311 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.1 m -62.15 118.15 36.83 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.723 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -68.43 147.55 71.47 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 123.056 2.504 . . . . 0.0 113.528 -178.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.6 25.78 71.44 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.133 -0.939 . . . . 0.0 113.53 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.714 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 89.5 m -114.2 122.49 46.96 Favored 'General case' 0 N--CA 1.444 -0.765 0 O-C-N 122.288 -0.536 . . . . 0.0 110.665 179.257 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -79.44 127.55 32.25 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.415 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.6 t -74.93 90.22 2.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.333 0.587 . . . . 0.0 112.107 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.1 m -88.5 68.06 8.69 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 177.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 4.3 t90 -26.44 123.54 0.22 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.896 -1.502 . . . . 0.0 113.317 -176.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -101.04 30.76 10.71 Favored 'Cis proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.51 -1.454 . . . . 0.0 114.092 0.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.413 HG12 HG22 ' A' ' 4' ' ' THR . 65.5 mt -131.12 131.31 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 O-C-N 122.029 -0.419 . . . . 0.0 111.358 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.714 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 37.9 m -79.08 132.45 36.61 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.312 0.577 . . . . 0.0 111.709 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -116.22 147.14 41.76 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.842 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.7 tpp85 -94.39 83.38 4.17 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.7 t70 64.74 49.32 2.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.866 -177.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.01 -26.56 18.29 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.724 -0.75 . . . . 0.0 113.956 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.9 mt -91.98 119.93 68.09 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 117.51 0.655 . . . . 0.0 111.388 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 9.2 Cg_exo -71.28 39.01 0.34 Allowed 'Trans proline' 0 CA--C 1.531 0.334 0 C-N-CA 123.137 2.558 . . . . 0.0 112.447 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.43 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.1 m . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.901 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.648 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 96.7 m . . . . . 0 N--CA 1.451 -0.409 0 CA-C-O 120.7 0.286 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.19 92.81 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.398 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.49 ' HG2' ' H ' ' A' ' 11' ' ' ASN . 6.9 tp10 -150.5 143.64 24.85 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.056 0.455 . . . . 0.0 110.326 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -101.1 148.88 24.56 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.122 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.765 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -124.82 56.08 1.32 Allowed 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.478 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -53.83 -32.32 52.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.177 0.513 . . . . 0.0 109.802 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.32 42.42 1.36 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 178.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.6 34.39 89.78 Favored Glycine 0 C--N 1.336 0.537 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.014 -179.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 p -89.58 50.58 1.93 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.461 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -81.92 95.0 7.23 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.946 179.346 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.49 ' H ' ' HG2' ' A' ' 3' ' ' GLU . 40.8 m-80 -68.31 -37.1 80.26 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.235 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.787 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.9 m -69.02 124.93 91.45 Favored Pre-proline 0 N--CA 1.451 -0.423 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.732 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -63.04 135.61 52.12 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 123.163 2.575 . . . . 0.0 114.601 -178.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.74 21.48 79.65 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.675 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.787 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 63.8 m -91.89 127.09 37.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 117.008 0.404 . . . . 0.0 111.202 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.2 t -79.47 130.83 35.78 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.8 t -78.26 87.65 4.32 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.153 0.502 . . . . 0.0 112.064 -178.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -86.03 66.84 9.77 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 176.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.52 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -27.49 124.01 0.24 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.537 -1.665 . . . . 0.0 113.267 -176.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 91.4 Cg_endo -101.36 33.25 8.36 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.507 -1.456 . . . . 0.0 114.067 0.574 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.423 HD12 HG23 ' A' ' 21' ' ' ILE . 68.0 mt -129.34 134.22 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.983 -0.448 . . . . 0.0 111.585 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.765 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.5 m -77.91 133.8 38.02 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.6 p -122.05 139.97 53.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 112.474 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.648 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 1.3 mmm180 -91.71 106.08 18.21 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 176.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 55.41 34.26 22.6 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 123.917 0.761 . . . . 0.0 110.443 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.24 -16.65 58.94 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.946 -0.645 . . . . 0.0 113.782 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.425 ' C ' ' H ' ' A' ' 29' ' ' VAL . 95.0 mt -95.52 125.44 49.51 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 117.497 0.648 . . . . 0.0 111.104 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.09 37.42 0.26 Allowed 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 122.943 2.429 . . . . 0.0 113.231 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.425 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.7 m . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.617 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.504 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 38.2 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 121.051 0.453 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.21 37.38 94.46 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -149.89 150.2 31.56 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-O 121.018 0.437 . . . . 0.0 110.26 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.416 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 43.2 p -105.92 148.3 27.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.538 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.634 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -117.8 53.0 0.96 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.236 0.541 . . . . 0.0 110.696 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.416 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 6.7 m-85 -55.18 -35.42 64.79 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.598 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.58 20.31 42.3 Favored Glycine 0 N--CA 1.445 -0.71 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.94 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.84 46.84 64.45 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.947 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -148.71 141.28 24.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.67 0.271 . . . . 0.0 110.546 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.9 m -130.57 131.94 45.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.532 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -72.85 -32.55 65.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.906 0.384 . . . . 0.0 110.541 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.638 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.0 m -80.3 124.77 82.32 Favored Pre-proline 0 N--CA 1.451 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.742 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.2 Cg_exo -67.26 136.1 39.19 Favored 'Trans proline' 0 N--CA 1.464 -0.214 0 C-N-CA 122.877 2.385 . . . . 0.0 112.582 -179.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.01 -6.85 82.53 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.046 -0.597 . . . . 0.0 113.503 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.638 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 72.8 m -79.74 130.05 35.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.144 0.497 . . . . 0.0 111.703 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -83.31 139.53 33.0 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 18.6 t -83.51 91.56 7.43 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.154 0.502 . . . . 0.0 111.908 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.5 m -89.28 67.09 7.76 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.488 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.0 t90 -28.01 122.95 0.25 Allowed Pre-proline 0 C--O 1.231 0.117 0 CA-C-N 113.807 -1.542 . . . . 0.0 113.143 -176.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.488 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 90.4 Cg_endo -102.0 30.68 10.01 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.511 -1.454 . . . . 0.0 113.916 0.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.8 mt -125.29 133.25 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 O-C-N 121.955 -0.465 . . . . 0.0 111.517 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.634 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.0 m -79.29 134.61 36.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.687 0.279 . . . . 0.0 111.516 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 23.9 p -126.18 133.54 51.53 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.219 0.533 . . . . 0.0 112.142 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.504 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 10.0 ttp180 -106.93 122.0 45.54 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 64.56 24.57 13.07 Favored 'General case' 0 C--N 1.32 -0.69 0 O-C-N 123.718 0.636 . . . . 0.0 109.402 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.74 -0.7 89.17 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.276 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.407 ' C ' ' H ' ' A' ' 29' ' ' VAL . 80.0 mt -106.97 131.32 21.79 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.66 0.267 . . . . 0.0 110.324 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.62 39.87 0.45 Allowed 'Trans proline' 0 CA--C 1.531 0.34 0 C-N-CA 122.827 2.351 . . . . 0.0 112.439 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.407 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.3 m . . . . . 0 C--N 1.326 -0.423 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.967 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 81.1 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.884 0.373 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.5 37.92 94.23 Favored Glycine 0 C--N 1.333 0.361 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.749 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.12 142.42 24.23 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.414 HG23 HG12 ' A' ' 21' ' ' ILE . 21.2 p -111.07 143.87 41.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.04 0.448 . . . . 0.0 110.759 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.553 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -112.08 60.45 0.63 Allowed 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.827 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -56.98 -32.24 65.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.63 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.79 14.76 58.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.631 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.33 44.16 66.76 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.875 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.8 t -150.53 142.42 23.84 Favored 'General case' 0 N--CA 1.447 -0.582 0 O-C-N 122.845 -0.209 . . . . 0.0 110.544 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.553 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -135.64 131.78 36.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.179 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -82.88 -32.96 27.12 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.186 0.517 . . . . 0.0 109.706 178.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.402 HG23 ' SG ' ' A' ' 15' ' ' CYS . 4.6 m -66.31 120.35 69.44 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.812 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -65.08 141.19 68.87 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.929 2.42 . . . . 0.0 113.071 -179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.03 26.1 73.21 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.272 -0.876 . . . . 0.0 113.161 179.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.402 ' SG ' HG23 ' A' ' 12' ' ' THR . 90.8 m -116.8 121.84 42.7 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.078 0.466 . . . . 0.0 110.632 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -81.32 135.0 35.67 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.364 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.2 t -77.35 88.71 3.75 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.232 0.539 . . . . 0.0 111.832 -179.254 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.8 m -87.6 67.42 9.28 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -28.26 124.05 0.25 Allowed Pre-proline 0 N--CA 1.461 0.12 0 CA-C-N 113.772 -1.558 . . . . 0.0 113.144 -176.75 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.7 Cg_endo -101.1 34.37 7.7 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.53 -1.446 . . . . 0.0 113.997 0.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.414 HG12 HG23 ' A' ' 4' ' ' THR . 61.9 mt -130.33 133.08 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 O-C-N 121.935 -0.478 . . . . 0.0 111.754 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.498 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 35.0 m -78.05 127.75 32.8 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.149 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.1 p -119.46 146.49 45.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.582 0.706 . . . . 0.0 112.416 -178.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.1 tpp85 -92.44 81.35 4.88 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.8 t70 64.49 49.84 2.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.766 -177.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.81 -26.72 19.09 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.774 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.422 ' C ' ' H ' ' A' ' 29' ' ' VAL . 91.0 mt -91.1 118.8 68.77 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 117.404 0.602 . . . . 0.0 111.47 -179.365 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.15 39.74 0.41 Allowed 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 122.882 2.388 . . . . 0.0 112.431 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.422 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.2 m . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.894 -179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.578 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.0 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 120.869 0.366 . . . . 0.0 110.153 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.05 35.04 90.06 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.604 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -150.14 143.18 24.89 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.583 HG23 HG12 ' A' ' 21' ' ' ILE . 21.1 p -111.67 144.5 40.83 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.106 0.479 . . . . 0.0 110.86 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.516 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.0 p -113.27 62.19 0.64 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.849 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -56.93 -34.61 68.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.256 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -101.42 18.1 54.24 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.625 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.431 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 66.82 43.45 91.58 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.808 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.86 136.67 27.29 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.49 0.186 . . . . 0.0 111.047 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 59.7 m -133.17 129.58 38.01 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.945 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -84.9 -32.26 23.24 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.303 0.573 . . . . 0.0 109.567 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.9 m -66.44 122.55 82.29 Favored Pre-proline 0 N--CA 1.452 -0.354 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.948 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.51 141.12 59.87 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.783 2.322 . . . . 0.0 112.933 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.427 ' O ' ' HD3' ' A' ' 24' ' ' ARG . . . 72.83 27.83 68.19 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.887 179.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.42 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 85.6 m -118.5 116.99 27.82 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 121.113 0.482 . . . . 0.0 111.239 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.1 p -80.34 131.89 35.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 178.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.431 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.8 t -74.22 95.01 2.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.322 0.582 . . . . 0.0 112.076 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.4 m -91.95 67.22 5.16 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 176.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.0 t90 -27.19 122.68 0.24 Allowed Pre-proline 0 C--O 1.231 0.11 0 CA-C-N 113.703 -1.589 . . . . 0.0 113.213 -176.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 93.3 Cg_endo -101.78 35.74 6.52 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.024 0.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.583 HG12 HG23 ' A' ' 4' ' ' THR . 64.4 mt -130.74 133.19 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.952 -0.468 . . . . 0.0 111.695 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.485 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.4 m -78.2 131.6 37.23 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 80.7 p -129.28 154.69 46.58 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.586 0.588 . . . . 0.0 112.586 -178.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.578 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 22.7 mmt85 -89.59 69.63 7.84 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 177.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 26.4 t70 65.98 53.34 1.12 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.926 0.869 . . . . 0.0 109.257 -177.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.48 -30.29 10.24 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.309 -0.859 . . . . 0.0 113.004 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.421 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 85.4 mt -81.92 113.43 42.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 117.006 0.403 . . . . 0.0 111.483 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.4 Cg_exo -73.77 39.36 0.5 Allowed 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 123.139 2.559 . . . . 0.0 112.422 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 111.929 -179.64 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.471 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 58.5 m . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 59.44 37.78 92.55 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -139.28 144.76 38.51 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 115.314 -0.443 . . . . 0.0 110.346 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.417 HG21 HD13 ' A' ' 21' ' ' ILE . 82.0 p -108.41 151.16 26.4 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.077 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.934 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -131.99 58.8 1.73 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.152 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -52.88 -31.92 42.21 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.19 0.519 . . . . 0.0 109.873 178.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -137.81 37.31 1.84 Allowed Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 177.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.544 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.59 42.06 99.69 Favored Glycine 0 C--N 1.337 0.619 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.3 p -108.41 44.5 1.11 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.934 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.8 m -81.85 123.43 28.81 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.104 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.411 ' N ' HD21 ' A' ' 11' ' ' ASN . 1.6 m120 -70.79 -36.28 72.94 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.6 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.7 m -73.44 118.56 69.94 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.981 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -74.56 142.16 28.98 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.932 2.421 . . . . 0.0 112.698 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.96 -22.42 40.96 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.325 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.71 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 96.4 m -69.69 125.26 26.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 0.0 111.063 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -79.31 128.57 33.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.2 t -76.31 94.41 3.58 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.574 0.583 . . . . 0.0 112.574 -178.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.2 m -91.38 65.45 5.32 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.512 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -23.2 120.68 0.17 Allowed Pre-proline 0 N--CA 1.462 0.169 0 CA-C-N 113.389 -1.732 . . . . 0.0 113.75 -176.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.512 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.9 Cg_endo -101.8 29.04 11.66 Favored 'Cis proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.876 -1.302 . . . . 0.0 113.699 0.287 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.417 HD13 HG21 ' A' ' 4' ' ' THR . 35.0 mm -123.02 128.39 75.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 O-C-N 122.218 -0.302 . . . . 0.0 111.459 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.71 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.65 131.81 36.07 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.434 0.635 . . . . 0.0 111.607 178.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.5 p -117.87 140.06 50.24 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.863 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.471 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 17.9 tpt85 -93.11 103.08 15.4 Favored 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 59.46 36.31 23.06 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 124.032 0.832 . . . . 0.0 110.159 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.23 -15.78 62.62 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.345 179.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.457 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.1 mt -92.8 121.1 66.66 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 117.205 0.502 . . . . 0.0 111.148 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.9 Cg_exo -71.94 39.32 0.39 Allowed 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 123.118 2.545 . . . . 0.0 112.215 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.436 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.0 m . . . . . 0 C--N 1.326 -0.436 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.748 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 87.5 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.469 0.176 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.67 36.96 94.01 Favored Glycine 0 N--CA 1.449 -0.435 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.461 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -141.59 145.65 35.31 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 115.125 -0.537 . . . . 0.0 109.812 -178.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.4 p -118.02 144.48 45.53 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.555 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -117.97 55.65 0.87 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.045 0.45 . . . . 0.0 111.006 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -56.38 -34.16 66.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.309 178.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.85 20.09 42.27 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.885 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.49 43.88 75.44 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.352 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.9 t -150.41 143.67 24.96 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.555 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.9 m -135.15 129.23 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.208 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 59.3 m-80 -70.51 -39.57 74.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.896 0.379 . . . . 0.0 110.36 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.9 m -71.8 117.22 55.76 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.562 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -68.84 138.96 42.22 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 123.122 2.548 . . . . 0.0 112.846 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.78 -20.05 51.57 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.765 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 71.4 m -77.18 126.24 30.62 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.073 0.463 . . . . 0.0 111.353 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -81.07 135.94 35.88 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.0 t -77.78 94.84 4.55 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.291 0.567 . . . . 0.0 112.227 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 15.9 m -93.81 67.7 3.83 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 107.089 -1.449 . . . . 0.0 107.089 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.3 t90 -27.18 122.47 0.24 Allowed Pre-proline 0 N--CA 1.463 0.184 0 CA-C-N 113.75 -1.568 . . . . 0.0 113.219 -176.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.84 30.28 10.5 Favored 'Cis proline' 0 N--CA 1.455 -0.774 0 C-N-CA 123.564 -1.432 . . . . 0.0 114.01 0.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.57 132.6 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 O-C-N 122.051 -0.405 . . . . 0.0 111.682 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 29.4 m -79.72 128.41 33.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.764 0.316 . . . . 0.0 110.552 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.439 ' HB ' ' N ' ' A' ' 27' ' ' LEU . 47.0 p -117.43 137.41 52.52 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.078 0.466 . . . . 0.0 112.043 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.59 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.1 tpt85 -90.58 101.3 14.04 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 177.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 59.6 38.56 22.1 Favored 'General case' 0 C--N 1.328 -0.345 0 O-C-N 123.891 0.744 . . . . 0.0 111.207 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.5 32.54 24.7 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.156 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.716 ' HG ' HG13 ' A' ' 29' ' ' VAL . 24.3 tp -144.83 117.77 5.48 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.068 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.497 ' HD2' HD11 ' A' ' 27' ' ' LEU . 56.3 Cg_endo -70.8 44.49 0.51 Allowed 'Trans proline' 0 N--CA 1.475 0.396 0 C-N-CA 123.25 2.633 . . . . 0.0 114.059 -178.277 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.716 HG13 ' HG ' ' A' ' 27' ' ' LEU . 18.6 m . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 120.933 0.397 . . . . 0.0 111.082 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 94.4 m . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 120.427 0.156 . . . . 0.0 111.077 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.72 40.72 98.82 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -150.31 147.63 27.87 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.0 p -117.61 143.24 46.33 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.979 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.539 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -114.67 56.14 0.73 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.011 0.434 . . . . 0.0 111.4 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.65 -34.47 67.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.214 178.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.48 20.93 38.39 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.866 179.148 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.26 42.91 81.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.468 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 13.4 t -150.53 143.4 24.67 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.539 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 58.1 m -132.83 128.82 37.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.687 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -68.82 -44.87 72.6 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.8 m -64.91 117.5 39.51 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.732 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -71.1 142.57 42.38 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.84 2.36 . . . . 0.0 113.067 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.41 33.65 38.61 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.161 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.4 m -124.31 133.74 53.38 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.868 0.366 . . . . 0.0 110.797 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -84.06 135.14 34.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.458 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 14.5 t -81.43 95.28 7.01 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.258 0.552 . . . . 0.0 111.759 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 12.5 m -93.66 67.91 3.94 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.483 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.5 t90 -27.95 122.79 0.25 Allowed Pre-proline 0 C--O 1.232 0.138 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.176 -176.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.483 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.7 Cg_endo -101.61 30.26 10.72 Favored 'Cis proline' 0 N--CA 1.455 -0.759 0 C-N-CA 123.59 -1.421 . . . . 0.0 114.083 0.635 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.403 HG23 HD12 ' A' ' 21' ' ' ILE . 66.0 mt -125.94 132.64 70.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 O-C-N 122.007 -0.433 . . . . 0.0 111.511 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.438 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 29.7 m -80.64 127.67 32.74 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.876 0.37 . . . . 0.0 110.768 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.7 p -119.48 142.48 48.24 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.233 0.539 . . . . 0.0 111.56 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.592 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 31.3 ttt85 -99.47 106.28 18.3 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 58.96 34.96 23.91 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 123.89 0.744 . . . . 0.0 110.14 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.31 -17.01 60.13 Favored Glycine 0 CA--C 1.52 0.403 0 CA-C-N 115.712 -0.676 . . . . 0.0 113.489 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.4 mt -93.84 122.59 61.84 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.213 0.507 . . . . 0.0 111.32 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.8 Cg_exo -72.16 39.09 0.39 Allowed 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 123.074 2.516 . . . . 0.0 112.343 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.418 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.1 m . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.667 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.486 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.6 m . . . . . 0 N--CA 1.448 -0.534 0 CA-C-O 120.527 0.203 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.55 37.96 95.57 Favored Glycine 0 C--N 1.333 0.378 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 -178.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.531 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.6 tp10 -144.56 142.88 30.5 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.167 -0.516 . . . . 0.0 109.678 -178.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.9 p -116.17 144.49 44.11 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.915 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.525 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.4 p -118.48 56.7 0.87 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -55.79 -35.18 66.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.474 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.17 20.87 36.96 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.966 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.07 44.54 66.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.202 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.6 m -147.63 135.75 21.36 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.525 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 62.8 m -127.95 126.18 40.94 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.181 0.3 . . . . 0.0 110.355 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -66.4 -43.62 85.32 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.2 m -71.63 117.18 55.1 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.487 179.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_exo -70.13 139.16 38.31 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.978 2.452 . . . . 0.0 112.825 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.89 -23.53 35.62 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.655 179.54 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.5 m -73.7 127.68 33.44 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.071 0.462 . . . . 0.0 111.462 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.8 t -79.93 134.77 36.3 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.5 t -77.86 93.88 4.44 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.301 0.572 . . . . 0.0 112.274 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.8 m -92.38 67.98 4.89 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 176.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 6.2 t90 -27.4 122.82 0.24 Allowed Pre-proline 0 N--CA 1.463 0.175 0 CA-C-N 113.861 -1.518 . . . . 0.0 113.305 -176.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -101.69 30.55 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.516 -1.452 . . . . 0.0 114.047 0.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.6 mt -126.53 132.57 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 120.973 0.416 . . . . 0.0 111.487 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.531 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.5 m -79.62 128.79 33.83 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.805 0.336 . . . . 0.0 110.389 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -122.96 146.36 47.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.978 0.418 . . . . 0.0 112.003 -178.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.486 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 3.4 mmm-85 -91.25 95.54 10.09 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 177.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.97 37.35 21.44 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 123.928 0.768 . . . . 0.0 110.104 -178.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.15 -18.81 56.12 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.721 -0.672 . . . . 0.0 113.338 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 20.5 tp -89.53 113.82 58.13 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.157 0.478 . . . . 0.0 110.559 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 8.0 Cg_exo -73.14 46.74 1.18 Allowed 'Trans proline' 0 CA--C 1.531 0.36 0 C-N-CA 123.431 2.754 . . . . 0.0 113.59 -178.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.418 HG13 ' HG ' ' A' ' 27' ' ' LEU . 24.5 m . . . . . 0 C--N 1.325 -0.466 0 CA-C-O 121.085 0.469 . . . . 0.0 111.199 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.8 m . . . . . 0 N--CA 1.45 -0.434 0 CA-C-O 121.012 0.434 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 36.77 92.29 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.373 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -150.31 151.38 32.84 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.935 0.398 . . . . 0.0 110.129 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 38.7 p -110.3 146.69 35.27 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.952 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.541 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 28.2 p -115.12 54.82 0.78 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.135 0.493 . . . . 0.0 110.64 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -55.22 -35.42 64.9 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.68 179.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.11 19.56 45.88 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.91 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.1 46.16 67.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.975 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -149.78 142.36 24.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.629 0.252 . . . . 0.0 110.524 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.541 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 65.6 m -136.02 128.34 30.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.182 -179.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.5 p30 -77.61 -28.26 51.45 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.864 0.364 . . . . 0.0 110.404 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.99 123.42 89.29 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.497 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -69.51 136.12 32.83 Favored 'Trans proline' 0 N--CA 1.464 -0.221 0 C-N-CA 122.614 2.209 . . . . 0.0 113.114 -179.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.38 66.42 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.878 179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.1 m -112.71 128.05 56.3 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.065 0.459 . . . . 0.0 111.09 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.3 t -84.44 141.59 30.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.229 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.5 t -83.29 95.28 8.13 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.199 0.523 . . . . 0.0 111.995 -179.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.9 m -92.67 66.71 4.47 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.9 t90 -27.71 123.0 0.24 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.177 -176.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.8 Cg_endo -101.55 31.89 9.35 Favored 'Cis proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.497 -1.46 . . . . 0.0 114.039 0.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.6 mt -126.45 134.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 O-C-N 121.994 -0.441 . . . . 0.0 111.648 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.489 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -79.3 132.58 36.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.712 0.291 . . . . 0.0 110.85 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.5 p -128.31 136.61 51.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 111.37 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.5 ttt-85 -95.3 107.01 19.1 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 60.28 34.89 20.86 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 123.731 0.644 . . . . 0.0 110.067 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.62 -13.39 67.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.183 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.706 ' HB3' HG21 ' A' ' 29' ' ' VAL . 90.9 mt -94.11 118.68 67.19 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 117.159 0.479 . . . . 0.0 111.097 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -72.82 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.066 2.511 . . . . 0.0 112.512 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.706 HG21 ' HB3' ' A' ' 27' ' ' LEU . 3.2 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-O 121.348 0.595 . . . . 0.0 110.732 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.483 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 80.8 m . . . . . 0 N--CA 1.449 -0.522 0 CA-C-O 120.73 0.3 . . . . 0.0 110.593 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 41.13 97.21 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -146.87 145.19 29.76 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.958 0.409 . . . . 0.0 110.13 -179.213 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -114.02 144.35 43.25 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.767 178.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.495 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 27.6 p -118.38 55.36 0.9 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.052 0.453 . . . . 0.0 111.289 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -56.62 -33.74 66.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.313 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.77 20.48 38.84 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.889 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.16 44.85 74.6 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.386 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.0 t -150.19 142.79 24.52 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.586 0.231 . . . . 0.0 110.541 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.485 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 56.0 m -134.52 131.01 37.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.254 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -66.7 -35.02 79.14 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.93 0.395 . . . . 0.0 110.382 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -80.89 117.23 67.1 Favored Pre-proline 0 N--CA 1.45 -0.442 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.977 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.69 136.87 28.91 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.71 2.274 . . . . 0.0 112.157 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.07 -27.23 21.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.655 -0.783 . . . . 0.0 111.999 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.3 m -72.54 127.81 33.68 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.989 0.423 . . . . 0.0 110.952 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -79.93 134.84 36.3 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.403 179.366 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.6 t -77.85 93.47 4.37 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.268 0.556 . . . . 0.0 111.727 -179.292 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.5 m -90.97 68.05 6.13 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.5 t90 -27.75 122.98 0.25 Allowed Pre-proline 0 N--CA 1.463 0.194 0 CA-C-N 113.932 -1.485 . . . . 0.0 113.268 -176.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.67 30.57 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.589 -1.421 . . . . 0.0 113.972 0.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.5 mt -126.86 132.52 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 O-C-N 122.058 -0.401 . . . . 0.0 111.567 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.495 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 28.6 m -79.35 128.96 33.98 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.823 0.344 . . . . 0.0 110.689 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -121.28 144.05 48.84 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.277 0.56 . . . . 0.0 111.393 -179.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.483 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 59.9 ttp180 -95.59 84.1 3.9 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.1 t70 67.27 49.95 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 O-C-N 124.248 0.968 . . . . 0.0 109.631 -177.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.29 -24.9 20.13 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.925 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.436 ' C ' ' H ' ' A' ' 29' ' ' VAL . 87.4 mt -92.14 116.02 65.72 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 117.378 0.589 . . . . 0.0 111.547 -179.268 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -73.21 39.02 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.005 2.47 . . . . 0.0 112.196 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.436 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.5 m . . . . . 0 C--N 1.324 -0.503 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.61 -179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 82.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 120.67 0.271 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 34.32 87.86 Favored Glycine 0 N--CA 1.451 -0.33 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -178.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.461 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -134.0 145.16 49.23 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.9 -0.65 . . . . 0.0 109.959 -179.034 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.441 HG21 HD12 ' A' ' 21' ' ' ILE . 65.0 p -114.17 146.03 40.88 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.614 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.58 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 27.9 p -124.21 54.07 1.38 Allowed 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.15 0.5 . . . . 0.0 110.854 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -56.43 -33.3 65.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.387 179.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.53 19.87 41.05 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.807 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.42 45.03 70.86 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.324 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.9 t -150.11 142.8 24.6 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.542 0.21 . . . . 0.0 110.591 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.475 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 46.4 m -134.34 127.75 32.32 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.025 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -72.04 -34.55 68.86 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.931 0.396 . . . . 0.0 110.232 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.5 m -72.47 118.24 65.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.483 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.85 135.45 32.7 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.638 2.225 . . . . 0.0 112.864 -179.472 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.66 -22.5 39.98 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 76.9 m -78.12 121.59 24.5 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.085 0.469 . . . . 0.0 111.014 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.5 t -82.59 138.16 34.31 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.29 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 26.6 t -74.49 113.81 12.16 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.469 0.652 . . . . 0.0 111.941 -179.219 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.0 m -113.13 66.12 0.65 Allowed 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 177.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.517 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.1 t90 -23.55 120.36 0.18 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 113.489 -1.687 . . . . 0.0 113.665 -176.584 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.517 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 76.0 Cg_endo -101.96 25.62 14.53 Favored 'Cis proline' 0 N--CA 1.456 -0.729 0 C-N-CA 123.668 -1.388 . . . . 0.0 113.784 0.432 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.441 HD12 HG21 ' A' ' 4' ' ' THR . 41.4 mm -119.74 132.77 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-O 120.729 0.299 . . . . 0.0 111.628 -179.063 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.58 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.0 m -81.4 128.28 33.69 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.3 p -115.79 145.78 42.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.222 0.534 . . . . 0.0 111.532 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.9 tpt85 -89.7 85.24 6.4 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 62.58 43.14 7.86 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.2 -177.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.99 -23.68 34.71 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.702 -0.761 . . . . 0.0 113.616 179.301 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.553 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.3 tp -92.6 111.6 51.66 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 117.355 0.578 . . . . 0.0 110.617 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.449 ' HD2' HD12 ' A' ' 27' ' ' LEU . 60.4 Cg_endo -72.86 47.38 1.22 Allowed 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 123.184 2.589 . . . . 0.0 113.817 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.553 HG13 ' HG ' ' A' ' 27' ' ' LEU . 30.3 m . . . . . 0 C--N 1.324 -0.511 0 CA-C-O 120.87 0.367 . . . . 0.0 111.416 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.612 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 52.5 m . . . . . 0 N--CA 1.448 -0.573 0 CA-C-O 120.402 0.144 . . . . 0.0 111.148 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.32 37.74 94.24 Favored Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -178.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.467 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.1 tp10 -140.91 145.85 36.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.142 -0.529 . . . . 0.0 109.858 -179.032 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 64.4 p -115.6 146.73 41.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.784 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.536 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.1 p -125.02 55.58 1.36 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.239 0.543 . . . . 0.0 110.715 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -57.05 -33.0 66.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.271 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.98 18.89 48.35 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.73 -0.747 . . . . 0.0 111.657 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.57 42.77 79.69 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.045 -0.597 . . . . 0.0 112.298 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.6 t -150.62 143.77 24.82 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 110.452 -0.203 . . . . 0.0 110.452 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.474 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 39.6 m -132.1 129.5 40.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -70.69 -35.45 72.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.978 0.418 . . . . 0.0 110.344 179.72 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 10.6 m -76.66 116.6 58.07 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.792 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.17 139.6 46.79 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.948 2.432 . . . . 0.0 112.489 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.05 -27.37 20.33 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.015 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.0 m -76.34 125.63 29.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.094 0.473 . . . . 0.0 110.967 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.8 m -85.99 134.81 33.84 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.71 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 27.2 t -73.49 116.18 13.75 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.339 0.59 . . . . 0.0 111.873 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.8 m -115.96 66.87 0.71 Allowed 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.57 -1.641 . . . . 0.0 106.57 177.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.504 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.8 t90 -23.51 119.48 0.18 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.518 -1.674 . . . . 0.0 113.643 -176.555 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 75.5 Cg_endo -102.7 26.7 12.49 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.855 0.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 38.6 mm -120.33 133.73 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 111.624 -179.07 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 40.6 m -82.31 126.06 31.7 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 178.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -113.19 150.84 31.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.529 0.68 . . . . 0.0 111.71 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.612 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.5 ttm180 -103.72 86.65 2.65 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.118 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.7 t0 66.52 49.51 1.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 O-C-N 124.245 0.965 . . . . 0.0 109.509 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.82 -25.01 12.51 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.773 179.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.417 ' C ' ' H ' ' A' ' 29' ' ' VAL . 88.8 mt -88.92 117.9 68.73 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 117.316 0.558 . . . . 0.0 111.547 -179.267 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -73.96 38.71 0.48 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.027 2.485 . . . . 0.0 112.269 179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.417 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.3 m . . . . . 0 C--N 1.325 -0.491 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.617 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.0 m . . . . . 0 N--CA 1.45 -0.468 0 CA-C-O 120.644 0.259 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.75 38.71 94.72 Favored Glycine 0 N--CA 1.451 -0.345 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -178.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.465 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -141.88 147.18 36.71 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.797 -178.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.2 p -118.46 145.66 45.08 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.973 0.416 . . . . 0.0 110.752 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.2 p -120.69 56.49 1.0 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.006 0.431 . . . . 0.0 111.028 -179.691 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.61 -34.02 66.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.29 179.018 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.49 20.23 40.19 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.82 179.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.5 43.61 76.63 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.339 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.7 t -150.22 142.88 24.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.461 0.172 . . . . 0.0 110.565 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.6 m -132.71 128.74 37.58 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.037 -179.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.3 m-80 -69.67 -34.58 74.17 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.021 0.439 . . . . 0.0 110.021 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.1 m -75.27 115.66 47.21 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.362 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -70.3 136.18 30.94 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.92 2.413 . . . . 0.0 112.472 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.45 -24.23 32.84 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.454 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -77.72 130.47 36.8 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.151 0.5 . . . . 0.0 111.219 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.1 t -84.77 137.52 33.15 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.468 179.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 25.0 t -77.16 112.62 14.02 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.301 0.572 . . . . 0.0 111.739 -179.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.7 m -111.25 67.6 0.65 Allowed 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 177.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.485 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.0 t90 -26.33 122.53 0.22 Allowed Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 113.776 -1.556 . . . . 0.0 113.344 -176.602 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.5 Cg_endo -101.36 28.84 12.35 Favored 'Cis proline' 0 N--CA 1.454 -0.804 0 C-N-CA 123.6 -1.417 . . . . 0.0 114.086 0.534 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 61.3 mt -127.55 134.71 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 O-C-N 121.997 -0.439 . . . . 0.0 111.538 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 31.4 m -79.87 130.41 35.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.908 0.385 . . . . 0.0 110.43 179.442 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 54.4 p -121.48 157.95 29.49 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.215 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.407 ' HA ' ' HD2' ' A' ' 24' ' ' ARG . 13.9 tpt85 -87.99 58.33 4.76 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.264 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 64.45 45.88 3.56 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.955 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 142.43 -47.94 0.8 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.385 -0.912 . . . . 0.0 113.479 178.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 99.0 mt -108.93 127.87 26.52 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 122.553 -0.38 . . . . 0.0 111.777 -179.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.8 Cg_endo -75.6 39.03 0.6 Allowed 'Trans proline' 0 CA--C 1.528 0.22 0 C-N-CA 123.209 2.606 . . . . 0.0 112.47 179.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 -179.642 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 60.9 m . . . . . 0 N--CA 1.448 -0.542 0 CA-C-O 120.695 0.283 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.52 45.01 96.76 Favored Glycine 0 C--N 1.335 0.479 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.437 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -150.16 149.86 30.83 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.958 0.408 . . . . 0.0 110.698 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.529 HG21 HD11 ' A' ' 21' ' ' ILE . 42.4 p -123.41 142.85 50.56 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.61 178.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 29.3 p -105.34 57.32 0.68 Allowed 'General case' 0 C--N 1.315 -0.923 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.688 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -56.59 -33.54 66.32 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -106.02 23.36 29.34 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.61 178.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 66.92 37.33 92.11 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 121.197 -0.525 . . . . 0.0 113.082 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.4 t -151.06 142.61 23.55 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.717 0.294 . . . . 0.0 111.371 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.746 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.8 m -122.54 132.44 54.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.634 179.371 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -64.68 -34.56 78.59 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.921 0.391 . . . . 0.0 110.394 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.4 m -79.71 115.74 55.89 Favored Pre-proline 0 N--CA 1.45 -0.465 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.717 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.97 135.8 26.1 Favored 'Trans proline' 0 N--CA 1.462 -0.349 0 C-N-CA 122.516 2.144 . . . . 0.0 112.37 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.03 -26.65 23.89 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.071 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.8 m -71.65 125.82 28.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.974 0.416 . . . . 0.0 111.234 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -89.58 121.21 31.56 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.822 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 19.6 t -86.86 116.95 25.28 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 113.464 0.912 . . . . 0.0 113.464 -177.17 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.9 m -88.72 72.64 8.62 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 174.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 12.7 t90 -21.56 122.25 0.12 Allowed Pre-proline 0 N--CA 1.468 0.433 0 CA-C-N 113.889 -1.505 . . . . 0.0 113.834 -175.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 88.8 Cg_endo -101.78 31.31 9.65 Favored 'Cis proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.228 0.502 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.529 HD11 HG21 ' A' ' 4' ' ' THR . 43.8 mm -116.52 120.54 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.236 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.822 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 28.8 m -74.67 130.2 39.09 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 37.2 p -131.04 139.67 49.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.124 0.488 . . . . 0.0 111.876 -178.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 5.6 tmm_? -96.7 102.22 13.97 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 59.41 40.4 20.9 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 123.807 0.692 . . . . 0.0 110.302 -177.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.25 -15.68 60.58 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.557 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.416 ' C ' ' H ' ' A' ' 29' ' ' VAL . 90.5 mt -91.61 118.93 68.63 Favored Pre-proline 0 C--N 1.327 -0.396 0 CA-C-N 117.232 0.516 . . . . 0.0 111.5 -179.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -74.82 38.82 0.54 Allowed 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 123.081 2.521 . . . . 0.0 112.049 179.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.416 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.0 m . . . . . 0 C--N 1.324 -0.525 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.818 -179.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.451 -0.402 0 CA-C-O 120.664 0.269 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.65 37.67 95.16 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -143.29 141.48 31.03 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.7 p -111.88 146.86 36.99 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.036 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.796 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 23.2 p -122.69 57.94 1.09 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -56.09 -36.05 67.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.127 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.56 20.56 43.91 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.684 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.08 40.22 88.45 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.351 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.2 t -151.19 142.92 23.74 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.555 -0.165 . . . . 0.0 110.555 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.796 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -139.06 137.5 36.29 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.8 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -67.24 -41.29 85.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.518 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.2 m -70.67 114.41 26.36 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.409 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.89 137.93 27.73 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.058 2.505 . . . . 0.0 112.449 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.8 -25.25 28.62 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.301 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.686 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 91.2 m -71.04 127.79 33.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.022 0.439 . . . . 0.0 111.272 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -79.64 126.7 31.25 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.8 t -73.88 96.89 2.67 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.488 0.661 . . . . 0.0 112.191 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.7 m -94.11 68.15 3.69 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.102 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.524 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.2 t90 -25.7 122.26 0.22 Allowed Pre-proline 0 N--CA 1.463 0.22 0 CA-C-N 113.918 -1.492 . . . . 0.0 113.313 -176.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.524 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.7 Cg_endo -101.55 30.31 10.72 Favored 'Cis proline' 0 N--CA 1.456 -0.71 0 C-N-CA 123.606 -1.414 . . . . 0.0 114.159 0.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 67.6 mt -131.26 131.83 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.954 -0.466 . . . . 0.0 111.341 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.686 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -79.4 134.97 36.57 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.306 0.574 . . . . 0.0 111.982 179.587 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 70.6 p -120.9 149.51 42.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.076 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.492 ' HG2' ' OD1' ' A' ' 25' ' ' ASP . 17.0 ttt-85 -88.17 94.86 9.95 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.672 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.492 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 1.1 p-10 46.38 42.78 11.03 Favored 'General case' 0 N--CA 1.469 0.483 0 O-C-N 124.334 1.022 . . . . 0.0 111.434 -177.163 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.57 -22.18 29.0 Favored Glycine 0 C--N 1.335 0.49 0 CA-C-N 115.52 -0.763 . . . . 0.0 113.865 178.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.748 ' HG ' HG12 ' A' ' 29' ' ' VAL . 20.6 tp -93.45 113.82 61.22 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 117.256 0.528 . . . . 0.0 111.015 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 11.2 Cg_exo -71.59 48.26 1.0 Allowed 'Trans proline' 0 CA--C 1.533 0.431 0 C-N-CA 123.498 2.799 . . . . 0.0 113.772 -179.236 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.748 HG12 ' HG ' ' A' ' 27' ' ' LEU . 31.1 m . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 121.004 0.431 . . . . 0.0 111.257 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.1 m . . . . . 0 N--CA 1.449 -0.492 0 CA-C-O 120.786 0.327 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.51 37.8 94.74 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.543 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -144.25 143.88 31.24 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 45.2 p -105.75 153.63 21.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.701 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.898 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 22.2 p -131.67 56.97 1.79 Allowed 'General case' 0 C--N 1.321 -0.643 0 O-C-N 122.269 -0.27 . . . . 0.0 110.95 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -52.01 -35.99 48.58 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.215 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.23 31.65 3.98 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 178.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.514 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.99 48.36 83.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.143 -0.551 . . . . 0.0 111.823 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.6 m -130.7 69.27 1.46 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 111.975 0.361 . . . . 0.0 111.975 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.898 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 92.6 m -90.88 130.98 36.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.763 0.316 . . . . 0.0 111.18 179.515 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.8 p-10 -64.51 -35.12 79.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.935 -179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.444 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 18.1 m -85.01 114.68 57.27 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.196 -179.127 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 8.0 Cg_exo -71.94 139.73 33.65 Favored 'Trans proline' 0 N--CA 1.462 -0.341 0 C-N-CA 123.111 2.541 . . . . 0.0 111.932 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.02 -25.93 26.11 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.079 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.689 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 97.6 m -67.05 128.34 35.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.839 0.352 . . . . 0.0 110.744 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.7 m -78.87 123.5 27.3 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.6 t -72.6 98.83 2.41 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.362 0.601 . . . . 0.0 112.232 -178.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 9.0 m -94.49 68.38 3.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.6 t90 -25.18 121.06 0.21 Allowed Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.355 -176.464 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.5 Cg_endo -102.76 33.6 7.5 Favored 'Cis proline' 0 N--CA 1.455 -0.764 0 C-N-CA 123.69 -1.379 . . . . 0.0 114.153 0.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 67.9 mt -132.23 132.99 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 O-C-N 121.992 -0.442 . . . . 0.0 111.576 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.689 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.58 134.93 36.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.34 0.59 . . . . 0.0 112.474 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 42.5 p -123.0 143.82 49.67 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.651 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 2.3 mmm-85 -95.25 101.9 13.67 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 60.03 36.14 21.42 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 123.944 0.778 . . . . 0.0 110.006 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.56 -14.49 65.16 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.623 -0.717 . . . . 0.0 113.192 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.734 ' HG ' HG12 ' A' ' 29' ' ' VAL . 21.6 tp -92.96 116.35 66.37 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 117.067 0.433 . . . . 0.0 110.273 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.7 45.61 0.73 Allowed 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 123.122 2.548 . . . . 0.0 113.83 -178.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.734 HG12 ' HG ' ' A' ' 27' ' ' LEU . 16.0 m . . . . . 0 C--N 1.326 -0.421 0 CA-C-O 120.928 0.394 . . . . 0.0 111.465 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 N--CA 1.448 -0.538 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.11 34.32 87.56 Favored Glycine 0 C--N 1.333 0.387 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.791 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -140.53 134.21 30.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 77.8 p -96.21 146.19 24.91 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.429 -178.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -120.65 58.48 0.94 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.204 179.217 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -55.92 -34.66 65.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.48 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.77 17.33 56.6 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.485 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.451 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 67.81 41.57 88.32 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 121.144 -0.55 . . . . 0.0 111.946 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.3 t -151.47 144.92 24.84 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.077 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 30.2 m -146.62 140.8 26.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.9 m-80 -73.23 -35.24 66.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.569 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.416 HG23 ' SG ' ' A' ' 15' ' ' CYS . 4.4 m -66.78 115.24 22.76 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.842 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.86 134.48 27.87 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.654 2.236 . . . . 0.0 112.837 -179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.61 -18.53 57.16 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.69 -0.767 . . . . 0.0 113.001 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.554 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 94.9 m -77.41 120.63 22.67 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.179 0.514 . . . . 0.0 111.016 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -79.41 131.27 36.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.451 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 32.9 t -75.52 92.73 2.91 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.338 0.59 . . . . 0.0 112.24 -178.466 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.0 m -89.58 66.74 7.35 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -25.22 121.33 0.21 Allowed Pre-proline 0 C--O 1.232 0.168 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.68 -176.543 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 85.4 Cg_endo -101.75 26.31 14.26 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.59 -1.421 . . . . 0.0 113.787 0.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.417 HG22 HD13 ' A' ' 21' ' ' ILE . 35.9 mm -120.56 127.87 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 O-C-N 122.257 -0.277 . . . . 0.0 111.424 -179.208 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.554 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 13.0 m -79.78 130.36 35.26 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.254 0.55 . . . . 0.0 111.35 179.062 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 69.0 p -118.59 140.6 49.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.723 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 35.8 tpt85 -89.66 92.14 8.95 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 61.04 40.61 14.92 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 124.028 0.83 . . . . 0.0 110.48 -178.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.75 -22.89 35.63 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 113.841 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.437 ' C ' ' H ' ' A' ' 29' ' ' VAL . 87.9 mt -93.86 117.45 67.23 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 117.381 0.59 . . . . 0.0 111.589 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.85 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.924 2.416 . . . . 0.0 112.266 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.437 ' H ' ' C ' ' A' ' 27' ' ' LEU . 26.9 m . . . . . 0 C--N 1.326 -0.451 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.875 -179.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 N--CA 1.45 -0.47 0 CA-C-O 120.86 0.362 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.42 40.38 97.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.887 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -147.44 142.09 26.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.976 0.417 . . . . 0.0 110.19 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.615 HG21 HG12 ' A' ' 21' ' ' ILE . 41.7 p -107.36 146.79 31.16 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.694 179.581 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.781 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 21.4 p -122.38 56.82 1.1 Allowed 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.989 0.423 . . . . 0.0 110.757 179.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -55.99 -36.77 68.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.252 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.91 21.31 40.71 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.516 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.7 40.71 90.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.183 -0.532 . . . . 0.0 112.408 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.2 t -150.78 142.92 24.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.781 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 89.4 m -137.49 137.58 38.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.744 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -64.44 -35.67 81.66 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.1 m -76.89 113.77 33.18 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.709 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.52 136.02 27.6 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.539 2.159 . . . . 0.0 112.376 -179.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.64 -19.32 54.83 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.502 -0.856 . . . . 0.0 113.037 179.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 68.6 m -74.65 131.7 41.11 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 117.287 0.543 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.1 m -81.96 119.36 23.86 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.743 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 10.4 t -68.76 112.41 5.47 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.433 0.635 . . . . 0.0 111.775 -178.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.8 m -109.06 69.61 0.71 Allowed 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -25.19 122.1 0.21 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.352 -176.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.4 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 83.7 Cg_endo -101.57 31.22 9.88 Favored 'Cis proline' 0 N--CA 1.455 -0.739 0 C-N-CA 123.541 -1.441 . . . . 0.0 114.277 0.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.615 HG12 HG21 ' A' ' 4' ' ' THR . 64.4 mt -135.7 134.19 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 O-C-N 121.97 -0.456 . . . . 0.0 111.436 -179.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.503 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -76.77 137.02 39.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.14 0.495 . . . . 0.0 111.491 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.4 p -128.99 158.84 37.74 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.939 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.01 55.0 3.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 178.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 65.12 43.1 3.8 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.872 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 148.63 -45.77 0.71 Allowed Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.325 -0.941 . . . . 0.0 113.263 179.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 98.1 mt -114.96 129.86 24.69 Favored Pre-proline 0 C--N 1.327 -0.383 0 O-C-N 122.509 -0.407 . . . . 0.0 111.686 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.6 Cg_endo -75.39 39.92 0.65 Allowed 'Trans proline' 0 CA--C 1.53 0.279 0 C-N-CA 123.247 2.631 . . . . 0.0 112.506 179.606 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.6 m . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.034 -179.656 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.9 m . . . . . 0 N--CA 1.448 -0.546 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.98 39.1 96.57 Favored Glycine 0 C--N 1.335 0.495 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.864 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -147.74 152.29 37.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.769 0.318 . . . . 0.0 110.388 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.402 HG22 HG12 ' A' ' 21' ' ' ILE . 22.7 p -122.45 146.0 47.78 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.506 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.496 ' HB2' ' N ' ' A' ' 9' ' ' THR . 21.6 p -107.63 60.35 0.62 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.135 0.493 . . . . 0.0 111.028 -179.625 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -56.17 -30.24 61.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.101 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.55 17.38 46.66 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.789 -0.719 . . . . 0.0 111.564 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 39.82 86.93 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.558 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.496 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.2 m -150.92 137.27 18.57 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 122.581 -0.364 . . . . 0.0 111.087 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.721 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 57.8 m -125.15 129.95 51.19 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 178.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -77.0 -34.11 57.53 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.041 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.439 HG21 ' SG ' ' A' ' 15' ' ' CYS . 6.4 m -63.96 119.18 52.82 Favored Pre-proline 0 C--O 1.236 0.361 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.599 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.88 135.89 36.69 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.952 2.435 . . . . 0.0 113.801 -178.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.22 17.07 78.74 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.465 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.439 ' SG ' HG21 ' A' ' 12' ' ' THR . 55.9 m -105.33 121.36 43.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 117.141 0.471 . . . . 0.0 111.078 179.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.7 m -90.23 117.71 29.19 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 107.305 -1.368 . . . . 0.0 107.305 178.089 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.842 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 17.9 t -81.6 118.34 22.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 113.491 0.922 . . . . 0.0 113.491 -176.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.8 m -92.34 73.35 5.3 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 104.964 -2.235 . . . . 0.0 104.964 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.415 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -23.04 125.59 0.12 Allowed Pre-proline 0 N--CA 1.467 0.42 0 CA-C-N 113.767 -1.561 . . . . 0.0 113.661 -175.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 94.6 Cg_endo -100.52 33.53 8.56 Favored 'Cis proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.332 -1.528 . . . . 0.0 114.449 0.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.402 HG12 HG22 ' A' ' 4' ' ' THR . 66.4 mt -124.58 125.83 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 O-C-N 121.865 -0.522 . . . . 0.0 112.097 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.842 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 14.0 m -72.1 129.11 37.73 Favored 'General case' 0 C--O 1.233 0.212 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.439 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.448 HG23 ' HA ' ' A' ' 28' ' ' PRO . 20.0 p -128.79 138.11 51.9 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.127 0.489 . . . . 0.0 111.844 -178.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.99 104.97 16.85 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.24 37.38 23.76 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.434 0.635 . . . . 0.0 110.043 -178.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.65 -11.45 70.18 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.522 -0.763 . . . . 0.0 113.447 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.409 ' C ' ' H ' ' A' ' 29' ' ' VAL . 93.1 mt -94.44 123.58 58.05 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 117.2 0.5 . . . . 0.0 111.202 -179.741 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.448 ' HA ' HG23 ' A' ' 23' ' ' THR . 6.2 Cg_exo -73.39 39.99 0.51 Allowed 'Trans proline' 0 CA--C 1.53 0.302 0 C-N-CA 123.072 2.515 . . . . 0.0 112.038 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.409 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.3 m . . . . . 0 C--N 1.326 -0.425 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.895 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 121.135 0.493 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.26 34.63 90.42 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.511 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -145.34 136.83 25.18 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-O 120.934 0.397 . . . . 0.0 110.026 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.413 HG22 HG12 ' A' ' 21' ' ' ILE . 36.7 p -99.41 143.57 29.51 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.164 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.6 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -115.36 60.45 0.7 Allowed 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.412 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -55.97 -34.91 66.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.494 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.52 16.95 57.36 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.593 178.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.415 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 68.13 40.82 88.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.877 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.6 t -151.55 146.46 25.89 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 121.272 -0.171 . . . . 0.0 110.685 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.6 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 18.8 m -145.69 138.74 26.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.015 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -74.01 -42.58 60.15 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.311 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.1 m -62.15 118.15 36.83 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.723 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -68.43 147.55 71.47 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 123.056 2.504 . . . . 0.0 113.528 -178.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.6 25.78 71.44 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.133 -0.939 . . . . 0.0 113.53 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.714 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 89.5 m -114.2 122.49 46.96 Favored 'General case' 0 N--CA 1.444 -0.765 0 O-C-N 122.288 -0.536 . . . . 0.0 110.665 179.257 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -79.44 127.55 32.25 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.415 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.6 t -74.93 90.22 2.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.333 0.587 . . . . 0.0 112.107 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.1 m -88.5 68.06 8.69 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 177.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 4.3 t90 -26.44 123.54 0.22 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.896 -1.502 . . . . 0.0 113.317 -176.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -101.04 30.76 10.71 Favored 'Cis proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.51 -1.454 . . . . 0.0 114.092 0.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.413 HG12 HG22 ' A' ' 4' ' ' THR . 65.5 mt -131.12 131.31 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 O-C-N 122.029 -0.419 . . . . 0.0 111.358 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.714 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 37.9 m -79.08 132.45 36.61 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.312 0.577 . . . . 0.0 111.709 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -116.22 147.14 41.76 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.842 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.7 tpp85 -94.39 83.38 4.17 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.7 t70 64.74 49.32 2.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.866 -177.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.01 -26.56 18.29 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.724 -0.75 . . . . 0.0 113.956 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.9 mt -91.98 119.93 68.09 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 117.51 0.655 . . . . 0.0 111.388 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 9.2 Cg_exo -71.28 39.01 0.34 Allowed 'Trans proline' 0 CA--C 1.531 0.334 0 C-N-CA 123.137 2.558 . . . . 0.0 112.447 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.43 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.1 m . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.901 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.648 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 96.7 m . . . . . 0 N--CA 1.451 -0.409 0 CA-C-O 120.7 0.286 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.19 92.81 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.398 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.49 ' HG2' ' H ' ' A' ' 11' ' ' ASN . 6.9 tp10 -150.5 143.64 24.85 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.056 0.455 . . . . 0.0 110.326 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -101.1 148.88 24.56 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.122 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.765 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -124.82 56.08 1.32 Allowed 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.478 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -53.83 -32.32 52.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.177 0.513 . . . . 0.0 109.802 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.32 42.42 1.36 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 178.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.6 34.39 89.78 Favored Glycine 0 C--N 1.336 0.537 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.014 -179.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 p -89.58 50.58 1.93 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.461 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -81.92 95.0 7.23 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.946 179.346 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.49 ' H ' ' HG2' ' A' ' 3' ' ' GLU . 40.8 m-80 -68.31 -37.1 80.26 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.235 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.787 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.9 m -69.02 124.93 91.45 Favored Pre-proline 0 N--CA 1.451 -0.423 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.732 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -63.04 135.61 52.12 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 123.163 2.575 . . . . 0.0 114.601 -178.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.74 21.48 79.65 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.675 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.787 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 63.8 m -91.89 127.09 37.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 117.008 0.404 . . . . 0.0 111.202 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.2 t -79.47 130.83 35.78 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.8 t -78.26 87.65 4.32 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.153 0.502 . . . . 0.0 112.064 -178.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -86.03 66.84 9.77 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 176.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.52 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -27.49 124.01 0.24 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.537 -1.665 . . . . 0.0 113.267 -176.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 91.4 Cg_endo -101.36 33.25 8.36 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.507 -1.456 . . . . 0.0 114.067 0.574 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.423 HD12 HG23 ' A' ' 21' ' ' ILE . 68.0 mt -129.34 134.22 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.983 -0.448 . . . . 0.0 111.585 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.765 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.5 m -77.91 133.8 38.02 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.6 p -122.05 139.97 53.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 112.474 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.648 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 1.3 mmm180 -91.71 106.08 18.21 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 176.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 55.41 34.26 22.6 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 123.917 0.761 . . . . 0.0 110.443 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.24 -16.65 58.94 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.946 -0.645 . . . . 0.0 113.782 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.425 ' C ' ' H ' ' A' ' 29' ' ' VAL . 95.0 mt -95.52 125.44 49.51 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 117.497 0.648 . . . . 0.0 111.104 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.09 37.42 0.26 Allowed 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 122.943 2.429 . . . . 0.0 113.231 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.425 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.7 m . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.617 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.504 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 38.2 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 121.051 0.453 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.21 37.38 94.46 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -149.89 150.2 31.56 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-O 121.018 0.437 . . . . 0.0 110.26 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.416 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 43.2 p -105.92 148.3 27.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.538 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.634 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -117.8 53.0 0.96 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.236 0.541 . . . . 0.0 110.696 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.416 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 6.7 m-85 -55.18 -35.42 64.79 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.598 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.58 20.31 42.3 Favored Glycine 0 N--CA 1.445 -0.71 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.94 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.84 46.84 64.45 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.947 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -148.71 141.28 24.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.67 0.271 . . . . 0.0 110.546 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.9 m -130.57 131.94 45.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.532 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -72.85 -32.55 65.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.906 0.384 . . . . 0.0 110.541 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.638 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.0 m -80.3 124.77 82.32 Favored Pre-proline 0 N--CA 1.451 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.742 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.2 Cg_exo -67.26 136.1 39.19 Favored 'Trans proline' 0 N--CA 1.464 -0.214 0 C-N-CA 122.877 2.385 . . . . 0.0 112.582 -179.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.01 -6.85 82.53 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.046 -0.597 . . . . 0.0 113.503 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.638 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 72.8 m -79.74 130.05 35.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.144 0.497 . . . . 0.0 111.703 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -83.31 139.53 33.0 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 18.6 t -83.51 91.56 7.43 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.154 0.502 . . . . 0.0 111.908 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.5 m -89.28 67.09 7.76 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.488 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.0 t90 -28.01 122.95 0.25 Allowed Pre-proline 0 C--O 1.231 0.117 0 CA-C-N 113.807 -1.542 . . . . 0.0 113.143 -176.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.488 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 90.4 Cg_endo -102.0 30.68 10.01 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.511 -1.454 . . . . 0.0 113.916 0.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.8 mt -125.29 133.25 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 O-C-N 121.955 -0.465 . . . . 0.0 111.517 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.634 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.0 m -79.29 134.61 36.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.687 0.279 . . . . 0.0 111.516 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 23.9 p -126.18 133.54 51.53 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.219 0.533 . . . . 0.0 112.142 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.504 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 10.0 ttp180 -106.93 122.0 45.54 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 64.56 24.57 13.07 Favored 'General case' 0 C--N 1.32 -0.69 0 O-C-N 123.718 0.636 . . . . 0.0 109.402 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.74 -0.7 89.17 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.276 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.407 ' C ' ' H ' ' A' ' 29' ' ' VAL . 80.0 mt -106.97 131.32 21.79 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.66 0.267 . . . . 0.0 110.324 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.62 39.87 0.45 Allowed 'Trans proline' 0 CA--C 1.531 0.34 0 C-N-CA 122.827 2.351 . . . . 0.0 112.439 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.407 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.3 m . . . . . 0 C--N 1.326 -0.423 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.967 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 81.1 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.884 0.373 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.5 37.92 94.23 Favored Glycine 0 C--N 1.333 0.361 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.749 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.12 142.42 24.23 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.414 HG23 HG12 ' A' ' 21' ' ' ILE . 21.2 p -111.07 143.87 41.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.04 0.448 . . . . 0.0 110.759 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.553 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -112.08 60.45 0.63 Allowed 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.827 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -56.98 -32.24 65.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.63 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.79 14.76 58.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.631 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.33 44.16 66.76 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.875 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.8 t -150.53 142.42 23.84 Favored 'General case' 0 N--CA 1.447 -0.582 0 O-C-N 122.845 -0.209 . . . . 0.0 110.544 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.553 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -135.64 131.78 36.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.179 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -82.88 -32.96 27.12 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.186 0.517 . . . . 0.0 109.706 178.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.402 HG23 ' SG ' ' A' ' 15' ' ' CYS . 4.6 m -66.31 120.35 69.44 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.812 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -65.08 141.19 68.87 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.929 2.42 . . . . 0.0 113.071 -179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.03 26.1 73.21 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.272 -0.876 . . . . 0.0 113.161 179.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.402 ' SG ' HG23 ' A' ' 12' ' ' THR . 90.8 m -116.8 121.84 42.7 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.078 0.466 . . . . 0.0 110.632 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -81.32 135.0 35.67 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.364 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.2 t -77.35 88.71 3.75 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.232 0.539 . . . . 0.0 111.832 -179.254 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.8 m -87.6 67.42 9.28 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -28.26 124.05 0.25 Allowed Pre-proline 0 N--CA 1.461 0.12 0 CA-C-N 113.772 -1.558 . . . . 0.0 113.144 -176.75 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.7 Cg_endo -101.1 34.37 7.7 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.53 -1.446 . . . . 0.0 113.997 0.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.414 HG12 HG23 ' A' ' 4' ' ' THR . 61.9 mt -130.33 133.08 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 O-C-N 121.935 -0.478 . . . . 0.0 111.754 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.498 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 35.0 m -78.05 127.75 32.8 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.149 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.1 p -119.46 146.49 45.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.582 0.706 . . . . 0.0 112.416 -178.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.1 tpp85 -92.44 81.35 4.88 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.8 t70 64.49 49.84 2.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.766 -177.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.81 -26.72 19.09 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.774 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.422 ' C ' ' H ' ' A' ' 29' ' ' VAL . 91.0 mt -91.1 118.8 68.77 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 117.404 0.602 . . . . 0.0 111.47 -179.365 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.15 39.74 0.41 Allowed 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 122.882 2.388 . . . . 0.0 112.431 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.422 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.2 m . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.894 -179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.578 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.0 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 120.869 0.366 . . . . 0.0 110.153 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.05 35.04 90.06 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.604 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -150.14 143.18 24.89 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.583 HG23 HG12 ' A' ' 21' ' ' ILE . 21.1 p -111.67 144.5 40.83 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.106 0.479 . . . . 0.0 110.86 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.516 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.0 p -113.27 62.19 0.64 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.849 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -56.93 -34.61 68.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.256 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -101.42 18.1 54.24 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.625 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.431 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 66.82 43.45 91.58 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.808 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.86 136.67 27.29 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.49 0.186 . . . . 0.0 111.047 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 59.7 m -133.17 129.58 38.01 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.945 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -84.9 -32.26 23.24 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.303 0.573 . . . . 0.0 109.567 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.9 m -66.44 122.55 82.29 Favored Pre-proline 0 N--CA 1.452 -0.354 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.948 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.51 141.12 59.87 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.783 2.322 . . . . 0.0 112.933 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.427 ' O ' ' HD3' ' A' ' 24' ' ' ARG . . . 72.83 27.83 68.19 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.887 179.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.42 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 85.6 m -118.5 116.99 27.82 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 121.113 0.482 . . . . 0.0 111.239 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.1 p -80.34 131.89 35.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 178.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.431 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.8 t -74.22 95.01 2.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.322 0.582 . . . . 0.0 112.076 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.4 m -91.95 67.22 5.16 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 176.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.0 t90 -27.19 122.68 0.24 Allowed Pre-proline 0 C--O 1.231 0.11 0 CA-C-N 113.703 -1.589 . . . . 0.0 113.213 -176.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 93.3 Cg_endo -101.78 35.74 6.52 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.024 0.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.583 HG12 HG23 ' A' ' 4' ' ' THR . 64.4 mt -130.74 133.19 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.952 -0.468 . . . . 0.0 111.695 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.485 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.4 m -78.2 131.6 37.23 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 80.7 p -129.28 154.69 46.58 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.586 0.588 . . . . 0.0 112.586 -178.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.578 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 22.7 mmt85 -89.59 69.63 7.84 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 177.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 26.4 t70 65.98 53.34 1.12 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.926 0.869 . . . . 0.0 109.257 -177.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.48 -30.29 10.24 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.309 -0.859 . . . . 0.0 113.004 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.421 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 85.4 mt -81.92 113.43 42.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 117.006 0.403 . . . . 0.0 111.483 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.4 Cg_exo -73.77 39.36 0.5 Allowed 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 123.139 2.559 . . . . 0.0 112.422 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 111.929 -179.64 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.471 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 58.5 m . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 59.44 37.78 92.55 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -139.28 144.76 38.51 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 115.314 -0.443 . . . . 0.0 110.346 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.417 HG21 HD13 ' A' ' 21' ' ' ILE . 82.0 p -108.41 151.16 26.4 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.077 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.934 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -131.99 58.8 1.73 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.152 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -52.88 -31.92 42.21 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.19 0.519 . . . . 0.0 109.873 178.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -137.81 37.31 1.84 Allowed Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 177.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.544 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.59 42.06 99.69 Favored Glycine 0 C--N 1.337 0.619 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.3 p -108.41 44.5 1.11 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.934 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.8 m -81.85 123.43 28.81 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.104 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.411 ' N ' HD21 ' A' ' 11' ' ' ASN . 1.6 m120 -70.79 -36.28 72.94 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.6 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.7 m -73.44 118.56 69.94 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.981 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -74.56 142.16 28.98 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.932 2.421 . . . . 0.0 112.698 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.96 -22.42 40.96 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.325 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.71 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 96.4 m -69.69 125.26 26.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 0.0 111.063 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -79.31 128.57 33.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.2 t -76.31 94.41 3.58 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.574 0.583 . . . . 0.0 112.574 -178.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.2 m -91.38 65.45 5.32 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.512 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -23.2 120.68 0.17 Allowed Pre-proline 0 N--CA 1.462 0.169 0 CA-C-N 113.389 -1.732 . . . . 0.0 113.75 -176.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.512 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.9 Cg_endo -101.8 29.04 11.66 Favored 'Cis proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.876 -1.302 . . . . 0.0 113.699 0.287 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.417 HD13 HG21 ' A' ' 4' ' ' THR . 35.0 mm -123.02 128.39 75.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 O-C-N 122.218 -0.302 . . . . 0.0 111.459 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.71 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.65 131.81 36.07 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.434 0.635 . . . . 0.0 111.607 178.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.5 p -117.87 140.06 50.24 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.863 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.471 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 17.9 tpt85 -93.11 103.08 15.4 Favored 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 59.46 36.31 23.06 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 124.032 0.832 . . . . 0.0 110.159 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.23 -15.78 62.62 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.345 179.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.457 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.1 mt -92.8 121.1 66.66 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 117.205 0.502 . . . . 0.0 111.148 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.9 Cg_exo -71.94 39.32 0.39 Allowed 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 123.118 2.545 . . . . 0.0 112.215 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.436 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.0 m . . . . . 0 C--N 1.326 -0.436 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.748 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.59 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 87.5 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.469 0.176 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.67 36.96 94.01 Favored Glycine 0 N--CA 1.449 -0.435 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.461 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -141.59 145.65 35.31 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 115.125 -0.537 . . . . 0.0 109.812 -178.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.4 p -118.02 144.48 45.53 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.555 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -117.97 55.65 0.87 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.045 0.45 . . . . 0.0 111.006 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -56.38 -34.16 66.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.309 178.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.85 20.09 42.27 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.885 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.49 43.88 75.44 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.352 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.9 t -150.41 143.67 24.96 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.555 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.9 m -135.15 129.23 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.208 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 59.3 m-80 -70.51 -39.57 74.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.896 0.379 . . . . 0.0 110.36 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.9 m -71.8 117.22 55.76 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.562 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -68.84 138.96 42.22 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 123.122 2.548 . . . . 0.0 112.846 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.78 -20.05 51.57 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.765 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 71.4 m -77.18 126.24 30.62 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.073 0.463 . . . . 0.0 111.353 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -81.07 135.94 35.88 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.0 t -77.78 94.84 4.55 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.291 0.567 . . . . 0.0 112.227 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 15.9 m -93.81 67.7 3.83 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 107.089 -1.449 . . . . 0.0 107.089 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.3 t90 -27.18 122.47 0.24 Allowed Pre-proline 0 N--CA 1.463 0.184 0 CA-C-N 113.75 -1.568 . . . . 0.0 113.219 -176.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.49 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.84 30.28 10.5 Favored 'Cis proline' 0 N--CA 1.455 -0.774 0 C-N-CA 123.564 -1.432 . . . . 0.0 114.01 0.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.57 132.6 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 O-C-N 122.051 -0.405 . . . . 0.0 111.682 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 29.4 m -79.72 128.41 33.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.764 0.316 . . . . 0.0 110.552 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.439 ' HB ' ' N ' ' A' ' 27' ' ' LEU . 47.0 p -117.43 137.41 52.52 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.078 0.466 . . . . 0.0 112.043 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.59 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.1 tpt85 -90.58 101.3 14.04 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 177.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 59.6 38.56 22.1 Favored 'General case' 0 C--N 1.328 -0.345 0 O-C-N 123.891 0.744 . . . . 0.0 111.207 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.5 32.54 24.7 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.156 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.716 ' HG ' HG13 ' A' ' 29' ' ' VAL . 24.3 tp -144.83 117.77 5.48 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.068 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.497 ' HD2' HD11 ' A' ' 27' ' ' LEU . 56.3 Cg_endo -70.8 44.49 0.51 Allowed 'Trans proline' 0 N--CA 1.475 0.396 0 C-N-CA 123.25 2.633 . . . . 0.0 114.059 -178.277 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.716 HG13 ' HG ' ' A' ' 27' ' ' LEU . 18.6 m . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 120.933 0.397 . . . . 0.0 111.082 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 94.4 m . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 120.427 0.156 . . . . 0.0 111.077 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.72 40.72 98.82 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -150.31 147.63 27.87 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.0 p -117.61 143.24 46.33 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.979 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.539 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -114.67 56.14 0.73 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.011 0.434 . . . . 0.0 111.4 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.65 -34.47 67.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.214 178.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.48 20.93 38.39 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.866 179.148 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.26 42.91 81.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.468 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 13.4 t -150.53 143.4 24.67 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.539 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 58.1 m -132.83 128.82 37.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.687 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -68.82 -44.87 72.6 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.8 m -64.91 117.5 39.51 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.732 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -71.1 142.57 42.38 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.84 2.36 . . . . 0.0 113.067 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.41 33.65 38.61 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.161 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.4 m -124.31 133.74 53.38 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.868 0.366 . . . . 0.0 110.797 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -84.06 135.14 34.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.458 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 14.5 t -81.43 95.28 7.01 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.258 0.552 . . . . 0.0 111.759 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 12.5 m -93.66 67.91 3.94 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.483 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.5 t90 -27.95 122.79 0.25 Allowed Pre-proline 0 C--O 1.232 0.138 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.176 -176.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.483 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.7 Cg_endo -101.61 30.26 10.72 Favored 'Cis proline' 0 N--CA 1.455 -0.759 0 C-N-CA 123.59 -1.421 . . . . 0.0 114.083 0.635 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.403 HG23 HD12 ' A' ' 21' ' ' ILE . 66.0 mt -125.94 132.64 70.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 O-C-N 122.007 -0.433 . . . . 0.0 111.511 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.438 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 29.7 m -80.64 127.67 32.74 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.876 0.37 . . . . 0.0 110.768 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.7 p -119.48 142.48 48.24 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.233 0.539 . . . . 0.0 111.56 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.592 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 31.3 ttt85 -99.47 106.28 18.3 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 58.96 34.96 23.91 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 123.89 0.744 . . . . 0.0 110.14 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.31 -17.01 60.13 Favored Glycine 0 CA--C 1.52 0.403 0 CA-C-N 115.712 -0.676 . . . . 0.0 113.489 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.4 mt -93.84 122.59 61.84 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.213 0.507 . . . . 0.0 111.32 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.8 Cg_exo -72.16 39.09 0.39 Allowed 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 123.074 2.516 . . . . 0.0 112.343 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.418 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.1 m . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.667 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.486 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.6 m . . . . . 0 N--CA 1.448 -0.534 0 CA-C-O 120.527 0.203 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.55 37.96 95.57 Favored Glycine 0 C--N 1.333 0.378 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 -178.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.531 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.6 tp10 -144.56 142.88 30.5 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.167 -0.516 . . . . 0.0 109.678 -178.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.9 p -116.17 144.49 44.11 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.915 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.525 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.4 p -118.48 56.7 0.87 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -55.79 -35.18 66.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.474 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.17 20.87 36.96 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.966 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.07 44.54 66.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.202 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.6 m -147.63 135.75 21.36 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.525 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 62.8 m -127.95 126.18 40.94 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.181 0.3 . . . . 0.0 110.355 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -66.4 -43.62 85.32 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.2 m -71.63 117.18 55.1 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.487 179.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_exo -70.13 139.16 38.31 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.978 2.452 . . . . 0.0 112.825 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.89 -23.53 35.62 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.655 179.54 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.5 m -73.7 127.68 33.44 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.071 0.462 . . . . 0.0 111.462 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.8 t -79.93 134.77 36.3 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.5 t -77.86 93.88 4.44 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.301 0.572 . . . . 0.0 112.274 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.8 m -92.38 67.98 4.89 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 176.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 6.2 t90 -27.4 122.82 0.24 Allowed Pre-proline 0 N--CA 1.463 0.175 0 CA-C-N 113.861 -1.518 . . . . 0.0 113.305 -176.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -101.69 30.55 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.516 -1.452 . . . . 0.0 114.047 0.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.6 mt -126.53 132.57 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 120.973 0.416 . . . . 0.0 111.487 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.531 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.5 m -79.62 128.79 33.83 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.805 0.336 . . . . 0.0 110.389 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -122.96 146.36 47.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.978 0.418 . . . . 0.0 112.003 -178.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.486 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 3.4 mmm-85 -91.25 95.54 10.09 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 177.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.97 37.35 21.44 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 123.928 0.768 . . . . 0.0 110.104 -178.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.15 -18.81 56.12 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.721 -0.672 . . . . 0.0 113.338 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 20.5 tp -89.53 113.82 58.13 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.157 0.478 . . . . 0.0 110.559 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 8.0 Cg_exo -73.14 46.74 1.18 Allowed 'Trans proline' 0 CA--C 1.531 0.36 0 C-N-CA 123.431 2.754 . . . . 0.0 113.59 -178.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.418 HG13 ' HG ' ' A' ' 27' ' ' LEU . 24.5 m . . . . . 0 C--N 1.325 -0.466 0 CA-C-O 121.085 0.469 . . . . 0.0 111.199 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.8 m . . . . . 0 N--CA 1.45 -0.434 0 CA-C-O 121.012 0.434 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 36.77 92.29 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.373 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -150.31 151.38 32.84 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.935 0.398 . . . . 0.0 110.129 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 38.7 p -110.3 146.69 35.27 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.952 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.541 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 28.2 p -115.12 54.82 0.78 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.135 0.493 . . . . 0.0 110.64 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -55.22 -35.42 64.9 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.68 179.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.11 19.56 45.88 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.91 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.1 46.16 67.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.975 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -149.78 142.36 24.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.629 0.252 . . . . 0.0 110.524 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.541 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 65.6 m -136.02 128.34 30.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.182 -179.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.5 p30 -77.61 -28.26 51.45 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.864 0.364 . . . . 0.0 110.404 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.99 123.42 89.29 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.497 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -69.51 136.12 32.83 Favored 'Trans proline' 0 N--CA 1.464 -0.221 0 C-N-CA 122.614 2.209 . . . . 0.0 113.114 -179.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.38 66.42 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.878 179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.1 m -112.71 128.05 56.3 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.065 0.459 . . . . 0.0 111.09 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.3 t -84.44 141.59 30.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.229 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.5 t -83.29 95.28 8.13 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.199 0.523 . . . . 0.0 111.995 -179.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.9 m -92.67 66.71 4.47 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.9 t90 -27.71 123.0 0.24 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.177 -176.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.8 Cg_endo -101.55 31.89 9.35 Favored 'Cis proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.497 -1.46 . . . . 0.0 114.039 0.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.6 mt -126.45 134.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 O-C-N 121.994 -0.441 . . . . 0.0 111.648 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.489 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -79.3 132.58 36.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.712 0.291 . . . . 0.0 110.85 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.5 p -128.31 136.61 51.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 111.37 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.5 ttt-85 -95.3 107.01 19.1 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 60.28 34.89 20.86 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 123.731 0.644 . . . . 0.0 110.067 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.62 -13.39 67.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.183 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.706 ' HB3' HG21 ' A' ' 29' ' ' VAL . 90.9 mt -94.11 118.68 67.19 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 117.159 0.479 . . . . 0.0 111.097 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -72.82 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.066 2.511 . . . . 0.0 112.512 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.706 HG21 ' HB3' ' A' ' 27' ' ' LEU . 3.2 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-O 121.348 0.595 . . . . 0.0 110.732 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.483 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 80.8 m . . . . . 0 N--CA 1.449 -0.522 0 CA-C-O 120.73 0.3 . . . . 0.0 110.593 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 41.13 97.21 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -146.87 145.19 29.76 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.958 0.409 . . . . 0.0 110.13 -179.213 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -114.02 144.35 43.25 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.767 178.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.495 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 27.6 p -118.38 55.36 0.9 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.052 0.453 . . . . 0.0 111.289 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -56.62 -33.74 66.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.313 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.77 20.48 38.84 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.889 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.16 44.85 74.6 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.386 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.0 t -150.19 142.79 24.52 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.586 0.231 . . . . 0.0 110.541 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.485 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 56.0 m -134.52 131.01 37.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.254 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -66.7 -35.02 79.14 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.93 0.395 . . . . 0.0 110.382 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -80.89 117.23 67.1 Favored Pre-proline 0 N--CA 1.45 -0.442 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.977 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.69 136.87 28.91 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.71 2.274 . . . . 0.0 112.157 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.07 -27.23 21.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.655 -0.783 . . . . 0.0 111.999 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.3 m -72.54 127.81 33.68 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.989 0.423 . . . . 0.0 110.952 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -79.93 134.84 36.3 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.403 179.366 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.6 t -77.85 93.47 4.37 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.268 0.556 . . . . 0.0 111.727 -179.292 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.5 m -90.97 68.05 6.13 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.5 t90 -27.75 122.98 0.25 Allowed Pre-proline 0 N--CA 1.463 0.194 0 CA-C-N 113.932 -1.485 . . . . 0.0 113.268 -176.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.67 30.57 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.589 -1.421 . . . . 0.0 113.972 0.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.5 mt -126.86 132.52 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 O-C-N 122.058 -0.401 . . . . 0.0 111.567 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.495 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 28.6 m -79.35 128.96 33.98 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.823 0.344 . . . . 0.0 110.689 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -121.28 144.05 48.84 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.277 0.56 . . . . 0.0 111.393 -179.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.483 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 59.9 ttp180 -95.59 84.1 3.9 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.1 t70 67.27 49.95 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 O-C-N 124.248 0.968 . . . . 0.0 109.631 -177.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.29 -24.9 20.13 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.925 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.436 ' C ' ' H ' ' A' ' 29' ' ' VAL . 87.4 mt -92.14 116.02 65.72 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 117.378 0.589 . . . . 0.0 111.547 -179.268 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -73.21 39.02 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.005 2.47 . . . . 0.0 112.196 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.436 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.5 m . . . . . 0 C--N 1.324 -0.503 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.61 -179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 82.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 120.67 0.271 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 34.32 87.86 Favored Glycine 0 N--CA 1.451 -0.33 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -178.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.461 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -134.0 145.16 49.23 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.9 -0.65 . . . . 0.0 109.959 -179.034 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.441 HG21 HD12 ' A' ' 21' ' ' ILE . 65.0 p -114.17 146.03 40.88 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.614 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.58 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 27.9 p -124.21 54.07 1.38 Allowed 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.15 0.5 . . . . 0.0 110.854 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -56.43 -33.3 65.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.387 179.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.53 19.87 41.05 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.807 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.42 45.03 70.86 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.324 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.9 t -150.11 142.8 24.6 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.542 0.21 . . . . 0.0 110.591 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.475 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 46.4 m -134.34 127.75 32.32 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.025 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -72.04 -34.55 68.86 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.931 0.396 . . . . 0.0 110.232 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.5 m -72.47 118.24 65.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.483 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.85 135.45 32.7 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.638 2.225 . . . . 0.0 112.864 -179.472 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.66 -22.5 39.98 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 76.9 m -78.12 121.59 24.5 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.085 0.469 . . . . 0.0 111.014 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.5 t -82.59 138.16 34.31 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.29 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 26.6 t -74.49 113.81 12.16 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.469 0.652 . . . . 0.0 111.941 -179.219 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.0 m -113.13 66.12 0.65 Allowed 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 177.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.517 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.1 t90 -23.55 120.36 0.18 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 113.489 -1.687 . . . . 0.0 113.665 -176.584 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.517 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 76.0 Cg_endo -101.96 25.62 14.53 Favored 'Cis proline' 0 N--CA 1.456 -0.729 0 C-N-CA 123.668 -1.388 . . . . 0.0 113.784 0.432 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.441 HD12 HG21 ' A' ' 4' ' ' THR . 41.4 mm -119.74 132.77 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-O 120.729 0.299 . . . . 0.0 111.628 -179.063 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.58 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.0 m -81.4 128.28 33.69 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.3 p -115.79 145.78 42.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.222 0.534 . . . . 0.0 111.532 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.9 tpt85 -89.7 85.24 6.4 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 62.58 43.14 7.86 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.2 -177.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.99 -23.68 34.71 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.702 -0.761 . . . . 0.0 113.616 179.301 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.553 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.3 tp -92.6 111.6 51.66 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 117.355 0.578 . . . . 0.0 110.617 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.449 ' HD2' HD12 ' A' ' 27' ' ' LEU . 60.4 Cg_endo -72.86 47.38 1.22 Allowed 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 123.184 2.589 . . . . 0.0 113.817 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.553 HG13 ' HG ' ' A' ' 27' ' ' LEU . 30.3 m . . . . . 0 C--N 1.324 -0.511 0 CA-C-O 120.87 0.367 . . . . 0.0 111.416 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.612 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 52.5 m . . . . . 0 N--CA 1.448 -0.573 0 CA-C-O 120.402 0.144 . . . . 0.0 111.148 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.32 37.74 94.24 Favored Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -178.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.467 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.1 tp10 -140.91 145.85 36.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.142 -0.529 . . . . 0.0 109.858 -179.032 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 64.4 p -115.6 146.73 41.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.784 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.536 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.1 p -125.02 55.58 1.36 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.239 0.543 . . . . 0.0 110.715 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -57.05 -33.0 66.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.271 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.98 18.89 48.35 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.73 -0.747 . . . . 0.0 111.657 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.57 42.77 79.69 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.045 -0.597 . . . . 0.0 112.298 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.6 t -150.62 143.77 24.82 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 110.452 -0.203 . . . . 0.0 110.452 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.474 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 39.6 m -132.1 129.5 40.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -70.69 -35.45 72.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.978 0.418 . . . . 0.0 110.344 179.72 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 10.6 m -76.66 116.6 58.07 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.792 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.17 139.6 46.79 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.948 2.432 . . . . 0.0 112.489 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.05 -27.37 20.33 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.015 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.0 m -76.34 125.63 29.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.094 0.473 . . . . 0.0 110.967 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.8 m -85.99 134.81 33.84 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.71 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 27.2 t -73.49 116.18 13.75 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.339 0.59 . . . . 0.0 111.873 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.8 m -115.96 66.87 0.71 Allowed 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.57 -1.641 . . . . 0.0 106.57 177.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.504 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.8 t90 -23.51 119.48 0.18 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.518 -1.674 . . . . 0.0 113.643 -176.555 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 75.5 Cg_endo -102.7 26.7 12.49 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.855 0.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 38.6 mm -120.33 133.73 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 111.624 -179.07 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 40.6 m -82.31 126.06 31.7 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 178.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -113.19 150.84 31.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.529 0.68 . . . . 0.0 111.71 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.612 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.5 ttm180 -103.72 86.65 2.65 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.118 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.7 t0 66.52 49.51 1.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 O-C-N 124.245 0.965 . . . . 0.0 109.509 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.82 -25.01 12.51 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.773 179.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.417 ' C ' ' H ' ' A' ' 29' ' ' VAL . 88.8 mt -88.92 117.9 68.73 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 117.316 0.558 . . . . 0.0 111.547 -179.267 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -73.96 38.71 0.48 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.027 2.485 . . . . 0.0 112.269 179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.417 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.3 m . . . . . 0 C--N 1.325 -0.491 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.617 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.0 m . . . . . 0 N--CA 1.45 -0.468 0 CA-C-O 120.644 0.259 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.75 38.71 94.72 Favored Glycine 0 N--CA 1.451 -0.345 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -178.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.465 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -141.88 147.18 36.71 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.797 -178.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.2 p -118.46 145.66 45.08 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.973 0.416 . . . . 0.0 110.752 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.2 p -120.69 56.49 1.0 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.006 0.431 . . . . 0.0 111.028 -179.691 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.61 -34.02 66.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.29 179.018 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.49 20.23 40.19 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.82 179.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.5 43.61 76.63 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.339 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.7 t -150.22 142.88 24.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.461 0.172 . . . . 0.0 110.565 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.6 m -132.71 128.74 37.58 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.037 -179.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.3 m-80 -69.67 -34.58 74.17 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.021 0.439 . . . . 0.0 110.021 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.1 m -75.27 115.66 47.21 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.362 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -70.3 136.18 30.94 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.92 2.413 . . . . 0.0 112.472 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.45 -24.23 32.84 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.454 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -77.72 130.47 36.8 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.151 0.5 . . . . 0.0 111.219 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.1 t -84.77 137.52 33.15 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.468 179.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 25.0 t -77.16 112.62 14.02 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.301 0.572 . . . . 0.0 111.739 -179.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.7 m -111.25 67.6 0.65 Allowed 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 177.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.485 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.0 t90 -26.33 122.53 0.22 Allowed Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 113.776 -1.556 . . . . 0.0 113.344 -176.602 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.5 Cg_endo -101.36 28.84 12.35 Favored 'Cis proline' 0 N--CA 1.454 -0.804 0 C-N-CA 123.6 -1.417 . . . . 0.0 114.086 0.534 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 61.3 mt -127.55 134.71 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 O-C-N 121.997 -0.439 . . . . 0.0 111.538 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 31.4 m -79.87 130.41 35.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.908 0.385 . . . . 0.0 110.43 179.442 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.478 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 54.4 p -121.48 157.95 29.49 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.215 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.407 ' HA ' ' HD2' ' A' ' 24' ' ' ARG . 13.9 tpt85 -87.99 58.33 4.76 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.264 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 64.45 45.88 3.56 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.955 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 142.43 -47.94 0.8 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.385 -0.912 . . . . 0.0 113.479 178.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 99.0 mt -108.93 127.87 26.52 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 122.553 -0.38 . . . . 0.0 111.777 -179.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.8 Cg_endo -75.6 39.03 0.6 Allowed 'Trans proline' 0 CA--C 1.528 0.22 0 C-N-CA 123.209 2.606 . . . . 0.0 112.47 179.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 -179.642 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 60.9 m . . . . . 0 N--CA 1.448 -0.542 0 CA-C-O 120.695 0.283 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.52 45.01 96.76 Favored Glycine 0 C--N 1.335 0.479 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.437 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -150.16 149.86 30.83 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.958 0.408 . . . . 0.0 110.698 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.529 HG21 HD11 ' A' ' 21' ' ' ILE . 42.4 p -123.41 142.85 50.56 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.61 178.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 29.3 p -105.34 57.32 0.68 Allowed 'General case' 0 C--N 1.315 -0.923 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.688 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -56.59 -33.54 66.32 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -106.02 23.36 29.34 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.61 178.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 66.92 37.33 92.11 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 121.197 -0.525 . . . . 0.0 113.082 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.4 t -151.06 142.61 23.55 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.717 0.294 . . . . 0.0 111.371 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.746 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.8 m -122.54 132.44 54.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.634 179.371 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -64.68 -34.56 78.59 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.921 0.391 . . . . 0.0 110.394 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.4 m -79.71 115.74 55.89 Favored Pre-proline 0 N--CA 1.45 -0.465 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.717 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.97 135.8 26.1 Favored 'Trans proline' 0 N--CA 1.462 -0.349 0 C-N-CA 122.516 2.144 . . . . 0.0 112.37 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.03 -26.65 23.89 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.071 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.8 m -71.65 125.82 28.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.974 0.416 . . . . 0.0 111.234 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -89.58 121.21 31.56 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.822 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 19.6 t -86.86 116.95 25.28 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 113.464 0.912 . . . . 0.0 113.464 -177.17 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.9 m -88.72 72.64 8.62 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 174.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 12.7 t90 -21.56 122.25 0.12 Allowed Pre-proline 0 N--CA 1.468 0.433 0 CA-C-N 113.889 -1.505 . . . . 0.0 113.834 -175.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 88.8 Cg_endo -101.78 31.31 9.65 Favored 'Cis proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.228 0.502 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.529 HD11 HG21 ' A' ' 4' ' ' THR . 43.8 mm -116.52 120.54 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.236 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.822 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 28.8 m -74.67 130.2 39.09 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 37.2 p -131.04 139.67 49.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.124 0.488 . . . . 0.0 111.876 -178.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 5.6 tmm_? -96.7 102.22 13.97 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 59.41 40.4 20.9 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 123.807 0.692 . . . . 0.0 110.302 -177.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.25 -15.68 60.58 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.557 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.416 ' C ' ' H ' ' A' ' 29' ' ' VAL . 90.5 mt -91.61 118.93 68.63 Favored Pre-proline 0 C--N 1.327 -0.396 0 CA-C-N 117.232 0.516 . . . . 0.0 111.5 -179.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -74.82 38.82 0.54 Allowed 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 123.081 2.521 . . . . 0.0 112.049 179.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.416 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.0 m . . . . . 0 C--N 1.324 -0.525 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.818 -179.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.451 -0.402 0 CA-C-O 120.664 0.269 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.65 37.67 95.16 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -143.29 141.48 31.03 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.7 p -111.88 146.86 36.99 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.036 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.796 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 23.2 p -122.69 57.94 1.09 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -56.09 -36.05 67.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.127 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.56 20.56 43.91 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.684 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.08 40.22 88.45 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.351 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.2 t -151.19 142.92 23.74 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.555 -0.165 . . . . 0.0 110.555 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.796 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -139.06 137.5 36.29 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.8 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -67.24 -41.29 85.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.518 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.2 m -70.67 114.41 26.36 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.409 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.89 137.93 27.73 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.058 2.505 . . . . 0.0 112.449 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.8 -25.25 28.62 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.301 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.686 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 91.2 m -71.04 127.79 33.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.022 0.439 . . . . 0.0 111.272 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -79.64 126.7 31.25 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.8 t -73.88 96.89 2.67 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.488 0.661 . . . . 0.0 112.191 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.7 m -94.11 68.15 3.69 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.102 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.524 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.2 t90 -25.7 122.26 0.22 Allowed Pre-proline 0 N--CA 1.463 0.22 0 CA-C-N 113.918 -1.492 . . . . 0.0 113.313 -176.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.524 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.7 Cg_endo -101.55 30.31 10.72 Favored 'Cis proline' 0 N--CA 1.456 -0.71 0 C-N-CA 123.606 -1.414 . . . . 0.0 114.159 0.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 67.6 mt -131.26 131.83 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.954 -0.466 . . . . 0.0 111.341 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.686 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -79.4 134.97 36.57 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.306 0.574 . . . . 0.0 111.982 179.587 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 70.6 p -120.9 149.51 42.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.076 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.492 ' HG2' ' OD1' ' A' ' 25' ' ' ASP . 17.0 ttt-85 -88.17 94.86 9.95 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.672 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.492 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 1.1 p-10 46.38 42.78 11.03 Favored 'General case' 0 N--CA 1.469 0.483 0 O-C-N 124.334 1.022 . . . . 0.0 111.434 -177.163 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.57 -22.18 29.0 Favored Glycine 0 C--N 1.335 0.49 0 CA-C-N 115.52 -0.763 . . . . 0.0 113.865 178.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.748 ' HG ' HG12 ' A' ' 29' ' ' VAL . 20.6 tp -93.45 113.82 61.22 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 117.256 0.528 . . . . 0.0 111.015 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 11.2 Cg_exo -71.59 48.26 1.0 Allowed 'Trans proline' 0 CA--C 1.533 0.431 0 C-N-CA 123.498 2.799 . . . . 0.0 113.772 -179.236 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.748 HG12 ' HG ' ' A' ' 27' ' ' LEU . 31.1 m . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 121.004 0.431 . . . . 0.0 111.257 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.1 m . . . . . 0 N--CA 1.449 -0.492 0 CA-C-O 120.786 0.327 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.51 37.8 94.74 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.543 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -144.25 143.88 31.24 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 45.2 p -105.75 153.63 21.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.701 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.898 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 22.2 p -131.67 56.97 1.79 Allowed 'General case' 0 C--N 1.321 -0.643 0 O-C-N 122.269 -0.27 . . . . 0.0 110.95 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -52.01 -35.99 48.58 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.215 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.23 31.65 3.98 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 178.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.514 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.99 48.36 83.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.143 -0.551 . . . . 0.0 111.823 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.6 m -130.7 69.27 1.46 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 111.975 0.361 . . . . 0.0 111.975 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.898 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 92.6 m -90.88 130.98 36.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.763 0.316 . . . . 0.0 111.18 179.515 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.8 p-10 -64.51 -35.12 79.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.935 -179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.444 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 18.1 m -85.01 114.68 57.27 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.196 -179.127 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 8.0 Cg_exo -71.94 139.73 33.65 Favored 'Trans proline' 0 N--CA 1.462 -0.341 0 C-N-CA 123.111 2.541 . . . . 0.0 111.932 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.02 -25.93 26.11 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.079 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.689 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 97.6 m -67.05 128.34 35.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.839 0.352 . . . . 0.0 110.744 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.7 m -78.87 123.5 27.3 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.6 t -72.6 98.83 2.41 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.362 0.601 . . . . 0.0 112.232 -178.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 9.0 m -94.49 68.38 3.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.6 t90 -25.18 121.06 0.21 Allowed Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.355 -176.464 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.5 Cg_endo -102.76 33.6 7.5 Favored 'Cis proline' 0 N--CA 1.455 -0.764 0 C-N-CA 123.69 -1.379 . . . . 0.0 114.153 0.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 67.9 mt -132.23 132.99 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 O-C-N 121.992 -0.442 . . . . 0.0 111.576 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.689 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.58 134.93 36.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.34 0.59 . . . . 0.0 112.474 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 42.5 p -123.0 143.82 49.67 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.651 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 2.3 mmm-85 -95.25 101.9 13.67 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 60.03 36.14 21.42 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 123.944 0.778 . . . . 0.0 110.006 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.56 -14.49 65.16 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.623 -0.717 . . . . 0.0 113.192 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.734 ' HG ' HG12 ' A' ' 29' ' ' VAL . 21.6 tp -92.96 116.35 66.37 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 117.067 0.433 . . . . 0.0 110.273 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.7 45.61 0.73 Allowed 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 123.122 2.548 . . . . 0.0 113.83 -178.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.734 HG12 ' HG ' ' A' ' 27' ' ' LEU . 16.0 m . . . . . 0 C--N 1.326 -0.421 0 CA-C-O 120.928 0.394 . . . . 0.0 111.465 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 N--CA 1.448 -0.538 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.11 34.32 87.56 Favored Glycine 0 C--N 1.333 0.387 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.791 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -140.53 134.21 30.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 77.8 p -96.21 146.19 24.91 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.429 -178.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -120.65 58.48 0.94 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.204 179.217 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -55.92 -34.66 65.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.48 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.77 17.33 56.6 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.485 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.451 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 67.81 41.57 88.32 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 121.144 -0.55 . . . . 0.0 111.946 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.3 t -151.47 144.92 24.84 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.077 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 30.2 m -146.62 140.8 26.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.9 m-80 -73.23 -35.24 66.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.569 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.416 HG23 ' SG ' ' A' ' 15' ' ' CYS . 4.4 m -66.78 115.24 22.76 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.842 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.86 134.48 27.87 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.654 2.236 . . . . 0.0 112.837 -179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.61 -18.53 57.16 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.69 -0.767 . . . . 0.0 113.001 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.554 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 94.9 m -77.41 120.63 22.67 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.179 0.514 . . . . 0.0 111.016 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -79.41 131.27 36.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.451 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 32.9 t -75.52 92.73 2.91 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.338 0.59 . . . . 0.0 112.24 -178.466 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.0 m -89.58 66.74 7.35 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -25.22 121.33 0.21 Allowed Pre-proline 0 C--O 1.232 0.168 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.68 -176.543 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 85.4 Cg_endo -101.75 26.31 14.26 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.59 -1.421 . . . . 0.0 113.787 0.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.417 HG22 HD13 ' A' ' 21' ' ' ILE . 35.9 mm -120.56 127.87 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 O-C-N 122.257 -0.277 . . . . 0.0 111.424 -179.208 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.554 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 13.0 m -79.78 130.36 35.26 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.254 0.55 . . . . 0.0 111.35 179.062 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 69.0 p -118.59 140.6 49.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.723 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 35.8 tpt85 -89.66 92.14 8.95 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 61.04 40.61 14.92 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 124.028 0.83 . . . . 0.0 110.48 -178.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.75 -22.89 35.63 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 113.841 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.437 ' C ' ' H ' ' A' ' 29' ' ' VAL . 87.9 mt -93.86 117.45 67.23 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 117.381 0.59 . . . . 0.0 111.589 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.85 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.924 2.416 . . . . 0.0 112.266 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.437 ' H ' ' C ' ' A' ' 27' ' ' LEU . 26.9 m . . . . . 0 C--N 1.326 -0.451 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.875 -179.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 N--CA 1.45 -0.47 0 CA-C-O 120.86 0.362 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.42 40.38 97.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.887 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -147.44 142.09 26.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.976 0.417 . . . . 0.0 110.19 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.615 HG21 HG12 ' A' ' 21' ' ' ILE . 41.7 p -107.36 146.79 31.16 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.694 179.581 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.781 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 21.4 p -122.38 56.82 1.1 Allowed 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.989 0.423 . . . . 0.0 110.757 179.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -55.99 -36.77 68.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.252 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.91 21.31 40.71 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.516 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.7 40.71 90.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.183 -0.532 . . . . 0.0 112.408 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.2 t -150.78 142.92 24.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.781 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 89.4 m -137.49 137.58 38.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.744 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -64.44 -35.67 81.66 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.1 m -76.89 113.77 33.18 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.709 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.52 136.02 27.6 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.539 2.159 . . . . 0.0 112.376 -179.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.64 -19.32 54.83 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.502 -0.856 . . . . 0.0 113.037 179.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 68.6 m -74.65 131.7 41.11 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 117.287 0.543 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.1 m -81.96 119.36 23.86 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.743 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 10.4 t -68.76 112.41 5.47 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.433 0.635 . . . . 0.0 111.775 -178.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.8 m -109.06 69.61 0.71 Allowed 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -25.19 122.1 0.21 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.352 -176.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.4 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 83.7 Cg_endo -101.57 31.22 9.88 Favored 'Cis proline' 0 N--CA 1.455 -0.739 0 C-N-CA 123.541 -1.441 . . . . 0.0 114.277 0.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.615 HG12 HG21 ' A' ' 4' ' ' THR . 64.4 mt -135.7 134.19 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 O-C-N 121.97 -0.456 . . . . 0.0 111.436 -179.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.503 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -76.77 137.02 39.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.14 0.495 . . . . 0.0 111.491 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.4 p -128.99 158.84 37.74 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.939 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.01 55.0 3.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 178.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 65.12 43.1 3.8 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.872 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 148.63 -45.77 0.71 Allowed Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.325 -0.941 . . . . 0.0 113.263 179.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 98.1 mt -114.96 129.86 24.69 Favored Pre-proline 0 C--N 1.327 -0.383 0 O-C-N 122.509 -0.407 . . . . 0.0 111.686 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.6 Cg_endo -75.39 39.92 0.65 Allowed 'Trans proline' 0 CA--C 1.53 0.279 0 C-N-CA 123.247 2.631 . . . . 0.0 112.506 179.606 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.6 m . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.034 -179.656 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.9 m . . . . . 0 N--CA 1.448 -0.546 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.98 39.1 96.57 Favored Glycine 0 C--N 1.335 0.495 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.864 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -147.74 152.29 37.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.769 0.318 . . . . 0.0 110.388 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.402 HG22 HG12 ' A' ' 21' ' ' ILE . 22.7 p -122.45 146.0 47.78 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.506 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.496 ' HB2' ' N ' ' A' ' 9' ' ' THR . 21.6 p -107.63 60.35 0.62 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.135 0.493 . . . . 0.0 111.028 -179.625 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -56.17 -30.24 61.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.101 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.55 17.38 46.66 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.789 -0.719 . . . . 0.0 111.564 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 39.82 86.93 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.558 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.496 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.2 m -150.92 137.27 18.57 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 122.581 -0.364 . . . . 0.0 111.087 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.721 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 57.8 m -125.15 129.95 51.19 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 178.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -77.0 -34.11 57.53 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.041 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.439 HG21 ' SG ' ' A' ' 15' ' ' CYS . 6.4 m -63.96 119.18 52.82 Favored Pre-proline 0 C--O 1.236 0.361 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.599 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.88 135.89 36.69 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.952 2.435 . . . . 0.0 113.801 -178.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.22 17.07 78.74 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.465 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.439 ' SG ' HG21 ' A' ' 12' ' ' THR . 55.9 m -105.33 121.36 43.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 117.141 0.471 . . . . 0.0 111.078 179.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.7 m -90.23 117.71 29.19 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 107.305 -1.368 . . . . 0.0 107.305 178.089 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.842 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 17.9 t -81.6 118.34 22.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 113.491 0.922 . . . . 0.0 113.491 -176.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.8 m -92.34 73.35 5.3 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 104.964 -2.235 . . . . 0.0 104.964 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.415 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -23.04 125.59 0.12 Allowed Pre-proline 0 N--CA 1.467 0.42 0 CA-C-N 113.767 -1.561 . . . . 0.0 113.661 -175.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 94.6 Cg_endo -100.52 33.53 8.56 Favored 'Cis proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.332 -1.528 . . . . 0.0 114.449 0.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.402 HG12 HG22 ' A' ' 4' ' ' THR . 66.4 mt -124.58 125.83 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 O-C-N 121.865 -0.522 . . . . 0.0 112.097 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.842 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 14.0 m -72.1 129.11 37.73 Favored 'General case' 0 C--O 1.233 0.212 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.439 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.448 HG23 ' HA ' ' A' ' 28' ' ' PRO . 20.0 p -128.79 138.11 51.9 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.127 0.489 . . . . 0.0 111.844 -178.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.99 104.97 16.85 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.24 37.38 23.76 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.434 0.635 . . . . 0.0 110.043 -178.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.65 -11.45 70.18 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.522 -0.763 . . . . 0.0 113.447 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.409 ' C ' ' H ' ' A' ' 29' ' ' VAL . 93.1 mt -94.44 123.58 58.05 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 117.2 0.5 . . . . 0.0 111.202 -179.741 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.448 ' HA ' HG23 ' A' ' 23' ' ' THR . 6.2 Cg_exo -73.39 39.99 0.51 Allowed 'Trans proline' 0 CA--C 1.53 0.302 0 C-N-CA 123.072 2.515 . . . . 0.0 112.038 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.409 ' H ' ' C ' ' A' ' 27' ' ' LEU . 27.3 m . . . . . 0 C--N 1.326 -0.425 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.895 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 121.135 0.493 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.26 34.63 90.42 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.511 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -145.34 136.83 25.18 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-O 120.934 0.397 . . . . 0.0 110.026 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.582 HG22 HG12 ' A' ' 21' ' ' ILE . 36.7 p -99.41 143.57 29.51 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.164 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.61 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -115.36 60.45 0.7 Allowed 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.412 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -55.97 -34.91 66.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.494 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.52 16.95 57.36 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.593 178.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.422 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 68.13 40.82 88.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.877 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.6 t -151.55 146.46 25.89 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 121.272 -0.171 . . . . 0.0 110.685 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.61 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 18.8 m -145.69 138.74 26.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.015 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -74.01 -42.58 60.15 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.311 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.1 m -62.15 118.15 36.83 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.723 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -68.43 147.55 71.47 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 123.056 2.504 . . . . 0.0 113.528 -178.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.6 25.78 71.44 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.133 -0.939 . . . . 0.0 113.53 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.753 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 89.5 m -114.2 122.49 46.96 Favored 'General case' 0 N--CA 1.444 -0.765 0 O-C-N 122.288 -0.536 . . . . 0.0 110.665 179.257 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -79.44 127.55 32.25 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.422 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.6 t -74.93 90.22 2.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.333 0.587 . . . . 0.0 112.107 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.1 m -88.5 68.06 8.69 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 177.007 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -26.44 123.54 0.22 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.896 -1.502 . . . . 0.0 113.317 -176.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.439 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 80.4 Cg_endo -101.04 30.76 10.71 Favored 'Cis proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.51 -1.454 . . . . 0.0 114.092 0.675 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.582 HG12 HG22 ' A' ' 4' ' ' THR . 65.5 mt -131.12 131.31 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 O-C-N 122.029 -0.419 . . . . 0.0 111.358 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.753 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 37.9 m -79.08 132.45 36.61 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.312 0.577 . . . . 0.0 111.709 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -116.22 147.14 41.76 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.842 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.7 tpp85 -94.39 83.38 4.17 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.7 t70 64.74 49.32 2.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.866 -177.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.01 -26.56 18.29 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.724 -0.75 . . . . 0.0 113.956 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.467 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.9 mt -91.98 119.93 68.09 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 117.51 0.655 . . . . 0.0 111.388 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 9.2 Cg_exo -71.28 39.01 0.34 Allowed 'Trans proline' 0 CA--C 1.531 0.334 0 C-N-CA 123.137 2.558 . . . . 0.0 112.447 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.901 -179.665 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.647 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 96.7 m . . . . . 0 N--CA 1.451 -0.409 0 CA-C-O 120.7 0.286 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.19 92.81 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.398 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.546 ' HG2' ' H ' ' A' ' 11' ' ' ASN . 6.9 tp10 -150.5 143.64 24.85 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.056 0.455 . . . . 0.0 110.326 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -101.1 148.88 24.56 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.122 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.765 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -124.82 56.08 1.32 Allowed 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.478 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -53.83 -32.32 52.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.177 0.513 . . . . 0.0 109.802 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.32 42.42 1.36 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 178.109 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.6 34.39 89.78 Favored Glycine 0 C--N 1.336 0.537 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.014 -179.253 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 p -89.58 50.58 1.93 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.469 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -81.92 95.0 7.23 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.946 179.346 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.546 ' H ' ' HG2' ' A' ' 3' ' ' GLU . 40.8 m-80 -68.31 -37.1 80.26 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.235 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.804 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.9 m -69.02 124.93 91.45 Favored Pre-proline 0 N--CA 1.451 -0.423 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.732 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 29.4 Cg_exo -63.04 135.61 52.12 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 123.163 2.575 . . . . 0.0 114.601 -178.049 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.74 21.48 79.65 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.675 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.804 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 63.8 m -91.89 127.09 37.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 117.008 0.404 . . . . 0.0 111.202 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.2 t -79.47 130.83 35.78 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.8 t -78.26 87.65 4.32 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.153 0.502 . . . . 0.0 112.064 -178.328 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -86.03 66.84 9.77 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 176.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -27.49 124.01 0.24 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.537 -1.665 . . . . 0.0 113.267 -176.794 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 91.4 Cg_endo -101.36 33.25 8.36 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.507 -1.456 . . . . 0.0 114.067 0.574 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 68.0 mt -129.34 134.22 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.983 -0.448 . . . . 0.0 111.585 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.765 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.5 m -77.91 133.8 38.02 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.6 p -122.05 139.97 53.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 112.474 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.647 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 1.3 mmm180 -91.71 106.08 18.21 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 176.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 55.41 34.26 22.6 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 123.917 0.761 . . . . 0.0 110.443 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.24 -16.65 58.94 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.946 -0.645 . . . . 0.0 113.782 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.0 mt -95.52 125.44 49.51 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 117.497 0.648 . . . . 0.0 111.104 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.09 37.42 0.26 Allowed 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 122.943 2.429 . . . . 0.0 113.231 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.617 179.96 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.514 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 38.2 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 121.051 0.453 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.21 37.38 94.46 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -149.89 150.2 31.56 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-O 121.018 0.437 . . . . 0.0 110.26 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.421 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 43.2 p -105.92 148.3 27.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.538 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.635 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -117.8 53.0 0.96 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.236 0.541 . . . . 0.0 110.696 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.421 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 6.7 m-85 -55.18 -35.42 64.79 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.598 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.58 20.31 42.3 Favored Glycine 0 N--CA 1.445 -0.71 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.94 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.84 46.84 64.45 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.947 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -148.71 141.28 24.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.67 0.271 . . . . 0.0 110.546 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.9 m -130.57 131.94 45.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.532 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -72.85 -32.55 65.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.906 0.384 . . . . 0.0 110.541 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.643 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.0 m -80.3 124.77 82.32 Favored Pre-proline 0 N--CA 1.451 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.742 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.2 Cg_exo -67.26 136.1 39.19 Favored 'Trans proline' 0 N--CA 1.464 -0.214 0 C-N-CA 122.877 2.385 . . . . 0.0 112.582 -179.646 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.01 -6.85 82.53 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.046 -0.597 . . . . 0.0 113.503 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.643 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 72.8 m -79.74 130.05 35.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.144 0.497 . . . . 0.0 111.703 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -83.31 139.53 33.0 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.592 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 18.6 t -83.51 91.56 7.43 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.154 0.502 . . . . 0.0 111.908 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.5 m -89.28 67.09 7.76 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.0 t90 -28.01 122.95 0.25 Allowed Pre-proline 0 C--O 1.231 0.117 0 CA-C-N 113.807 -1.542 . . . . 0.0 113.143 -176.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 90.4 Cg_endo -102.0 30.68 10.01 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.511 -1.454 . . . . 0.0 113.916 0.724 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.8 mt -125.29 133.25 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 O-C-N 121.955 -0.465 . . . . 0.0 111.517 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.635 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.0 m -79.29 134.61 36.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.687 0.279 . . . . 0.0 111.516 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 23.9 p -126.18 133.54 51.53 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.219 0.533 . . . . 0.0 112.142 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.514 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 10.0 ttp180 -106.93 122.0 45.54 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 64.56 24.57 13.07 Favored 'General case' 0 C--N 1.32 -0.69 0 O-C-N 123.718 0.636 . . . . 0.0 109.402 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.74 -0.7 89.17 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.276 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.0 mt -106.97 131.32 21.79 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.66 0.267 . . . . 0.0 110.324 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.62 39.87 0.45 Allowed 'Trans proline' 0 CA--C 1.531 0.34 0 C-N-CA 122.827 2.351 . . . . 0.0 112.439 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.326 -0.423 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.967 -179.495 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 81.1 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.884 0.373 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.5 37.92 94.23 Favored Glycine 0 C--N 1.333 0.361 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.749 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.12 142.42 24.23 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.537 HG22 HG12 ' A' ' 21' ' ' ILE . 21.2 p -111.07 143.87 41.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.04 0.448 . . . . 0.0 110.759 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.557 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -112.08 60.45 0.63 Allowed 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.827 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -56.98 -32.24 65.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.63 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.79 14.76 58.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.631 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.33 44.16 66.76 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.875 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.405 ' H ' ' HB2' ' A' ' 5' ' ' CYS . 12.8 t -150.53 142.42 23.84 Favored 'General case' 0 N--CA 1.447 -0.582 0 O-C-N 122.845 -0.209 . . . . 0.0 110.544 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.557 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -135.64 131.78 36.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.179 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -82.88 -32.96 27.12 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.186 0.517 . . . . 0.0 109.706 178.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.418 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 4.6 m -66.31 120.35 69.44 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.812 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.0 Cg_exo -65.08 141.19 68.87 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.929 2.42 . . . . 0.0 113.071 -179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.03 26.1 73.21 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.272 -0.876 . . . . 0.0 113.161 179.311 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.8 m -116.8 121.84 42.7 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.078 0.466 . . . . 0.0 110.632 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -81.32 135.0 35.67 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.364 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.2 t -77.35 88.71 3.75 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.232 0.539 . . . . 0.0 111.832 -179.254 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.8 m -87.6 67.42 9.28 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -28.26 124.05 0.25 Allowed Pre-proline 0 N--CA 1.461 0.12 0 CA-C-N 113.772 -1.558 . . . . 0.0 113.144 -176.75 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.7 Cg_endo -101.1 34.37 7.7 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.53 -1.446 . . . . 0.0 113.997 0.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.537 HG12 HG22 ' A' ' 4' ' ' THR . 61.9 mt -130.33 133.08 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 O-C-N 121.935 -0.478 . . . . 0.0 111.754 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.494 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 35.0 m -78.05 127.75 32.8 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.149 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.1 p -119.46 146.49 45.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.582 0.706 . . . . 0.0 112.416 -178.724 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.1 tpp85 -92.44 81.35 4.88 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.8 t70 64.49 49.84 2.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.766 -177.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.81 -26.72 19.09 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.774 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 91.0 mt -91.1 118.8 68.77 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 117.404 0.602 . . . . 0.0 111.47 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.15 39.74 0.41 Allowed 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 122.882 2.388 . . . . 0.0 112.431 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.894 -179.611 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.582 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.0 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 120.869 0.366 . . . . 0.0 110.153 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.05 35.04 90.06 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.604 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -150.14 143.18 24.89 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.557 HG22 HG12 ' A' ' 21' ' ' ILE . 21.1 p -111.67 144.5 40.83 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.106 0.479 . . . . 0.0 110.86 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.517 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.0 p -113.27 62.19 0.64 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.849 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -56.93 -34.61 68.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.256 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -101.42 18.1 54.24 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.625 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.44 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 66.82 43.45 91.58 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.808 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.86 136.67 27.29 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.49 0.186 . . . . 0.0 111.047 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.517 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 59.7 m -133.17 129.58 38.01 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.945 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -84.9 -32.26 23.24 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.303 0.573 . . . . 0.0 109.567 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.9 m -66.44 122.55 82.29 Favored Pre-proline 0 N--CA 1.452 -0.354 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.948 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.51 141.12 59.87 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.783 2.322 . . . . 0.0 112.933 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.445 ' O ' ' HD3' ' A' ' 24' ' ' ARG . . . 72.83 27.83 68.19 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.887 179.662 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.462 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 85.6 m -118.5 116.99 27.82 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 121.113 0.482 . . . . 0.0 111.239 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.1 p -80.34 131.89 35.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 178.463 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.44 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.8 t -74.22 95.01 2.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.322 0.582 . . . . 0.0 112.076 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.4 m -91.95 67.22 5.16 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 176.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.0 t90 -27.19 122.68 0.24 Allowed Pre-proline 0 C--O 1.231 0.11 0 CA-C-N 113.703 -1.589 . . . . 0.0 113.213 -176.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 93.3 Cg_endo -101.78 35.74 6.52 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.024 0.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 4' ' ' THR . 64.4 mt -130.74 133.19 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.952 -0.468 . . . . 0.0 111.695 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.4 m -78.2 131.6 37.23 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.41 HG22 ' HA ' ' A' ' 28' ' ' PRO . 80.7 p -129.28 154.69 46.58 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.586 0.588 . . . . 0.0 112.586 -178.438 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.582 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 22.7 mmt85 -89.59 69.63 7.84 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 177.444 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 26.4 t70 65.98 53.34 1.12 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.926 0.869 . . . . 0.0 109.257 -177.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.48 -30.29 10.24 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.309 -0.859 . . . . 0.0 113.004 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 85.4 mt -81.92 113.43 42.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 117.006 0.403 . . . . 0.0 111.483 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.4 Cg_exo -73.77 39.36 0.5 Allowed 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 123.139 2.559 . . . . 0.0 112.422 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 111.929 -179.64 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 58.5 m . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 59.44 37.78 92.55 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -139.28 144.76 38.51 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 115.314 -0.443 . . . . 0.0 110.346 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.43 HG22 HD13 ' A' ' 21' ' ' ILE . 82.0 p -108.41 151.16 26.4 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.077 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.939 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -131.99 58.8 1.73 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.152 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -52.88 -31.92 42.21 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.19 0.519 . . . . 0.0 109.873 178.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -137.81 37.31 1.84 Allowed Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 177.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.545 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.59 42.06 99.69 Favored Glycine 0 C--N 1.337 0.619 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.3 p -108.41 44.5 1.11 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.939 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.8 m -81.85 123.43 28.81 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.104 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.8 m-20 -70.79 -36.28 72.94 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.6 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.7 m -73.44 118.56 69.94 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.981 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -74.56 142.16 28.98 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.932 2.421 . . . . 0.0 112.698 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.96 -22.42 40.96 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.325 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.739 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 96.4 m -69.69 125.26 26.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 0.0 111.063 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -79.31 128.57 33.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.2 t -76.31 94.41 3.58 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.574 0.583 . . . . 0.0 112.574 -178.209 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.2 m -91.38 65.45 5.32 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -23.2 120.68 0.17 Allowed Pre-proline 0 N--CA 1.462 0.169 0 CA-C-N 113.389 -1.732 . . . . 0.0 113.75 -176.619 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.9 Cg_endo -101.8 29.04 11.66 Favored 'Cis proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.876 -1.302 . . . . 0.0 113.699 0.287 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.43 HD13 HG22 ' A' ' 4' ' ' THR . 35.0 mm -123.02 128.39 75.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 O-C-N 122.218 -0.302 . . . . 0.0 111.459 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.739 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.65 131.81 36.07 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.434 0.635 . . . . 0.0 111.607 178.835 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.5 p -117.87 140.06 50.24 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.863 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.479 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 17.9 tpt85 -93.11 103.08 15.4 Favored 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 59.46 36.31 23.06 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 124.032 0.832 . . . . 0.0 110.159 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.23 -15.78 62.62 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.345 179.626 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.1 mt -92.8 121.1 66.66 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 117.205 0.502 . . . . 0.0 111.148 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.473 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.9 Cg_exo -71.94 39.32 0.39 Allowed 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 123.118 2.545 . . . . 0.0 112.215 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--N 1.326 -0.436 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.748 -179.528 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.596 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 87.5 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.469 0.176 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.67 36.96 94.01 Favored Glycine 0 N--CA 1.449 -0.435 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.477 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -141.59 145.65 35.31 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 115.125 -0.537 . . . . 0.0 109.812 -178.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.4 p -118.02 144.48 45.53 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -117.97 55.65 0.87 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.045 0.45 . . . . 0.0 111.006 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -56.38 -34.16 66.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.309 178.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.85 20.09 42.27 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.885 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.49 43.88 75.44 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.352 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.9 t -150.41 143.67 24.96 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.9 m -135.15 129.23 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.208 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 59.3 m-80 -70.51 -39.57 74.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.896 0.379 . . . . 0.0 110.36 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.9 m -71.8 117.22 55.76 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.562 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -68.84 138.96 42.22 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 123.122 2.548 . . . . 0.0 112.846 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.78 -20.05 51.57 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.765 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 71.4 m -77.18 126.24 30.62 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.073 0.463 . . . . 0.0 111.353 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -81.07 135.94 35.88 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.0 t -77.78 94.84 4.55 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.291 0.567 . . . . 0.0 112.227 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 15.9 m -93.81 67.7 3.83 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 107.089 -1.449 . . . . 0.0 107.089 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.554 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.3 t90 -27.18 122.47 0.24 Allowed Pre-proline 0 N--CA 1.463 0.184 0 CA-C-N 113.75 -1.568 . . . . 0.0 113.219 -176.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.554 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.84 30.28 10.5 Favored 'Cis proline' 0 N--CA 1.455 -0.774 0 C-N-CA 123.564 -1.432 . . . . 0.0 114.01 0.695 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.57 132.6 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 O-C-N 122.051 -0.405 . . . . 0.0 111.682 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.477 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.4 m -79.72 128.41 33.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.764 0.316 . . . . 0.0 110.552 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.447 ' HB ' ' N ' ' A' ' 27' ' ' LEU . 47.0 p -117.43 137.41 52.52 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.078 0.466 . . . . 0.0 112.043 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.596 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.1 tpt85 -90.58 101.3 14.04 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 177.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 59.6 38.56 22.1 Favored 'General case' 0 C--N 1.328 -0.345 0 O-C-N 123.891 0.744 . . . . 0.0 111.207 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.5 32.54 24.7 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.156 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.597 HD12 ' HD2' ' A' ' 28' ' ' PRO . 24.3 tp -144.83 117.77 5.48 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.068 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.597 ' HD2' HD12 ' A' ' 27' ' ' LEU . 56.3 Cg_endo -70.8 44.49 0.51 Allowed 'Trans proline' 0 N--CA 1.475 0.396 0 C-N-CA 123.25 2.633 . . . . 0.0 114.059 -178.277 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.591 HG13 ' HG ' ' A' ' 27' ' ' LEU . 18.6 m . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 120.933 0.397 . . . . 0.0 111.082 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.597 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 94.4 m . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 120.427 0.156 . . . . 0.0 111.077 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.72 40.72 98.82 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -150.31 147.63 27.87 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.0 p -117.61 143.24 46.33 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.979 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.544 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -114.67 56.14 0.73 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.011 0.434 . . . . 0.0 111.4 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.65 -34.47 67.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.214 178.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.48 20.93 38.39 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.866 179.148 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.26 42.91 81.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.468 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 13.4 t -150.53 143.4 24.67 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 58.1 m -132.83 128.82 37.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.687 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -68.82 -44.87 72.6 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.8 m -64.91 117.5 39.51 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.732 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -71.1 142.57 42.38 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.84 2.36 . . . . 0.0 113.067 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.41 33.65 38.61 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.161 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.4 m -124.31 133.74 53.38 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.868 0.366 . . . . 0.0 110.797 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -84.06 135.14 34.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.458 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 14.5 t -81.43 95.28 7.01 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.258 0.552 . . . . 0.0 111.759 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 12.5 m -93.66 67.91 3.94 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.5 t90 -27.95 122.79 0.25 Allowed Pre-proline 0 C--O 1.232 0.138 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.176 -176.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.7 Cg_endo -101.61 30.26 10.72 Favored 'Cis proline' 0 N--CA 1.455 -0.759 0 C-N-CA 123.59 -1.421 . . . . 0.0 114.083 0.635 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.0 mt -125.94 132.64 70.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 O-C-N 122.007 -0.433 . . . . 0.0 111.511 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.431 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 29.7 m -80.64 127.67 32.74 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.876 0.37 . . . . 0.0 110.768 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.7 p -119.48 142.48 48.24 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.233 0.539 . . . . 0.0 111.56 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.597 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 31.3 ttt85 -99.47 106.28 18.3 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 58.96 34.96 23.91 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 123.89 0.744 . . . . 0.0 110.14 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.31 -17.01 60.13 Favored Glycine 0 CA--C 1.52 0.403 0 CA-C-N 115.712 -0.676 . . . . 0.0 113.489 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.4 mt -93.84 122.59 61.84 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.213 0.507 . . . . 0.0 111.32 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.8 Cg_exo -72.16 39.09 0.39 Allowed 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 123.074 2.516 . . . . 0.0 112.343 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.667 -179.731 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.487 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.6 m . . . . . 0 N--CA 1.448 -0.534 0 CA-C-O 120.527 0.203 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.55 37.96 95.57 Favored Glycine 0 C--N 1.333 0.378 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 -178.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.546 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.6 tp10 -144.56 142.88 30.5 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.167 -0.516 . . . . 0.0 109.678 -178.738 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.9 p -116.17 144.49 44.11 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.915 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.4 p -118.48 56.7 0.87 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -55.79 -35.18 66.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.474 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.17 20.87 36.96 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.966 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.07 44.54 66.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.202 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.6 m -147.63 135.75 21.36 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 62.8 m -127.95 126.18 40.94 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.181 0.3 . . . . 0.0 110.355 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 49.4 t-20 -66.4 -43.62 85.32 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.2 m -71.63 117.18 55.1 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.487 179.61 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_exo -70.13 139.16 38.31 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.978 2.452 . . . . 0.0 112.825 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.89 -23.53 35.62 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.655 179.54 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.5 m -73.7 127.68 33.44 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.071 0.462 . . . . 0.0 111.462 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.8 t -79.93 134.77 36.3 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.5 t -77.86 93.88 4.44 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.301 0.572 . . . . 0.0 112.274 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.8 m -92.38 67.98 4.89 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 176.839 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.2 t90 -27.4 122.82 0.24 Allowed Pre-proline 0 N--CA 1.463 0.175 0 CA-C-N 113.861 -1.518 . . . . 0.0 113.305 -176.796 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 87.3 Cg_endo -101.69 30.55 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.516 -1.452 . . . . 0.0 114.047 0.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.6 mt -126.53 132.57 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 120.973 0.416 . . . . 0.0 111.487 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.546 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.5 m -79.62 128.79 33.83 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.805 0.336 . . . . 0.0 110.389 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -122.96 146.36 47.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.978 0.418 . . . . 0.0 112.003 -178.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.487 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 3.4 mmm-85 -91.25 95.54 10.09 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 177.094 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.97 37.35 21.44 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 123.928 0.768 . . . . 0.0 110.104 -178.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.15 -18.81 56.12 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.721 -0.672 . . . . 0.0 113.338 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.573 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.5 tp -89.53 113.82 58.13 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.157 0.478 . . . . 0.0 110.559 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 8.0 Cg_exo -73.14 46.74 1.18 Allowed 'Trans proline' 0 CA--C 1.531 0.36 0 C-N-CA 123.431 2.754 . . . . 0.0 113.59 -178.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.573 HG13 ' HG ' ' A' ' 27' ' ' LEU . 24.5 m . . . . . 0 C--N 1.325 -0.466 0 CA-C-O 121.085 0.469 . . . . 0.0 111.199 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.8 m . . . . . 0 N--CA 1.45 -0.434 0 CA-C-O 121.012 0.434 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 36.77 92.29 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.373 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -150.31 151.38 32.84 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.935 0.398 . . . . 0.0 110.129 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 38.7 p -110.3 146.69 35.27 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.952 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.549 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 28.2 p -115.12 54.82 0.78 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.135 0.493 . . . . 0.0 110.64 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -55.22 -35.42 64.9 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.68 179.287 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.11 19.56 45.88 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.91 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.1 46.16 67.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.975 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -149.78 142.36 24.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.629 0.252 . . . . 0.0 110.524 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 65.6 m -136.02 128.34 30.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.182 -179.449 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.5 p30 -77.61 -28.26 51.45 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.864 0.364 . . . . 0.0 110.404 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.41 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -70.99 123.42 89.29 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.497 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -69.51 136.12 32.83 Favored 'Trans proline' 0 N--CA 1.464 -0.221 0 C-N-CA 122.614 2.209 . . . . 0.0 113.114 -179.189 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.38 66.42 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.878 179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.41 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 66.1 m -112.71 128.05 56.3 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.065 0.459 . . . . 0.0 111.09 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.3 t -84.44 141.59 30.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.229 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.5 t -83.29 95.28 8.13 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.199 0.523 . . . . 0.0 111.995 -179.203 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.9 m -92.67 66.71 4.47 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.9 t90 -27.71 123.0 0.24 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.177 -176.764 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.8 Cg_endo -101.55 31.89 9.35 Favored 'Cis proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.497 -1.46 . . . . 0.0 114.039 0.625 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.6 mt -126.45 134.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 O-C-N 121.994 -0.441 . . . . 0.0 111.648 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.489 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -79.3 132.58 36.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.712 0.291 . . . . 0.0 110.85 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.5 p -128.31 136.61 51.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 111.37 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.5 ttt-85 -95.3 107.01 19.1 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.356 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 60.28 34.89 20.86 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 123.731 0.644 . . . . 0.0 110.067 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.62 -13.39 67.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.183 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.689 ' HB3' HG23 ' A' ' 29' ' ' VAL . 90.9 mt -94.11 118.68 67.19 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 117.159 0.479 . . . . 0.0 111.097 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -72.82 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.066 2.511 . . . . 0.0 112.512 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.689 HG23 ' HB3' ' A' ' 27' ' ' LEU . 3.2 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-O 121.348 0.595 . . . . 0.0 110.732 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 80.8 m . . . . . 0 N--CA 1.449 -0.522 0 CA-C-O 120.73 0.3 . . . . 0.0 110.593 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 41.13 97.21 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.406 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -146.87 145.19 29.76 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.958 0.409 . . . . 0.0 110.13 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -114.02 144.35 43.25 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.767 178.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.493 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.6 p -118.38 55.36 0.9 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.052 0.453 . . . . 0.0 111.289 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -56.62 -33.74 66.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.313 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.77 20.48 38.84 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.889 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.16 44.85 74.6 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.386 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.0 t -150.19 142.79 24.52 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.586 0.231 . . . . 0.0 110.541 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.493 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 56.0 m -134.52 131.01 37.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.254 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -66.7 -35.02 79.14 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.93 0.395 . . . . 0.0 110.382 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -80.89 117.23 67.1 Favored Pre-proline 0 N--CA 1.45 -0.442 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.977 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.69 136.87 28.91 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.71 2.274 . . . . 0.0 112.157 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.07 -27.23 21.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.655 -0.783 . . . . 0.0 111.999 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.3 m -72.54 127.81 33.68 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.989 0.423 . . . . 0.0 110.952 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -79.93 134.84 36.3 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.403 179.366 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.6 t -77.85 93.47 4.37 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.268 0.556 . . . . 0.0 111.727 -179.292 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.5 m -90.97 68.05 6.13 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.5 t90 -27.75 122.98 0.25 Allowed Pre-proline 0 N--CA 1.463 0.194 0 CA-C-N 113.932 -1.485 . . . . 0.0 113.268 -176.786 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.67 30.57 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.589 -1.421 . . . . 0.0 113.972 0.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.5 mt -126.86 132.52 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 O-C-N 122.058 -0.401 . . . . 0.0 111.567 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.492 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 28.6 m -79.35 128.96 33.98 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.823 0.344 . . . . 0.0 110.689 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -121.28 144.05 48.84 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.277 0.56 . . . . 0.0 111.393 -179.38 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.49 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 59.9 ttp180 -95.59 84.1 3.9 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.1 t70 67.27 49.95 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 O-C-N 124.248 0.968 . . . . 0.0 109.631 -177.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.29 -24.9 20.13 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.925 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -92.14 116.02 65.72 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 117.378 0.589 . . . . 0.0 111.547 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -73.21 39.02 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.005 2.47 . . . . 0.0 112.196 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 C--N 1.324 -0.503 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.61 -179.505 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.401 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 82.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 120.67 0.271 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 34.32 87.86 Favored Glycine 0 N--CA 1.451 -0.33 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -178.604 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.478 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -134.0 145.16 49.23 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.9 -0.65 . . . . 0.0 109.959 -179.034 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.427 HG22 HD13 ' A' ' 21' ' ' ILE . 65.0 p -114.17 146.03 40.88 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.614 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.578 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 27.9 p -124.21 54.07 1.38 Allowed 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.15 0.5 . . . . 0.0 110.854 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -56.43 -33.3 65.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.387 179.078 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.53 19.87 41.05 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.807 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.42 45.03 70.86 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.324 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.9 t -150.11 142.8 24.6 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.542 0.21 . . . . 0.0 110.591 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.482 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 46.4 m -134.34 127.75 32.32 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.025 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -72.04 -34.55 68.86 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.931 0.396 . . . . 0.0 110.232 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.5 m -72.47 118.24 65.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.483 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.85 135.45 32.7 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.638 2.225 . . . . 0.0 112.864 -179.472 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.66 -22.5 39.98 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 76.9 m -78.12 121.59 24.5 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.085 0.469 . . . . 0.0 111.014 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.5 t -82.59 138.16 34.31 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.29 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 26.6 t -74.49 113.81 12.16 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.469 0.652 . . . . 0.0 111.941 -179.219 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.0 m -113.13 66.12 0.65 Allowed 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 177.228 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.1 t90 -23.55 120.36 0.18 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 113.489 -1.687 . . . . 0.0 113.665 -176.584 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.518 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 76.0 Cg_endo -101.96 25.62 14.53 Favored 'Cis proline' 0 N--CA 1.456 -0.729 0 C-N-CA 123.668 -1.388 . . . . 0.0 113.784 0.432 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.427 HD13 HG22 ' A' ' 4' ' ' THR . 41.4 mm -119.74 132.77 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-O 120.729 0.299 . . . . 0.0 111.628 -179.063 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.0 m -81.4 128.28 33.69 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.3 p -115.79 145.78 42.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.222 0.534 . . . . 0.0 111.532 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.402 ' HD2' ' HA ' ' A' ' 24' ' ' ARG . 16.9 tpt85 -89.7 85.24 6.4 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.294 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 62.58 43.14 7.86 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.2 -177.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.99 -23.68 34.71 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.702 -0.761 . . . . 0.0 113.616 179.301 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.57 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.3 tp -92.6 111.6 51.66 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 117.355 0.578 . . . . 0.0 110.617 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.454 ' HD2' HD12 ' A' ' 27' ' ' LEU . 60.4 Cg_endo -72.86 47.38 1.22 Allowed 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 123.184 2.589 . . . . 0.0 113.817 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.57 HG13 ' HG ' ' A' ' 27' ' ' LEU . 30.3 m . . . . . 0 C--N 1.324 -0.511 0 CA-C-O 120.87 0.367 . . . . 0.0 111.416 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.617 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 52.5 m . . . . . 0 N--CA 1.448 -0.573 0 CA-C-O 120.402 0.144 . . . . 0.0 111.148 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.32 37.74 94.24 Favored Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -178.778 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.484 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.1 tp10 -140.91 145.85 36.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.142 -0.529 . . . . 0.0 109.858 -179.032 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.403 HG22 HD13 ' A' ' 21' ' ' ILE . 64.4 p -115.6 146.73 41.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.784 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.1 p -125.02 55.58 1.36 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.239 0.543 . . . . 0.0 110.715 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -57.05 -33.0 66.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.271 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.98 18.89 48.35 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.73 -0.747 . . . . 0.0 111.657 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.57 42.77 79.69 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.045 -0.597 . . . . 0.0 112.298 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.6 t -150.62 143.77 24.82 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 110.452 -0.203 . . . . 0.0 110.452 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.482 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 39.6 m -132.1 129.5 40.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -70.69 -35.45 72.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.978 0.418 . . . . 0.0 110.344 179.72 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 10.6 m -76.66 116.6 58.07 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.792 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.17 139.6 46.79 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.948 2.432 . . . . 0.0 112.489 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.05 -27.37 20.33 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.015 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.0 m -76.34 125.63 29.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.094 0.473 . . . . 0.0 110.967 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.8 m -85.99 134.81 33.84 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.71 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 27.2 t -73.49 116.18 13.75 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.339 0.59 . . . . 0.0 111.873 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.8 m -115.96 66.87 0.71 Allowed 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.57 -1.641 . . . . 0.0 106.57 177.339 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.8 t90 -23.51 119.48 0.18 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.518 -1.674 . . . . 0.0 113.643 -176.555 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 75.5 Cg_endo -102.7 26.7 12.49 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.855 0.544 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.403 HD13 HG22 ' A' ' 4' ' ' THR . 38.6 mm -120.33 133.73 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 111.624 -179.07 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 40.6 m -82.31 126.06 31.7 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 178.888 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -113.19 150.84 31.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.529 0.68 . . . . 0.0 111.71 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.617 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.5 ttm180 -103.72 86.65 2.65 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.118 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.7 t0 66.52 49.51 1.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 O-C-N 124.245 0.965 . . . . 0.0 109.509 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.82 -25.01 12.51 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.773 179.684 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.8 mt -88.92 117.9 68.73 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 117.316 0.558 . . . . 0.0 111.547 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -73.96 38.71 0.48 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.027 2.485 . . . . 0.0 112.269 179.313 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.325 -0.491 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.617 -179.476 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.0 m . . . . . 0 N--CA 1.45 -0.468 0 CA-C-O 120.644 0.259 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.75 38.71 94.72 Favored Glycine 0 N--CA 1.451 -0.345 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -178.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.482 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -141.88 147.18 36.71 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.797 -178.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.2 p -118.46 145.66 45.08 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.973 0.416 . . . . 0.0 110.752 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.2 p -120.69 56.49 1.0 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.006 0.431 . . . . 0.0 111.028 -179.691 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.61 -34.02 66.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.29 179.018 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.49 20.23 40.19 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.82 179.107 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.5 43.61 76.63 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.339 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.7 t -150.22 142.88 24.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.461 0.172 . . . . 0.0 110.565 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.49 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.6 m -132.71 128.74 37.58 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.037 -179.846 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.3 m-80 -69.67 -34.58 74.17 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.021 0.439 . . . . 0.0 110.021 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.1 m -75.27 115.66 47.21 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.362 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -70.3 136.18 30.94 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.92 2.413 . . . . 0.0 112.472 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.45 -24.23 32.84 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.454 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -77.72 130.47 36.8 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.151 0.5 . . . . 0.0 111.219 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.1 t -84.77 137.52 33.15 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.468 179.506 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 25.0 t -77.16 112.62 14.02 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.301 0.572 . . . . 0.0 111.739 -179.448 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.7 m -111.25 67.6 0.65 Allowed 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 177.472 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.0 t90 -26.33 122.53 0.22 Allowed Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 113.776 -1.556 . . . . 0.0 113.344 -176.602 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.5 Cg_endo -101.36 28.84 12.35 Favored 'Cis proline' 0 N--CA 1.454 -0.804 0 C-N-CA 123.6 -1.417 . . . . 0.0 114.086 0.534 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 61.3 mt -127.55 134.71 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 O-C-N 121.997 -0.439 . . . . 0.0 111.538 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 31.4 m -79.87 130.41 35.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.908 0.385 . . . . 0.0 110.43 179.442 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 54.4 p -121.48 157.95 29.49 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.215 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.434 ' HA ' ' HD2' ' A' ' 24' ' ' ARG . 13.9 tpt85 -87.99 58.33 4.76 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.264 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 64.45 45.88 3.56 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.955 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 142.43 -47.94 0.8 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.385 -0.912 . . . . 0.0 113.479 178.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 99.0 mt -108.93 127.87 26.52 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 122.553 -0.38 . . . . 0.0 111.777 -179.11 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.8 Cg_endo -75.6 39.03 0.6 Allowed 'Trans proline' 0 CA--C 1.528 0.22 0 C-N-CA 123.209 2.606 . . . . 0.0 112.47 179.559 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 -179.642 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 60.9 m . . . . . 0 N--CA 1.448 -0.542 0 CA-C-O 120.695 0.283 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.52 45.01 96.76 Favored Glycine 0 C--N 1.335 0.479 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.437 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.414 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -150.16 149.86 30.83 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.958 0.408 . . . . 0.0 110.698 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.472 HG22 HD13 ' A' ' 21' ' ' ILE . 42.4 p -123.41 142.85 50.56 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.61 178.618 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 29.3 p -105.34 57.32 0.68 Allowed 'General case' 0 C--N 1.315 -0.923 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.688 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -56.59 -33.54 66.32 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -106.02 23.36 29.34 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.61 178.365 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 66.92 37.33 92.11 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 121.197 -0.525 . . . . 0.0 113.082 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.4 t -151.06 142.61 23.55 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.717 0.294 . . . . 0.0 111.371 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.743 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.8 m -122.54 132.44 54.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.634 179.371 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -64.68 -34.56 78.59 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.921 0.391 . . . . 0.0 110.394 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.4 m -79.71 115.74 55.89 Favored Pre-proline 0 N--CA 1.45 -0.465 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.717 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.97 135.8 26.1 Favored 'Trans proline' 0 N--CA 1.462 -0.349 0 C-N-CA 122.516 2.144 . . . . 0.0 112.37 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.03 -26.65 23.89 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.071 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.8 m -71.65 125.82 28.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.974 0.416 . . . . 0.0 111.234 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -89.58 121.21 31.56 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.081 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.827 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 19.6 t -86.86 116.95 25.28 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 113.464 0.912 . . . . 0.0 113.464 -177.17 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.9 m -88.72 72.64 8.62 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 174.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.509 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 12.7 t90 -21.56 122.25 0.12 Allowed Pre-proline 0 N--CA 1.468 0.433 0 CA-C-N 113.889 -1.505 . . . . 0.0 113.834 -175.605 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 88.8 Cg_endo -101.78 31.31 9.65 Favored 'Cis proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.228 0.502 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.472 HD13 HG22 ' A' ' 4' ' ' THR . 43.8 mm -116.52 120.54 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.236 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.827 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 28.8 m -74.67 130.2 39.09 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.413 HG22 ' CA ' ' A' ' 28' ' ' PRO . 37.2 p -131.04 139.67 49.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.124 0.488 . . . . 0.0 111.876 -178.636 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 5.6 tmm_? -96.7 102.22 13.97 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 59.41 40.4 20.9 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 123.807 0.692 . . . . 0.0 110.302 -177.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.25 -15.68 60.58 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.557 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.5 mt -91.61 118.93 68.63 Favored Pre-proline 0 C--N 1.327 -0.396 0 CA-C-N 117.232 0.516 . . . . 0.0 111.5 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.413 ' CA ' HG22 ' A' ' 23' ' ' THR . 71.5 Cg_endo -74.82 38.82 0.54 Allowed 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 123.081 2.521 . . . . 0.0 112.049 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--N 1.324 -0.525 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.818 -179.452 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.451 -0.402 0 CA-C-O 120.664 0.269 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.65 37.67 95.16 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -143.29 141.48 31.03 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.47 HG22 HG12 ' A' ' 21' ' ' ILE . 37.7 p -111.88 146.86 36.99 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.036 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.805 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 23.2 p -122.69 57.94 1.09 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -56.09 -36.05 67.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.127 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.56 20.56 43.91 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.684 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.08 40.22 88.45 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.351 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.2 t -151.19 142.92 23.74 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.555 -0.165 . . . . 0.0 110.555 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.805 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -139.06 137.5 36.29 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.8 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -67.24 -41.29 85.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.518 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.2 m -70.67 114.41 26.36 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.409 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.89 137.93 27.73 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.058 2.505 . . . . 0.0 112.449 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.8 -25.25 28.62 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.301 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.703 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 91.2 m -71.04 127.79 33.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.022 0.439 . . . . 0.0 111.272 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -79.64 126.7 31.25 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.8 t -73.88 96.89 2.67 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.488 0.661 . . . . 0.0 112.191 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.7 m -94.11 68.15 3.69 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.102 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.2 t90 -25.7 122.26 0.22 Allowed Pre-proline 0 N--CA 1.463 0.22 0 CA-C-N 113.918 -1.492 . . . . 0.0 113.313 -176.702 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.7 Cg_endo -101.55 30.31 10.72 Favored 'Cis proline' 0 N--CA 1.456 -0.71 0 C-N-CA 123.606 -1.414 . . . . 0.0 114.159 0.754 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.47 HG12 HG22 ' A' ' 4' ' ' THR . 67.6 mt -131.26 131.83 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.954 -0.466 . . . . 0.0 111.341 -179.482 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.703 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -79.4 134.97 36.57 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.306 0.574 . . . . 0.0 111.982 179.587 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 70.6 p -120.9 149.51 42.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.076 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.511 ' HG2' ' OD1' ' A' ' 25' ' ' ASP . 17.0 ttt-85 -88.17 94.86 9.95 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.672 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.511 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 1.1 p-10 46.38 42.78 11.03 Favored 'General case' 0 N--CA 1.469 0.483 0 O-C-N 124.334 1.022 . . . . 0.0 111.434 -177.163 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.57 -22.18 29.0 Favored Glycine 0 C--N 1.335 0.49 0 CA-C-N 115.52 -0.763 . . . . 0.0 113.865 178.619 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.522 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.6 tp -93.45 113.82 61.22 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 117.256 0.528 . . . . 0.0 111.015 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 11.2 Cg_exo -71.59 48.26 1.0 Allowed 'Trans proline' 0 CA--C 1.533 0.431 0 C-N-CA 123.498 2.799 . . . . 0.0 113.772 -179.236 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.522 HG13 ' HG ' ' A' ' 27' ' ' LEU . 31.1 m . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 121.004 0.431 . . . . 0.0 111.257 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.1 m . . . . . 0 N--CA 1.449 -0.492 0 CA-C-O 120.786 0.327 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.51 37.8 94.74 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.543 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -144.25 143.88 31.24 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.126 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 45.2 p -105.75 153.63 21.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.701 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.903 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 22.2 p -131.67 56.97 1.79 Allowed 'General case' 0 C--N 1.321 -0.643 0 O-C-N 122.269 -0.27 . . . . 0.0 110.95 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -52.01 -35.99 48.58 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.215 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.23 31.65 3.98 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 178.218 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.517 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.99 48.36 83.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.143 -0.551 . . . . 0.0 111.823 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.6 m -130.7 69.27 1.46 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 111.975 0.361 . . . . 0.0 111.975 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.903 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 92.6 m -90.88 130.98 36.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.763 0.316 . . . . 0.0 111.18 179.515 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.8 p-10 -64.51 -35.12 79.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.935 -179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 18.1 m -85.01 114.68 57.27 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.196 -179.127 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 8.0 Cg_exo -71.94 139.73 33.65 Favored 'Trans proline' 0 N--CA 1.462 -0.341 0 C-N-CA 123.111 2.541 . . . . 0.0 111.932 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.02 -25.93 26.11 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.079 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.709 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 97.6 m -67.05 128.34 35.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.839 0.352 . . . . 0.0 110.744 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.7 m -78.87 123.5 27.3 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.6 t -72.6 98.83 2.41 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.362 0.601 . . . . 0.0 112.232 -178.215 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 9.0 m -94.49 68.38 3.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.536 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.6 t90 -25.18 121.06 0.21 Allowed Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.355 -176.464 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.536 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.5 Cg_endo -102.76 33.6 7.5 Favored 'Cis proline' 0 N--CA 1.455 -0.764 0 C-N-CA 123.69 -1.379 . . . . 0.0 114.153 0.853 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.421 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 67.9 mt -132.23 132.99 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 O-C-N 121.992 -0.442 . . . . 0.0 111.576 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.709 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.58 134.93 36.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.34 0.59 . . . . 0.0 112.474 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 42.5 p -123.0 143.82 49.67 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.651 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.453 ' HD2' ' HA ' ' A' ' 24' ' ' ARG . 2.3 mmm-85 -95.25 101.9 13.67 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.521 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 60.03 36.14 21.42 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 123.944 0.778 . . . . 0.0 110.006 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.56 -14.49 65.16 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.623 -0.717 . . . . 0.0 113.192 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.629 ' HG ' HG13 ' A' ' 29' ' ' VAL . 21.6 tp -92.96 116.35 66.37 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 117.067 0.433 . . . . 0.0 110.273 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.563 ' HD2' HD12 ' A' ' 27' ' ' LEU . 58.4 Cg_endo -71.7 45.61 0.73 Allowed 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 123.122 2.548 . . . . 0.0 113.83 -178.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.629 HG13 ' HG ' ' A' ' 27' ' ' LEU . 16.0 m . . . . . 0 C--N 1.326 -0.421 0 CA-C-O 120.928 0.394 . . . . 0.0 111.465 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 N--CA 1.448 -0.538 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.11 34.32 87.56 Favored Glycine 0 C--N 1.333 0.387 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.791 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -140.53 134.21 30.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.468 HG22 HD13 ' A' ' 21' ' ' ILE . 77.8 p -96.21 146.19 24.91 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.429 -178.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.638 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -120.65 58.48 0.94 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.204 179.217 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -55.92 -34.66 65.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.48 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.77 17.33 56.6 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.485 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.458 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 67.81 41.57 88.32 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 121.144 -0.55 . . . . 0.0 111.946 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.3 t -151.47 144.92 24.84 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.077 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.638 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 30.2 m -146.62 140.8 26.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.9 m-80 -73.23 -35.24 66.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.569 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.4 m -66.78 115.24 22.76 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.842 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.86 134.48 27.87 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.654 2.236 . . . . 0.0 112.837 -179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.61 -18.53 57.16 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.69 -0.767 . . . . 0.0 113.001 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.584 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 94.9 m -77.41 120.63 22.67 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.179 0.514 . . . . 0.0 111.016 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -79.41 131.27 36.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.458 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 32.9 t -75.52 92.73 2.91 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.338 0.59 . . . . 0.0 112.24 -178.466 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.0 m -89.58 66.74 7.35 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -25.22 121.33 0.21 Allowed Pre-proline 0 C--O 1.232 0.168 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.68 -176.543 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 85.4 Cg_endo -101.75 26.31 14.26 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.59 -1.421 . . . . 0.0 113.787 0.544 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.468 HD13 HG22 ' A' ' 4' ' ' THR . 35.9 mm -120.56 127.87 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 O-C-N 122.257 -0.277 . . . . 0.0 111.424 -179.208 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.584 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 13.0 m -79.78 130.36 35.26 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.254 0.55 . . . . 0.0 111.35 179.062 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 69.0 p -118.59 140.6 49.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.723 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 35.8 tpt85 -89.66 92.14 8.95 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.351 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 61.04 40.61 14.92 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 124.028 0.83 . . . . 0.0 110.48 -178.58 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.75 -22.89 35.63 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 113.841 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.9 mt -93.86 117.45 67.23 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 117.381 0.59 . . . . 0.0 111.589 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.85 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.924 2.416 . . . . 0.0 112.266 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 C--N 1.326 -0.451 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.875 -179.581 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 N--CA 1.45 -0.47 0 CA-C-O 120.86 0.362 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.42 40.38 97.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.887 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -147.44 142.09 26.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.976 0.417 . . . . 0.0 110.19 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.619 HG22 HG12 ' A' ' 21' ' ' ILE . 41.7 p -107.36 146.79 31.16 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.694 179.581 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.787 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 21.4 p -122.38 56.82 1.1 Allowed 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.989 0.423 . . . . 0.0 110.757 179.791 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -55.99 -36.77 68.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.252 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.91 21.31 40.71 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.516 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.7 40.71 90.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.183 -0.532 . . . . 0.0 112.408 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.2 t -150.78 142.92 24.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.787 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 89.4 m -137.49 137.58 38.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.744 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -64.44 -35.67 81.66 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.1 m -76.89 113.77 33.18 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.709 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.52 136.02 27.6 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.539 2.159 . . . . 0.0 112.376 -179.732 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.64 -19.32 54.83 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.502 -0.856 . . . . 0.0 113.037 179.643 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.512 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 68.6 m -74.65 131.7 41.11 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 117.287 0.543 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.1 m -81.96 119.36 23.86 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.743 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 10.4 t -68.76 112.41 5.47 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.433 0.635 . . . . 0.0 111.775 -178.85 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.8 m -109.06 69.61 0.71 Allowed 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -25.19 122.1 0.21 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.352 -176.623 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 83.7 Cg_endo -101.57 31.22 9.88 Favored 'Cis proline' 0 N--CA 1.455 -0.739 0 C-N-CA 123.541 -1.441 . . . . 0.0 114.277 0.806 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.619 HG12 HG22 ' A' ' 4' ' ' THR . 64.4 mt -135.7 134.19 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 O-C-N 121.97 -0.456 . . . . 0.0 111.436 -179.46 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.512 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -76.77 137.02 39.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.14 0.495 . . . . 0.0 111.491 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.4 p -128.99 158.84 37.74 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.939 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.01 55.0 3.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 178.271 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 65.12 43.1 3.8 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.872 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 148.63 -45.77 0.71 Allowed Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.325 -0.941 . . . . 0.0 113.263 179.236 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 98.1 mt -114.96 129.86 24.69 Favored Pre-proline 0 C--N 1.327 -0.383 0 O-C-N 122.509 -0.407 . . . . 0.0 111.686 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.6 Cg_endo -75.39 39.92 0.65 Allowed 'Trans proline' 0 CA--C 1.53 0.279 0 C-N-CA 123.247 2.631 . . . . 0.0 112.506 179.606 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.6 m . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.034 -179.656 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.9 m . . . . . 0 N--CA 1.448 -0.546 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.98 39.1 96.57 Favored Glycine 0 C--N 1.335 0.495 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.864 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -147.74 152.29 37.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.769 0.318 . . . . 0.0 110.388 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.414 HG22 HG12 ' A' ' 21' ' ' ILE . 22.7 p -122.45 146.0 47.78 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.506 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.513 ' HB2' ' N ' ' A' ' 9' ' ' THR . 21.6 p -107.63 60.35 0.62 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.135 0.493 . . . . 0.0 111.028 -179.625 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -56.17 -30.24 61.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.101 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.55 17.38 46.66 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.789 -0.719 . . . . 0.0 111.564 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 39.82 86.93 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.558 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.513 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.2 m -150.92 137.27 18.57 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 122.581 -0.364 . . . . 0.0 111.087 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.723 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 57.8 m -125.15 129.95 51.19 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 178.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -77.0 -34.11 57.53 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.041 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -63.96 119.18 52.82 Favored Pre-proline 0 C--O 1.236 0.361 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.599 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.88 135.89 36.69 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.952 2.435 . . . . 0.0 113.801 -178.728 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.22 17.07 78.74 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.465 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 55.9 m -105.33 121.36 43.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 117.141 0.471 . . . . 0.0 111.078 179.282 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.7 m -90.23 117.71 29.19 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 107.305 -1.368 . . . . 0.0 107.305 178.089 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.838 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 17.9 t -81.6 118.34 22.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 113.491 0.922 . . . . 0.0 113.491 -176.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.8 m -92.34 73.35 5.3 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 104.964 -2.235 . . . . 0.0 104.964 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -23.04 125.59 0.12 Allowed Pre-proline 0 N--CA 1.467 0.42 0 CA-C-N 113.767 -1.561 . . . . 0.0 113.661 -175.567 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.495 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 94.6 Cg_endo -100.52 33.53 8.56 Favored 'Cis proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.332 -1.528 . . . . 0.0 114.449 0.652 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.414 HG12 HG22 ' A' ' 4' ' ' THR . 66.4 mt -124.58 125.83 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 O-C-N 121.865 -0.522 . . . . 0.0 112.097 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.838 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 14.0 m -72.1 129.11 37.73 Favored 'General case' 0 C--O 1.233 0.212 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.439 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.0 p -128.79 138.11 51.9 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.127 0.489 . . . . 0.0 111.844 -178.528 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.99 104.97 16.85 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.24 37.38 23.76 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.434 0.635 . . . . 0.0 110.043 -178.16 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.65 -11.45 70.18 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.522 -0.763 . . . . 0.0 113.447 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.1 mt -94.44 123.58 58.05 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 117.2 0.5 . . . . 0.0 111.202 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -73.39 39.99 0.51 Allowed 'Trans proline' 0 CA--C 1.53 0.302 0 C-N-CA 123.072 2.515 . . . . 0.0 112.038 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.326 -0.425 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.895 -179.327 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 121.135 0.493 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.26 34.63 90.42 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.511 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -145.34 136.83 25.18 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-O 120.934 0.397 . . . . 0.0 110.026 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.582 HG22 HG12 ' A' ' 21' ' ' ILE . 36.7 p -99.41 143.57 29.51 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.164 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.61 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -115.36 60.45 0.7 Allowed 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.412 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -55.97 -34.91 66.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.494 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.52 16.95 57.36 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.593 178.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.422 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 68.13 40.82 88.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.877 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.6 t -151.55 146.46 25.89 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 121.272 -0.171 . . . . 0.0 110.685 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.61 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 18.8 m -145.69 138.74 26.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.015 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -74.01 -42.58 60.15 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.311 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.1 m -62.15 118.15 36.83 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.723 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -68.43 147.55 71.47 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 123.056 2.504 . . . . 0.0 113.528 -178.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.6 25.78 71.44 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.133 -0.939 . . . . 0.0 113.53 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.753 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 89.5 m -114.2 122.49 46.96 Favored 'General case' 0 N--CA 1.444 -0.765 0 O-C-N 122.288 -0.536 . . . . 0.0 110.665 179.257 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -79.44 127.55 32.25 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.422 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.6 t -74.93 90.22 2.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.333 0.587 . . . . 0.0 112.107 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.1 m -88.5 68.06 8.69 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 177.007 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -26.44 123.54 0.22 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.896 -1.502 . . . . 0.0 113.317 -176.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.439 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 80.4 Cg_endo -101.04 30.76 10.71 Favored 'Cis proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.51 -1.454 . . . . 0.0 114.092 0.675 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.582 HG12 HG22 ' A' ' 4' ' ' THR . 65.5 mt -131.12 131.31 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 O-C-N 122.029 -0.419 . . . . 0.0 111.358 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.753 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 37.9 m -79.08 132.45 36.61 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.312 0.577 . . . . 0.0 111.709 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -116.22 147.14 41.76 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.842 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.7 tpp85 -94.39 83.38 4.17 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.7 t70 64.74 49.32 2.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.866 -177.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.01 -26.56 18.29 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.724 -0.75 . . . . 0.0 113.956 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.467 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.9 mt -91.98 119.93 68.09 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 117.51 0.655 . . . . 0.0 111.388 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 9.2 Cg_exo -71.28 39.01 0.34 Allowed 'Trans proline' 0 CA--C 1.531 0.334 0 C-N-CA 123.137 2.558 . . . . 0.0 112.447 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.901 -179.665 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.647 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 96.7 m . . . . . 0 N--CA 1.451 -0.409 0 CA-C-O 120.7 0.286 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.19 92.81 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.398 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.546 ' HG2' ' H ' ' A' ' 11' ' ' ASN . 6.9 tp10 -150.5 143.64 24.85 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.056 0.455 . . . . 0.0 110.326 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -101.1 148.88 24.56 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.122 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.765 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -124.82 56.08 1.32 Allowed 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.478 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -53.83 -32.32 52.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.177 0.513 . . . . 0.0 109.802 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.32 42.42 1.36 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 178.109 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.6 34.39 89.78 Favored Glycine 0 C--N 1.336 0.537 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.014 -179.253 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 p -89.58 50.58 1.93 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.469 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -81.92 95.0 7.23 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.946 179.346 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.546 ' H ' ' HG2' ' A' ' 3' ' ' GLU . 40.8 m-80 -68.31 -37.1 80.26 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.235 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.804 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.9 m -69.02 124.93 91.45 Favored Pre-proline 0 N--CA 1.451 -0.423 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.732 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 29.4 Cg_exo -63.04 135.61 52.12 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 123.163 2.575 . . . . 0.0 114.601 -178.049 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.74 21.48 79.65 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.675 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.804 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 63.8 m -91.89 127.09 37.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 117.008 0.404 . . . . 0.0 111.202 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.2 t -79.47 130.83 35.78 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.8 t -78.26 87.65 4.32 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.153 0.502 . . . . 0.0 112.064 -178.328 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -86.03 66.84 9.77 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 176.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -27.49 124.01 0.24 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.537 -1.665 . . . . 0.0 113.267 -176.794 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 91.4 Cg_endo -101.36 33.25 8.36 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.507 -1.456 . . . . 0.0 114.067 0.574 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 68.0 mt -129.34 134.22 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.983 -0.448 . . . . 0.0 111.585 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.765 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.5 m -77.91 133.8 38.02 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.6 p -122.05 139.97 53.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 112.474 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.647 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 1.3 mmm180 -91.71 106.08 18.21 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 176.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 55.41 34.26 22.6 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 123.917 0.761 . . . . 0.0 110.443 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.24 -16.65 58.94 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.946 -0.645 . . . . 0.0 113.782 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.0 mt -95.52 125.44 49.51 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 117.497 0.648 . . . . 0.0 111.104 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.09 37.42 0.26 Allowed 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 122.943 2.429 . . . . 0.0 113.231 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.617 179.96 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.514 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 38.2 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 121.051 0.453 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.21 37.38 94.46 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -149.89 150.2 31.56 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-O 121.018 0.437 . . . . 0.0 110.26 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.421 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 43.2 p -105.92 148.3 27.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.538 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.635 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -117.8 53.0 0.96 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.236 0.541 . . . . 0.0 110.696 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.421 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 6.7 m-85 -55.18 -35.42 64.79 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.598 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.58 20.31 42.3 Favored Glycine 0 N--CA 1.445 -0.71 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.94 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.84 46.84 64.45 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.947 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -148.71 141.28 24.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.67 0.271 . . . . 0.0 110.546 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.9 m -130.57 131.94 45.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.532 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -72.85 -32.55 65.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.906 0.384 . . . . 0.0 110.541 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.643 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.0 m -80.3 124.77 82.32 Favored Pre-proline 0 N--CA 1.451 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.742 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.2 Cg_exo -67.26 136.1 39.19 Favored 'Trans proline' 0 N--CA 1.464 -0.214 0 C-N-CA 122.877 2.385 . . . . 0.0 112.582 -179.646 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.01 -6.85 82.53 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.046 -0.597 . . . . 0.0 113.503 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.643 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 72.8 m -79.74 130.05 35.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.144 0.497 . . . . 0.0 111.703 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -83.31 139.53 33.0 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.592 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 18.6 t -83.51 91.56 7.43 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.154 0.502 . . . . 0.0 111.908 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.5 m -89.28 67.09 7.76 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.0 t90 -28.01 122.95 0.25 Allowed Pre-proline 0 C--O 1.231 0.117 0 CA-C-N 113.807 -1.542 . . . . 0.0 113.143 -176.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 90.4 Cg_endo -102.0 30.68 10.01 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.511 -1.454 . . . . 0.0 113.916 0.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.8 mt -125.29 133.25 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 O-C-N 121.955 -0.465 . . . . 0.0 111.517 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.635 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.0 m -79.29 134.61 36.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.687 0.279 . . . . 0.0 111.516 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 23.9 p -126.18 133.54 51.53 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.219 0.533 . . . . 0.0 112.142 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.514 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 10.0 ttp180 -106.93 122.0 45.54 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 64.56 24.57 13.07 Favored 'General case' 0 C--N 1.32 -0.69 0 O-C-N 123.718 0.636 . . . . 0.0 109.402 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.74 -0.7 89.17 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.276 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.0 mt -106.97 131.32 21.79 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.66 0.267 . . . . 0.0 110.324 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.62 39.87 0.45 Allowed 'Trans proline' 0 CA--C 1.531 0.34 0 C-N-CA 122.827 2.351 . . . . 0.0 112.439 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.326 -0.423 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.967 -179.495 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 81.1 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.884 0.373 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.5 37.92 94.23 Favored Glycine 0 C--N 1.333 0.361 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.749 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.12 142.42 24.23 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.537 HG22 HG12 ' A' ' 21' ' ' ILE . 21.2 p -111.07 143.87 41.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.04 0.448 . . . . 0.0 110.759 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.557 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -112.08 60.45 0.63 Allowed 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.827 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -56.98 -32.24 65.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.63 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.79 14.76 58.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.631 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.33 44.16 66.76 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.875 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.405 ' H ' ' HB2' ' A' ' 5' ' ' CYS . 12.8 t -150.53 142.42 23.84 Favored 'General case' 0 N--CA 1.447 -0.582 0 O-C-N 122.845 -0.209 . . . . 0.0 110.544 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.557 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -135.64 131.78 36.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.179 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -82.88 -32.96 27.12 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.186 0.517 . . . . 0.0 109.706 178.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.418 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 4.6 m -66.31 120.35 69.44 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.812 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.0 Cg_exo -65.08 141.19 68.87 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.929 2.42 . . . . 0.0 113.071 -179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.03 26.1 73.21 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.272 -0.876 . . . . 0.0 113.161 179.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.8 m -116.8 121.84 42.7 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.078 0.466 . . . . 0.0 110.632 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -81.32 135.0 35.67 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.364 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.2 t -77.35 88.71 3.75 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.232 0.539 . . . . 0.0 111.832 -179.254 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.8 m -87.6 67.42 9.28 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -28.26 124.05 0.25 Allowed Pre-proline 0 N--CA 1.461 0.12 0 CA-C-N 113.772 -1.558 . . . . 0.0 113.144 -176.75 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.7 Cg_endo -101.1 34.37 7.7 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.53 -1.446 . . . . 0.0 113.997 0.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.537 HG12 HG22 ' A' ' 4' ' ' THR . 61.9 mt -130.33 133.08 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 O-C-N 121.935 -0.478 . . . . 0.0 111.754 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.494 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 35.0 m -78.05 127.75 32.8 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.149 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.1 p -119.46 146.49 45.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.582 0.706 . . . . 0.0 112.416 -178.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.1 tpp85 -92.44 81.35 4.88 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.8 t70 64.49 49.84 2.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.766 -177.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.81 -26.72 19.09 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.774 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 91.0 mt -91.1 118.8 68.77 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 117.404 0.602 . . . . 0.0 111.47 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.15 39.74 0.41 Allowed 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 122.882 2.388 . . . . 0.0 112.431 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.894 -179.611 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.582 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.0 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 120.869 0.366 . . . . 0.0 110.153 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.05 35.04 90.06 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.604 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -150.14 143.18 24.89 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.557 HG22 HG12 ' A' ' 21' ' ' ILE . 21.1 p -111.67 144.5 40.83 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.106 0.479 . . . . 0.0 110.86 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.517 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.0 p -113.27 62.19 0.64 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.849 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -56.93 -34.61 68.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.256 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -101.42 18.1 54.24 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.625 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.44 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 66.82 43.45 91.58 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.808 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.86 136.67 27.29 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.49 0.186 . . . . 0.0 111.047 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.517 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 59.7 m -133.17 129.58 38.01 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.945 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -84.9 -32.26 23.24 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.303 0.573 . . . . 0.0 109.567 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.9 m -66.44 122.55 82.29 Favored Pre-proline 0 N--CA 1.452 -0.354 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.948 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.51 141.12 59.87 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.783 2.322 . . . . 0.0 112.933 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.445 ' O ' ' HD3' ' A' ' 24' ' ' ARG . . . 72.83 27.83 68.19 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.887 179.662 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.462 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 85.6 m -118.5 116.99 27.82 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 121.113 0.482 . . . . 0.0 111.239 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.1 p -80.34 131.89 35.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 178.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.44 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.8 t -74.22 95.01 2.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.322 0.582 . . . . 0.0 112.076 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.4 m -91.95 67.22 5.16 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 176.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.0 t90 -27.19 122.68 0.24 Allowed Pre-proline 0 C--O 1.231 0.11 0 CA-C-N 113.703 -1.589 . . . . 0.0 113.213 -176.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 93.3 Cg_endo -101.78 35.74 6.52 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.024 0.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 4' ' ' THR . 64.4 mt -130.74 133.19 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.952 -0.468 . . . . 0.0 111.695 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.4 m -78.2 131.6 37.23 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.41 HG22 ' HA ' ' A' ' 28' ' ' PRO . 80.7 p -129.28 154.69 46.58 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.586 0.588 . . . . 0.0 112.586 -178.438 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.582 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 22.7 mmt85 -89.59 69.63 7.84 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 177.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 26.4 t70 65.98 53.34 1.12 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.926 0.869 . . . . 0.0 109.257 -177.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.48 -30.29 10.24 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.309 -0.859 . . . . 0.0 113.004 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 85.4 mt -81.92 113.43 42.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 117.006 0.403 . . . . 0.0 111.483 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.4 Cg_exo -73.77 39.36 0.5 Allowed 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 123.139 2.559 . . . . 0.0 112.422 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 111.929 -179.64 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 58.5 m . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 59.44 37.78 92.55 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -139.28 144.76 38.51 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 115.314 -0.443 . . . . 0.0 110.346 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.43 HG22 HD13 ' A' ' 21' ' ' ILE . 82.0 p -108.41 151.16 26.4 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.077 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.939 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -131.99 58.8 1.73 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.152 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -52.88 -31.92 42.21 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.19 0.519 . . . . 0.0 109.873 178.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -137.81 37.31 1.84 Allowed Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 177.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.545 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.59 42.06 99.69 Favored Glycine 0 C--N 1.337 0.619 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.3 p -108.41 44.5 1.11 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.939 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.8 m -81.85 123.43 28.81 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.104 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.8 m-20 -70.79 -36.28 72.94 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.6 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.7 m -73.44 118.56 69.94 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.981 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -74.56 142.16 28.98 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.932 2.421 . . . . 0.0 112.698 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.96 -22.42 40.96 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.325 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.739 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 96.4 m -69.69 125.26 26.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 0.0 111.063 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -79.31 128.57 33.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.2 t -76.31 94.41 3.58 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.574 0.583 . . . . 0.0 112.574 -178.209 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.2 m -91.38 65.45 5.32 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -23.2 120.68 0.17 Allowed Pre-proline 0 N--CA 1.462 0.169 0 CA-C-N 113.389 -1.732 . . . . 0.0 113.75 -176.619 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.9 Cg_endo -101.8 29.04 11.66 Favored 'Cis proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.876 -1.302 . . . . 0.0 113.699 0.287 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.43 HD13 HG22 ' A' ' 4' ' ' THR . 35.0 mm -123.02 128.39 75.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 O-C-N 122.218 -0.302 . . . . 0.0 111.459 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.739 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.65 131.81 36.07 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.434 0.635 . . . . 0.0 111.607 178.835 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.5 p -117.87 140.06 50.24 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.863 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.479 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 17.9 tpt85 -93.11 103.08 15.4 Favored 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 59.46 36.31 23.06 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 124.032 0.832 . . . . 0.0 110.159 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.23 -15.78 62.62 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.345 179.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.1 mt -92.8 121.1 66.66 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 117.205 0.502 . . . . 0.0 111.148 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.473 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.9 Cg_exo -71.94 39.32 0.39 Allowed 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 123.118 2.545 . . . . 0.0 112.215 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--N 1.326 -0.436 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.748 -179.528 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.596 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 87.5 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.469 0.176 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.67 36.96 94.01 Favored Glycine 0 N--CA 1.449 -0.435 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.477 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -141.59 145.65 35.31 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 115.125 -0.537 . . . . 0.0 109.812 -178.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.4 p -118.02 144.48 45.53 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -117.97 55.65 0.87 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.045 0.45 . . . . 0.0 111.006 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -56.38 -34.16 66.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.309 178.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.85 20.09 42.27 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.885 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.49 43.88 75.44 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.352 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.9 t -150.41 143.67 24.96 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.9 m -135.15 129.23 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.208 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 59.3 m-80 -70.51 -39.57 74.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.896 0.379 . . . . 0.0 110.36 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.9 m -71.8 117.22 55.76 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.562 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -68.84 138.96 42.22 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 123.122 2.548 . . . . 0.0 112.846 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.78 -20.05 51.57 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.765 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 71.4 m -77.18 126.24 30.62 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.073 0.463 . . . . 0.0 111.353 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -81.07 135.94 35.88 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.0 t -77.78 94.84 4.55 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.291 0.567 . . . . 0.0 112.227 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 15.9 m -93.81 67.7 3.83 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 107.089 -1.449 . . . . 0.0 107.089 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.554 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.3 t90 -27.18 122.47 0.24 Allowed Pre-proline 0 N--CA 1.463 0.184 0 CA-C-N 113.75 -1.568 . . . . 0.0 113.219 -176.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.554 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.84 30.28 10.5 Favored 'Cis proline' 0 N--CA 1.455 -0.774 0 C-N-CA 123.564 -1.432 . . . . 0.0 114.01 0.695 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.57 132.6 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 O-C-N 122.051 -0.405 . . . . 0.0 111.682 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.477 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.4 m -79.72 128.41 33.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.764 0.316 . . . . 0.0 110.552 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.447 ' HB ' ' N ' ' A' ' 27' ' ' LEU . 47.0 p -117.43 137.41 52.52 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.078 0.466 . . . . 0.0 112.043 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.596 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.1 tpt85 -90.58 101.3 14.04 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 177.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 59.6 38.56 22.1 Favored 'General case' 0 C--N 1.328 -0.345 0 O-C-N 123.891 0.744 . . . . 0.0 111.207 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.5 32.54 24.7 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.156 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.597 HD12 ' HD2' ' A' ' 28' ' ' PRO . 24.3 tp -144.83 117.77 5.48 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.068 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.597 ' HD2' HD12 ' A' ' 27' ' ' LEU . 56.3 Cg_endo -70.8 44.49 0.51 Allowed 'Trans proline' 0 N--CA 1.475 0.396 0 C-N-CA 123.25 2.633 . . . . 0.0 114.059 -178.277 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.591 HG13 ' HG ' ' A' ' 27' ' ' LEU . 18.6 m . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 120.933 0.397 . . . . 0.0 111.082 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.597 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 94.4 m . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 120.427 0.156 . . . . 0.0 111.077 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.72 40.72 98.82 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -150.31 147.63 27.87 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.0 p -117.61 143.24 46.33 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.979 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.544 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -114.67 56.14 0.73 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.011 0.434 . . . . 0.0 111.4 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.65 -34.47 67.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.214 178.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.48 20.93 38.39 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.866 179.148 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.26 42.91 81.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.468 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 13.4 t -150.53 143.4 24.67 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 58.1 m -132.83 128.82 37.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.687 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -68.82 -44.87 72.6 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.8 m -64.91 117.5 39.51 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.732 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -71.1 142.57 42.38 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.84 2.36 . . . . 0.0 113.067 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.41 33.65 38.61 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.161 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.4 m -124.31 133.74 53.38 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.868 0.366 . . . . 0.0 110.797 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -84.06 135.14 34.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.458 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 14.5 t -81.43 95.28 7.01 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.258 0.552 . . . . 0.0 111.759 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 12.5 m -93.66 67.91 3.94 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.5 t90 -27.95 122.79 0.25 Allowed Pre-proline 0 C--O 1.232 0.138 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.176 -176.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.7 Cg_endo -101.61 30.26 10.72 Favored 'Cis proline' 0 N--CA 1.455 -0.759 0 C-N-CA 123.59 -1.421 . . . . 0.0 114.083 0.635 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.0 mt -125.94 132.64 70.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 O-C-N 122.007 -0.433 . . . . 0.0 111.511 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.431 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 29.7 m -80.64 127.67 32.74 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.876 0.37 . . . . 0.0 110.768 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.7 p -119.48 142.48 48.24 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.233 0.539 . . . . 0.0 111.56 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.597 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 31.3 ttt85 -99.47 106.28 18.3 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 58.96 34.96 23.91 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 123.89 0.744 . . . . 0.0 110.14 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.31 -17.01 60.13 Favored Glycine 0 CA--C 1.52 0.403 0 CA-C-N 115.712 -0.676 . . . . 0.0 113.489 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.4 mt -93.84 122.59 61.84 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.213 0.507 . . . . 0.0 111.32 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.8 Cg_exo -72.16 39.09 0.39 Allowed 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 123.074 2.516 . . . . 0.0 112.343 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.667 -179.731 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.487 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.6 m . . . . . 0 N--CA 1.448 -0.534 0 CA-C-O 120.527 0.203 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.55 37.96 95.57 Favored Glycine 0 C--N 1.333 0.378 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 -178.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.546 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.6 tp10 -144.56 142.88 30.5 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.167 -0.516 . . . . 0.0 109.678 -178.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.9 p -116.17 144.49 44.11 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.915 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.4 p -118.48 56.7 0.87 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -55.79 -35.18 66.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.474 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.17 20.87 36.96 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.966 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.07 44.54 66.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.202 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.6 m -147.63 135.75 21.36 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 62.8 m -127.95 126.18 40.94 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.181 0.3 . . . . 0.0 110.355 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 49.4 t-20 -66.4 -43.62 85.32 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.2 m -71.63 117.18 55.1 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.487 179.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_exo -70.13 139.16 38.31 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.978 2.452 . . . . 0.0 112.825 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.89 -23.53 35.62 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.655 179.54 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.5 m -73.7 127.68 33.44 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.071 0.462 . . . . 0.0 111.462 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.8 t -79.93 134.77 36.3 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.5 t -77.86 93.88 4.44 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.301 0.572 . . . . 0.0 112.274 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.8 m -92.38 67.98 4.89 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 176.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.2 t90 -27.4 122.82 0.24 Allowed Pre-proline 0 N--CA 1.463 0.175 0 CA-C-N 113.861 -1.518 . . . . 0.0 113.305 -176.796 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 87.3 Cg_endo -101.69 30.55 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.516 -1.452 . . . . 0.0 114.047 0.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.6 mt -126.53 132.57 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 120.973 0.416 . . . . 0.0 111.487 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.546 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.5 m -79.62 128.79 33.83 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.805 0.336 . . . . 0.0 110.389 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -122.96 146.36 47.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.978 0.418 . . . . 0.0 112.003 -178.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.487 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 3.4 mmm-85 -91.25 95.54 10.09 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 177.094 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.97 37.35 21.44 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 123.928 0.768 . . . . 0.0 110.104 -178.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.15 -18.81 56.12 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.721 -0.672 . . . . 0.0 113.338 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.573 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.5 tp -89.53 113.82 58.13 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.157 0.478 . . . . 0.0 110.559 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 8.0 Cg_exo -73.14 46.74 1.18 Allowed 'Trans proline' 0 CA--C 1.531 0.36 0 C-N-CA 123.431 2.754 . . . . 0.0 113.59 -178.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.573 HG13 ' HG ' ' A' ' 27' ' ' LEU . 24.5 m . . . . . 0 C--N 1.325 -0.466 0 CA-C-O 121.085 0.469 . . . . 0.0 111.199 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.8 m . . . . . 0 N--CA 1.45 -0.434 0 CA-C-O 121.012 0.434 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 36.77 92.29 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.373 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -150.31 151.38 32.84 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.935 0.398 . . . . 0.0 110.129 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 38.7 p -110.3 146.69 35.27 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.952 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.549 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 28.2 p -115.12 54.82 0.78 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.135 0.493 . . . . 0.0 110.64 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -55.22 -35.42 64.9 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.68 179.287 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.11 19.56 45.88 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.91 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.1 46.16 67.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.975 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -149.78 142.36 24.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.629 0.252 . . . . 0.0 110.524 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 65.6 m -136.02 128.34 30.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.182 -179.449 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.5 p30 -77.61 -28.26 51.45 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.864 0.364 . . . . 0.0 110.404 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.41 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -70.99 123.42 89.29 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.497 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -69.51 136.12 32.83 Favored 'Trans proline' 0 N--CA 1.464 -0.221 0 C-N-CA 122.614 2.209 . . . . 0.0 113.114 -179.189 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.38 66.42 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.878 179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.41 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 66.1 m -112.71 128.05 56.3 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.065 0.459 . . . . 0.0 111.09 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.3 t -84.44 141.59 30.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.229 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.5 t -83.29 95.28 8.13 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.199 0.523 . . . . 0.0 111.995 -179.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.9 m -92.67 66.71 4.47 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.9 t90 -27.71 123.0 0.24 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.177 -176.764 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.8 Cg_endo -101.55 31.89 9.35 Favored 'Cis proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.497 -1.46 . . . . 0.0 114.039 0.625 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.6 mt -126.45 134.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 O-C-N 121.994 -0.441 . . . . 0.0 111.648 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.489 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -79.3 132.58 36.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.712 0.291 . . . . 0.0 110.85 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.5 p -128.31 136.61 51.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 111.37 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.5 ttt-85 -95.3 107.01 19.1 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.356 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 60.28 34.89 20.86 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 123.731 0.644 . . . . 0.0 110.067 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.62 -13.39 67.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.183 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.689 ' HB3' HG23 ' A' ' 29' ' ' VAL . 90.9 mt -94.11 118.68 67.19 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 117.159 0.479 . . . . 0.0 111.097 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -72.82 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.066 2.511 . . . . 0.0 112.512 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.689 HG23 ' HB3' ' A' ' 27' ' ' LEU . 3.2 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-O 121.348 0.595 . . . . 0.0 110.732 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 80.8 m . . . . . 0 N--CA 1.449 -0.522 0 CA-C-O 120.73 0.3 . . . . 0.0 110.593 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 41.13 97.21 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.406 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -146.87 145.19 29.76 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.958 0.409 . . . . 0.0 110.13 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -114.02 144.35 43.25 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.767 178.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.493 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.6 p -118.38 55.36 0.9 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.052 0.453 . . . . 0.0 111.289 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -56.62 -33.74 66.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.313 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.77 20.48 38.84 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.889 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.16 44.85 74.6 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.386 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.0 t -150.19 142.79 24.52 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.586 0.231 . . . . 0.0 110.541 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.493 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 56.0 m -134.52 131.01 37.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.254 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -66.7 -35.02 79.14 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.93 0.395 . . . . 0.0 110.382 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -80.89 117.23 67.1 Favored Pre-proline 0 N--CA 1.45 -0.442 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.977 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.69 136.87 28.91 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.71 2.274 . . . . 0.0 112.157 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.07 -27.23 21.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.655 -0.783 . . . . 0.0 111.999 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.3 m -72.54 127.81 33.68 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.989 0.423 . . . . 0.0 110.952 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -79.93 134.84 36.3 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.403 179.366 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.6 t -77.85 93.47 4.37 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.268 0.556 . . . . 0.0 111.727 -179.292 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.5 m -90.97 68.05 6.13 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.5 t90 -27.75 122.98 0.25 Allowed Pre-proline 0 N--CA 1.463 0.194 0 CA-C-N 113.932 -1.485 . . . . 0.0 113.268 -176.786 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.67 30.57 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.589 -1.421 . . . . 0.0 113.972 0.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.5 mt -126.86 132.52 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 O-C-N 122.058 -0.401 . . . . 0.0 111.567 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.492 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 28.6 m -79.35 128.96 33.98 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.823 0.344 . . . . 0.0 110.689 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -121.28 144.05 48.84 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.277 0.56 . . . . 0.0 111.393 -179.38 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.49 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 59.9 ttp180 -95.59 84.1 3.9 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.1 t70 67.27 49.95 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 O-C-N 124.248 0.968 . . . . 0.0 109.631 -177.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.29 -24.9 20.13 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.925 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -92.14 116.02 65.72 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 117.378 0.589 . . . . 0.0 111.547 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -73.21 39.02 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.005 2.47 . . . . 0.0 112.196 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 C--N 1.324 -0.503 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.61 -179.505 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.401 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 82.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 120.67 0.271 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 34.32 87.86 Favored Glycine 0 N--CA 1.451 -0.33 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -178.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.478 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -134.0 145.16 49.23 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.9 -0.65 . . . . 0.0 109.959 -179.034 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.427 HG22 HD13 ' A' ' 21' ' ' ILE . 65.0 p -114.17 146.03 40.88 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.614 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.578 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 27.9 p -124.21 54.07 1.38 Allowed 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.15 0.5 . . . . 0.0 110.854 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -56.43 -33.3 65.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.387 179.078 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.53 19.87 41.05 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.807 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.42 45.03 70.86 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.324 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.9 t -150.11 142.8 24.6 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.542 0.21 . . . . 0.0 110.591 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.482 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 46.4 m -134.34 127.75 32.32 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.025 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -72.04 -34.55 68.86 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.931 0.396 . . . . 0.0 110.232 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.5 m -72.47 118.24 65.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.483 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.85 135.45 32.7 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.638 2.225 . . . . 0.0 112.864 -179.472 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.66 -22.5 39.98 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 76.9 m -78.12 121.59 24.5 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.085 0.469 . . . . 0.0 111.014 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.5 t -82.59 138.16 34.31 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.29 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 26.6 t -74.49 113.81 12.16 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.469 0.652 . . . . 0.0 111.941 -179.219 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.0 m -113.13 66.12 0.65 Allowed 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 177.228 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.1 t90 -23.55 120.36 0.18 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 113.489 -1.687 . . . . 0.0 113.665 -176.584 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.518 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 76.0 Cg_endo -101.96 25.62 14.53 Favored 'Cis proline' 0 N--CA 1.456 -0.729 0 C-N-CA 123.668 -1.388 . . . . 0.0 113.784 0.432 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.427 HD13 HG22 ' A' ' 4' ' ' THR . 41.4 mm -119.74 132.77 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-O 120.729 0.299 . . . . 0.0 111.628 -179.063 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.0 m -81.4 128.28 33.69 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.3 p -115.79 145.78 42.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.222 0.534 . . . . 0.0 111.532 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.402 ' HD2' ' HA ' ' A' ' 24' ' ' ARG . 16.9 tpt85 -89.7 85.24 6.4 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.294 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 62.58 43.14 7.86 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.2 -177.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.99 -23.68 34.71 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.702 -0.761 . . . . 0.0 113.616 179.301 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.57 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.3 tp -92.6 111.6 51.66 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 117.355 0.578 . . . . 0.0 110.617 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.454 ' HD2' HD12 ' A' ' 27' ' ' LEU . 60.4 Cg_endo -72.86 47.38 1.22 Allowed 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 123.184 2.589 . . . . 0.0 113.817 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.57 HG13 ' HG ' ' A' ' 27' ' ' LEU . 30.3 m . . . . . 0 C--N 1.324 -0.511 0 CA-C-O 120.87 0.367 . . . . 0.0 111.416 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.617 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 52.5 m . . . . . 0 N--CA 1.448 -0.573 0 CA-C-O 120.402 0.144 . . . . 0.0 111.148 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.32 37.74 94.24 Favored Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -178.778 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.484 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.1 tp10 -140.91 145.85 36.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.142 -0.529 . . . . 0.0 109.858 -179.032 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.403 HG22 HD13 ' A' ' 21' ' ' ILE . 64.4 p -115.6 146.73 41.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.784 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.1 p -125.02 55.58 1.36 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.239 0.543 . . . . 0.0 110.715 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -57.05 -33.0 66.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.271 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.98 18.89 48.35 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.73 -0.747 . . . . 0.0 111.657 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.57 42.77 79.69 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.045 -0.597 . . . . 0.0 112.298 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.6 t -150.62 143.77 24.82 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 110.452 -0.203 . . . . 0.0 110.452 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.482 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 39.6 m -132.1 129.5 40.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -70.69 -35.45 72.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.978 0.418 . . . . 0.0 110.344 179.72 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 10.6 m -76.66 116.6 58.07 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.792 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.17 139.6 46.79 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.948 2.432 . . . . 0.0 112.489 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.05 -27.37 20.33 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.015 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.0 m -76.34 125.63 29.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.094 0.473 . . . . 0.0 110.967 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.8 m -85.99 134.81 33.84 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.71 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 27.2 t -73.49 116.18 13.75 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.339 0.59 . . . . 0.0 111.873 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.8 m -115.96 66.87 0.71 Allowed 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.57 -1.641 . . . . 0.0 106.57 177.339 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.8 t90 -23.51 119.48 0.18 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.518 -1.674 . . . . 0.0 113.643 -176.555 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 75.5 Cg_endo -102.7 26.7 12.49 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.855 0.544 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.403 HD13 HG22 ' A' ' 4' ' ' THR . 38.6 mm -120.33 133.73 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 111.624 -179.07 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 40.6 m -82.31 126.06 31.7 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 178.888 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -113.19 150.84 31.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.529 0.68 . . . . 0.0 111.71 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.617 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.5 ttm180 -103.72 86.65 2.65 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.118 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.7 t0 66.52 49.51 1.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 O-C-N 124.245 0.965 . . . . 0.0 109.509 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.82 -25.01 12.51 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.773 179.684 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.8 mt -88.92 117.9 68.73 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 117.316 0.558 . . . . 0.0 111.547 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -73.96 38.71 0.48 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.027 2.485 . . . . 0.0 112.269 179.313 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.325 -0.491 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.617 -179.476 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.0 m . . . . . 0 N--CA 1.45 -0.468 0 CA-C-O 120.644 0.259 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.75 38.71 94.72 Favored Glycine 0 N--CA 1.451 -0.345 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -178.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.482 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -141.88 147.18 36.71 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.797 -178.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.2 p -118.46 145.66 45.08 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.973 0.416 . . . . 0.0 110.752 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.2 p -120.69 56.49 1.0 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.006 0.431 . . . . 0.0 111.028 -179.691 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.61 -34.02 66.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.29 179.018 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.49 20.23 40.19 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.82 179.107 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.5 43.61 76.63 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.339 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.7 t -150.22 142.88 24.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.461 0.172 . . . . 0.0 110.565 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.49 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.6 m -132.71 128.74 37.58 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.037 -179.846 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.3 m-80 -69.67 -34.58 74.17 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.021 0.439 . . . . 0.0 110.021 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.1 m -75.27 115.66 47.21 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.362 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -70.3 136.18 30.94 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.92 2.413 . . . . 0.0 112.472 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.45 -24.23 32.84 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.454 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -77.72 130.47 36.8 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.151 0.5 . . . . 0.0 111.219 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.1 t -84.77 137.52 33.15 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.468 179.506 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 25.0 t -77.16 112.62 14.02 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.301 0.572 . . . . 0.0 111.739 -179.448 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.7 m -111.25 67.6 0.65 Allowed 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 177.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.0 t90 -26.33 122.53 0.22 Allowed Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 113.776 -1.556 . . . . 0.0 113.344 -176.602 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.5 Cg_endo -101.36 28.84 12.35 Favored 'Cis proline' 0 N--CA 1.454 -0.804 0 C-N-CA 123.6 -1.417 . . . . 0.0 114.086 0.534 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 61.3 mt -127.55 134.71 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 O-C-N 121.997 -0.439 . . . . 0.0 111.538 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 31.4 m -79.87 130.41 35.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.908 0.385 . . . . 0.0 110.43 179.442 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 54.4 p -121.48 157.95 29.49 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.215 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.434 ' HA ' ' HD2' ' A' ' 24' ' ' ARG . 13.9 tpt85 -87.99 58.33 4.76 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.264 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 64.45 45.88 3.56 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.955 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 142.43 -47.94 0.8 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.385 -0.912 . . . . 0.0 113.479 178.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 99.0 mt -108.93 127.87 26.52 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 122.553 -0.38 . . . . 0.0 111.777 -179.11 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.8 Cg_endo -75.6 39.03 0.6 Allowed 'Trans proline' 0 CA--C 1.528 0.22 0 C-N-CA 123.209 2.606 . . . . 0.0 112.47 179.559 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 -179.642 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 60.9 m . . . . . 0 N--CA 1.448 -0.542 0 CA-C-O 120.695 0.283 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.52 45.01 96.76 Favored Glycine 0 C--N 1.335 0.479 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.437 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.414 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -150.16 149.86 30.83 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.958 0.408 . . . . 0.0 110.698 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.472 HG22 HD13 ' A' ' 21' ' ' ILE . 42.4 p -123.41 142.85 50.56 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.61 178.618 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 29.3 p -105.34 57.32 0.68 Allowed 'General case' 0 C--N 1.315 -0.923 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.688 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -56.59 -33.54 66.32 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -106.02 23.36 29.34 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.61 178.365 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 66.92 37.33 92.11 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 121.197 -0.525 . . . . 0.0 113.082 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.4 t -151.06 142.61 23.55 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.717 0.294 . . . . 0.0 111.371 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.743 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.8 m -122.54 132.44 54.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.634 179.371 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -64.68 -34.56 78.59 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.921 0.391 . . . . 0.0 110.394 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.4 m -79.71 115.74 55.89 Favored Pre-proline 0 N--CA 1.45 -0.465 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.717 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.97 135.8 26.1 Favored 'Trans proline' 0 N--CA 1.462 -0.349 0 C-N-CA 122.516 2.144 . . . . 0.0 112.37 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.03 -26.65 23.89 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.071 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.8 m -71.65 125.82 28.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.974 0.416 . . . . 0.0 111.234 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -89.58 121.21 31.56 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.081 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.827 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 19.6 t -86.86 116.95 25.28 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 113.464 0.912 . . . . 0.0 113.464 -177.17 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.9 m -88.72 72.64 8.62 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 174.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.509 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 12.7 t90 -21.56 122.25 0.12 Allowed Pre-proline 0 N--CA 1.468 0.433 0 CA-C-N 113.889 -1.505 . . . . 0.0 113.834 -175.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 88.8 Cg_endo -101.78 31.31 9.65 Favored 'Cis proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.228 0.502 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.472 HD13 HG22 ' A' ' 4' ' ' THR . 43.8 mm -116.52 120.54 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.236 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.827 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 28.8 m -74.67 130.2 39.09 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.413 HG22 ' CA ' ' A' ' 28' ' ' PRO . 37.2 p -131.04 139.67 49.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.124 0.488 . . . . 0.0 111.876 -178.636 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 5.6 tmm_? -96.7 102.22 13.97 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 59.41 40.4 20.9 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 123.807 0.692 . . . . 0.0 110.302 -177.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.25 -15.68 60.58 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.557 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.5 mt -91.61 118.93 68.63 Favored Pre-proline 0 C--N 1.327 -0.396 0 CA-C-N 117.232 0.516 . . . . 0.0 111.5 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.413 ' CA ' HG22 ' A' ' 23' ' ' THR . 71.5 Cg_endo -74.82 38.82 0.54 Allowed 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 123.081 2.521 . . . . 0.0 112.049 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--N 1.324 -0.525 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.818 -179.452 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.451 -0.402 0 CA-C-O 120.664 0.269 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.65 37.67 95.16 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -143.29 141.48 31.03 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.47 HG22 HG12 ' A' ' 21' ' ' ILE . 37.7 p -111.88 146.86 36.99 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.036 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.805 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 23.2 p -122.69 57.94 1.09 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -56.09 -36.05 67.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.127 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.56 20.56 43.91 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.684 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.08 40.22 88.45 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.351 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.2 t -151.19 142.92 23.74 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.555 -0.165 . . . . 0.0 110.555 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.805 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -139.06 137.5 36.29 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.8 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -67.24 -41.29 85.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.518 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.2 m -70.67 114.41 26.36 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.409 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.89 137.93 27.73 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.058 2.505 . . . . 0.0 112.449 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.8 -25.25 28.62 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.301 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.703 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 91.2 m -71.04 127.79 33.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.022 0.439 . . . . 0.0 111.272 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -79.64 126.7 31.25 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.8 t -73.88 96.89 2.67 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.488 0.661 . . . . 0.0 112.191 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.7 m -94.11 68.15 3.69 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.102 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.2 t90 -25.7 122.26 0.22 Allowed Pre-proline 0 N--CA 1.463 0.22 0 CA-C-N 113.918 -1.492 . . . . 0.0 113.313 -176.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.7 Cg_endo -101.55 30.31 10.72 Favored 'Cis proline' 0 N--CA 1.456 -0.71 0 C-N-CA 123.606 -1.414 . . . . 0.0 114.159 0.754 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.47 HG12 HG22 ' A' ' 4' ' ' THR . 67.6 mt -131.26 131.83 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.954 -0.466 . . . . 0.0 111.341 -179.482 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.703 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -79.4 134.97 36.57 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.306 0.574 . . . . 0.0 111.982 179.587 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 70.6 p -120.9 149.51 42.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.076 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.511 ' HG2' ' OD1' ' A' ' 25' ' ' ASP . 17.0 ttt-85 -88.17 94.86 9.95 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.672 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.511 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 1.1 p-10 46.38 42.78 11.03 Favored 'General case' 0 N--CA 1.469 0.483 0 O-C-N 124.334 1.022 . . . . 0.0 111.434 -177.163 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.57 -22.18 29.0 Favored Glycine 0 C--N 1.335 0.49 0 CA-C-N 115.52 -0.763 . . . . 0.0 113.865 178.619 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.522 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.6 tp -93.45 113.82 61.22 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 117.256 0.528 . . . . 0.0 111.015 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 11.2 Cg_exo -71.59 48.26 1.0 Allowed 'Trans proline' 0 CA--C 1.533 0.431 0 C-N-CA 123.498 2.799 . . . . 0.0 113.772 -179.236 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.522 HG13 ' HG ' ' A' ' 27' ' ' LEU . 31.1 m . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 121.004 0.431 . . . . 0.0 111.257 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.1 m . . . . . 0 N--CA 1.449 -0.492 0 CA-C-O 120.786 0.327 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.51 37.8 94.74 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.543 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -144.25 143.88 31.24 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.126 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 45.2 p -105.75 153.63 21.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.701 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.903 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 22.2 p -131.67 56.97 1.79 Allowed 'General case' 0 C--N 1.321 -0.643 0 O-C-N 122.269 -0.27 . . . . 0.0 110.95 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -52.01 -35.99 48.58 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.215 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.23 31.65 3.98 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 178.218 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.517 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.99 48.36 83.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.143 -0.551 . . . . 0.0 111.823 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.6 m -130.7 69.27 1.46 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 111.975 0.361 . . . . 0.0 111.975 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.903 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 92.6 m -90.88 130.98 36.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.763 0.316 . . . . 0.0 111.18 179.515 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.8 p-10 -64.51 -35.12 79.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.935 -179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 18.1 m -85.01 114.68 57.27 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.196 -179.127 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 8.0 Cg_exo -71.94 139.73 33.65 Favored 'Trans proline' 0 N--CA 1.462 -0.341 0 C-N-CA 123.111 2.541 . . . . 0.0 111.932 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.02 -25.93 26.11 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.079 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.709 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 97.6 m -67.05 128.34 35.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.839 0.352 . . . . 0.0 110.744 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.7 m -78.87 123.5 27.3 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.6 t -72.6 98.83 2.41 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.362 0.601 . . . . 0.0 112.232 -178.215 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 9.0 m -94.49 68.38 3.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.536 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.6 t90 -25.18 121.06 0.21 Allowed Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.355 -176.464 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.536 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.5 Cg_endo -102.76 33.6 7.5 Favored 'Cis proline' 0 N--CA 1.455 -0.764 0 C-N-CA 123.69 -1.379 . . . . 0.0 114.153 0.853 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.421 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 67.9 mt -132.23 132.99 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 O-C-N 121.992 -0.442 . . . . 0.0 111.576 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.709 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.58 134.93 36.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.34 0.59 . . . . 0.0 112.474 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 42.5 p -123.0 143.82 49.67 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.651 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.453 ' HD2' ' HA ' ' A' ' 24' ' ' ARG . 2.3 mmm-85 -95.25 101.9 13.67 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.521 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 60.03 36.14 21.42 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 123.944 0.778 . . . . 0.0 110.006 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.56 -14.49 65.16 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.623 -0.717 . . . . 0.0 113.192 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.629 ' HG ' HG13 ' A' ' 29' ' ' VAL . 21.6 tp -92.96 116.35 66.37 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 117.067 0.433 . . . . 0.0 110.273 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.563 ' HD2' HD12 ' A' ' 27' ' ' LEU . 58.4 Cg_endo -71.7 45.61 0.73 Allowed 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 123.122 2.548 . . . . 0.0 113.83 -178.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.629 HG13 ' HG ' ' A' ' 27' ' ' LEU . 16.0 m . . . . . 0 C--N 1.326 -0.421 0 CA-C-O 120.928 0.394 . . . . 0.0 111.465 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 N--CA 1.448 -0.538 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.11 34.32 87.56 Favored Glycine 0 C--N 1.333 0.387 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.791 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -140.53 134.21 30.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.468 HG22 HD13 ' A' ' 21' ' ' ILE . 77.8 p -96.21 146.19 24.91 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.429 -178.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.638 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -120.65 58.48 0.94 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.204 179.217 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -55.92 -34.66 65.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.48 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.77 17.33 56.6 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.485 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.458 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 67.81 41.57 88.32 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 121.144 -0.55 . . . . 0.0 111.946 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.3 t -151.47 144.92 24.84 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.077 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.638 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 30.2 m -146.62 140.8 26.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.9 m-80 -73.23 -35.24 66.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.569 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.4 m -66.78 115.24 22.76 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.842 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.86 134.48 27.87 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.654 2.236 . . . . 0.0 112.837 -179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.61 -18.53 57.16 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.69 -0.767 . . . . 0.0 113.001 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.584 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 94.9 m -77.41 120.63 22.67 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.179 0.514 . . . . 0.0 111.016 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -79.41 131.27 36.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.458 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 32.9 t -75.52 92.73 2.91 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.338 0.59 . . . . 0.0 112.24 -178.466 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.0 m -89.58 66.74 7.35 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -25.22 121.33 0.21 Allowed Pre-proline 0 C--O 1.232 0.168 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.68 -176.543 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 85.4 Cg_endo -101.75 26.31 14.26 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.59 -1.421 . . . . 0.0 113.787 0.544 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.468 HD13 HG22 ' A' ' 4' ' ' THR . 35.9 mm -120.56 127.87 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 O-C-N 122.257 -0.277 . . . . 0.0 111.424 -179.208 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.584 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 13.0 m -79.78 130.36 35.26 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.254 0.55 . . . . 0.0 111.35 179.062 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 69.0 p -118.59 140.6 49.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.723 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 35.8 tpt85 -89.66 92.14 8.95 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.351 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 61.04 40.61 14.92 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 124.028 0.83 . . . . 0.0 110.48 -178.58 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.75 -22.89 35.63 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 113.841 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.9 mt -93.86 117.45 67.23 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 117.381 0.59 . . . . 0.0 111.589 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.85 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.924 2.416 . . . . 0.0 112.266 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 C--N 1.326 -0.451 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.875 -179.581 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 N--CA 1.45 -0.47 0 CA-C-O 120.86 0.362 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.42 40.38 97.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.887 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -147.44 142.09 26.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.976 0.417 . . . . 0.0 110.19 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.619 HG22 HG12 ' A' ' 21' ' ' ILE . 41.7 p -107.36 146.79 31.16 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.694 179.581 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.787 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 21.4 p -122.38 56.82 1.1 Allowed 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.989 0.423 . . . . 0.0 110.757 179.791 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -55.99 -36.77 68.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.252 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.91 21.31 40.71 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.516 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.7 40.71 90.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.183 -0.532 . . . . 0.0 112.408 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.2 t -150.78 142.92 24.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.787 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 89.4 m -137.49 137.58 38.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.744 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -64.44 -35.67 81.66 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.1 m -76.89 113.77 33.18 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.709 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.52 136.02 27.6 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.539 2.159 . . . . 0.0 112.376 -179.732 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.64 -19.32 54.83 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.502 -0.856 . . . . 0.0 113.037 179.643 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.512 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 68.6 m -74.65 131.7 41.11 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 117.287 0.543 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.1 m -81.96 119.36 23.86 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.743 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 10.4 t -68.76 112.41 5.47 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.433 0.635 . . . . 0.0 111.775 -178.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.8 m -109.06 69.61 0.71 Allowed 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -25.19 122.1 0.21 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.352 -176.623 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 83.7 Cg_endo -101.57 31.22 9.88 Favored 'Cis proline' 0 N--CA 1.455 -0.739 0 C-N-CA 123.541 -1.441 . . . . 0.0 114.277 0.806 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.619 HG12 HG22 ' A' ' 4' ' ' THR . 64.4 mt -135.7 134.19 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 O-C-N 121.97 -0.456 . . . . 0.0 111.436 -179.46 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.512 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -76.77 137.02 39.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.14 0.495 . . . . 0.0 111.491 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.4 p -128.99 158.84 37.74 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.939 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.01 55.0 3.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 178.271 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 65.12 43.1 3.8 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.872 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 148.63 -45.77 0.71 Allowed Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.325 -0.941 . . . . 0.0 113.263 179.236 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 98.1 mt -114.96 129.86 24.69 Favored Pre-proline 0 C--N 1.327 -0.383 0 O-C-N 122.509 -0.407 . . . . 0.0 111.686 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.6 Cg_endo -75.39 39.92 0.65 Allowed 'Trans proline' 0 CA--C 1.53 0.279 0 C-N-CA 123.247 2.631 . . . . 0.0 112.506 179.606 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.6 m . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.034 -179.656 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.9 m . . . . . 0 N--CA 1.448 -0.546 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.98 39.1 96.57 Favored Glycine 0 C--N 1.335 0.495 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.864 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -147.74 152.29 37.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.769 0.318 . . . . 0.0 110.388 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.414 HG22 HG12 ' A' ' 21' ' ' ILE . 22.7 p -122.45 146.0 47.78 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.506 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.513 ' HB2' ' N ' ' A' ' 9' ' ' THR . 21.6 p -107.63 60.35 0.62 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.135 0.493 . . . . 0.0 111.028 -179.625 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -56.17 -30.24 61.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.101 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.55 17.38 46.66 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.789 -0.719 . . . . 0.0 111.564 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 39.82 86.93 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.558 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.513 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.2 m -150.92 137.27 18.57 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 122.581 -0.364 . . . . 0.0 111.087 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.723 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 57.8 m -125.15 129.95 51.19 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 178.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -77.0 -34.11 57.53 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.041 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -63.96 119.18 52.82 Favored Pre-proline 0 C--O 1.236 0.361 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.599 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.88 135.89 36.69 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.952 2.435 . . . . 0.0 113.801 -178.728 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.22 17.07 78.74 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.465 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 55.9 m -105.33 121.36 43.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 117.141 0.471 . . . . 0.0 111.078 179.282 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.7 m -90.23 117.71 29.19 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 107.305 -1.368 . . . . 0.0 107.305 178.089 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.838 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 17.9 t -81.6 118.34 22.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 113.491 0.922 . . . . 0.0 113.491 -176.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.8 m -92.34 73.35 5.3 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 104.964 -2.235 . . . . 0.0 104.964 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -23.04 125.59 0.12 Allowed Pre-proline 0 N--CA 1.467 0.42 0 CA-C-N 113.767 -1.561 . . . . 0.0 113.661 -175.567 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.495 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 94.6 Cg_endo -100.52 33.53 8.56 Favored 'Cis proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.332 -1.528 . . . . 0.0 114.449 0.652 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.414 HG12 HG22 ' A' ' 4' ' ' THR . 66.4 mt -124.58 125.83 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 O-C-N 121.865 -0.522 . . . . 0.0 112.097 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.838 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 14.0 m -72.1 129.11 37.73 Favored 'General case' 0 C--O 1.233 0.212 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.439 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.0 p -128.79 138.11 51.9 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.127 0.489 . . . . 0.0 111.844 -178.528 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.99 104.97 16.85 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.24 37.38 23.76 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.434 0.635 . . . . 0.0 110.043 -178.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.65 -11.45 70.18 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.522 -0.763 . . . . 0.0 113.447 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.1 mt -94.44 123.58 58.05 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 117.2 0.5 . . . . 0.0 111.202 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -73.39 39.99 0.51 Allowed 'Trans proline' 0 CA--C 1.53 0.302 0 C-N-CA 123.072 2.515 . . . . 0.0 112.038 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.326 -0.425 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.895 -179.327 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 121.135 0.493 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.26 34.63 90.42 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.511 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -145.34 136.83 25.18 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-O 120.934 0.397 . . . . 0.0 110.026 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.582 HG22 HG12 ' A' ' 21' ' ' ILE . 36.7 p -99.41 143.57 29.51 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.164 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.61 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -115.36 60.45 0.7 Allowed 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.412 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -55.97 -34.91 66.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.494 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.52 16.95 57.36 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.593 178.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.422 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 68.13 40.82 88.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.877 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.6 t -151.55 146.46 25.89 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 121.272 -0.171 . . . . 0.0 110.685 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.61 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 18.8 m -145.69 138.74 26.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.015 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -74.01 -42.58 60.15 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.311 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.1 m -62.15 118.15 36.83 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.723 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -68.43 147.55 71.47 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 123.056 2.504 . . . . 0.0 113.528 -178.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.6 25.78 71.44 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.133 -0.939 . . . . 0.0 113.53 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.753 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 89.5 m -114.2 122.49 46.96 Favored 'General case' 0 N--CA 1.444 -0.765 0 O-C-N 122.288 -0.536 . . . . 0.0 110.665 179.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -79.44 127.55 32.25 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.422 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.6 t -74.93 90.22 2.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.333 0.587 . . . . 0.0 112.107 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.1 m -88.5 68.06 8.69 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 177.007 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -26.44 123.54 0.22 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.896 -1.502 . . . . 0.0 113.317 -176.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.439 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 80.4 Cg_endo -101.04 30.76 10.71 Favored 'Cis proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.51 -1.454 . . . . 0.0 114.092 0.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.582 HG12 HG22 ' A' ' 4' ' ' THR . 65.5 mt -131.12 131.31 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 O-C-N 122.029 -0.419 . . . . 0.0 111.358 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.753 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 37.9 m -79.08 132.45 36.61 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.312 0.577 . . . . 0.0 111.709 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -116.22 147.14 41.76 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.842 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.7 tpp85 -94.39 83.38 4.17 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.7 t70 64.74 49.32 2.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.866 -177.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.01 -26.56 18.29 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.724 -0.75 . . . . 0.0 113.956 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.467 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.9 mt -91.98 119.93 68.09 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 117.51 0.655 . . . . 0.0 111.388 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 9.2 Cg_exo -71.28 39.01 0.34 Allowed 'Trans proline' 0 CA--C 1.531 0.334 0 C-N-CA 123.137 2.558 . . . . 0.0 112.447 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.901 -179.665 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.647 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 96.7 m . . . . . 0 N--CA 1.451 -0.409 0 CA-C-O 120.7 0.286 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.19 92.81 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.398 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.546 ' HG2' ' H ' ' A' ' 11' ' ' ASN . 6.9 tp10 -150.5 143.64 24.85 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.056 0.455 . . . . 0.0 110.326 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -101.1 148.88 24.56 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.122 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.765 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -124.82 56.08 1.32 Allowed 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.478 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -53.83 -32.32 52.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.177 0.513 . . . . 0.0 109.802 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.32 42.42 1.36 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 178.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.6 34.39 89.78 Favored Glycine 0 C--N 1.336 0.537 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.014 -179.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 p -89.58 50.58 1.93 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.469 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -81.92 95.0 7.23 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.946 179.346 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.546 ' H ' ' HG2' ' A' ' 3' ' ' GLU . 40.8 m-80 -68.31 -37.1 80.26 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.235 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.804 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.9 m -69.02 124.93 91.45 Favored Pre-proline 0 N--CA 1.451 -0.423 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.732 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 29.4 Cg_exo -63.04 135.61 52.12 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 123.163 2.575 . . . . 0.0 114.601 -178.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.74 21.48 79.65 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.675 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.804 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 63.8 m -91.89 127.09 37.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 117.008 0.404 . . . . 0.0 111.202 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.2 t -79.47 130.83 35.78 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.8 t -78.26 87.65 4.32 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.153 0.502 . . . . 0.0 112.064 -178.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -86.03 66.84 9.77 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 176.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -27.49 124.01 0.24 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.537 -1.665 . . . . 0.0 113.267 -176.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 91.4 Cg_endo -101.36 33.25 8.36 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.507 -1.456 . . . . 0.0 114.067 0.574 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 68.0 mt -129.34 134.22 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.983 -0.448 . . . . 0.0 111.585 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.765 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.5 m -77.91 133.8 38.02 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.6 p -122.05 139.97 53.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 112.474 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.647 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 1.3 mmm180 -91.71 106.08 18.21 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 176.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 55.41 34.26 22.6 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 123.917 0.761 . . . . 0.0 110.443 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.24 -16.65 58.94 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.946 -0.645 . . . . 0.0 113.782 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.0 mt -95.52 125.44 49.51 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 117.497 0.648 . . . . 0.0 111.104 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.09 37.42 0.26 Allowed 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 122.943 2.429 . . . . 0.0 113.231 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.617 179.96 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.514 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 38.2 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 121.051 0.453 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.21 37.38 94.46 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -149.89 150.2 31.56 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-O 121.018 0.437 . . . . 0.0 110.26 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.421 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 43.2 p -105.92 148.3 27.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.538 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.635 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -117.8 53.0 0.96 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.236 0.541 . . . . 0.0 110.696 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.421 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 6.7 m-85 -55.18 -35.42 64.79 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.598 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.58 20.31 42.3 Favored Glycine 0 N--CA 1.445 -0.71 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.94 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.84 46.84 64.45 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.947 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -148.71 141.28 24.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.67 0.271 . . . . 0.0 110.546 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.9 m -130.57 131.94 45.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.532 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -72.85 -32.55 65.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.906 0.384 . . . . 0.0 110.541 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.643 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.0 m -80.3 124.77 82.32 Favored Pre-proline 0 N--CA 1.451 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.742 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.2 Cg_exo -67.26 136.1 39.19 Favored 'Trans proline' 0 N--CA 1.464 -0.214 0 C-N-CA 122.877 2.385 . . . . 0.0 112.582 -179.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.01 -6.85 82.53 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.046 -0.597 . . . . 0.0 113.503 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.643 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 72.8 m -79.74 130.05 35.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.144 0.497 . . . . 0.0 111.703 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -83.31 139.53 33.0 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 18.6 t -83.51 91.56 7.43 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.154 0.502 . . . . 0.0 111.908 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.5 m -89.28 67.09 7.76 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.0 t90 -28.01 122.95 0.25 Allowed Pre-proline 0 C--O 1.231 0.117 0 CA-C-N 113.807 -1.542 . . . . 0.0 113.143 -176.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 90.4 Cg_endo -102.0 30.68 10.01 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.511 -1.454 . . . . 0.0 113.916 0.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.8 mt -125.29 133.25 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 O-C-N 121.955 -0.465 . . . . 0.0 111.517 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.635 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.0 m -79.29 134.61 36.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.687 0.279 . . . . 0.0 111.516 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 23.9 p -126.18 133.54 51.53 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.219 0.533 . . . . 0.0 112.142 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.514 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 10.0 ttp180 -106.93 122.0 45.54 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 64.56 24.57 13.07 Favored 'General case' 0 C--N 1.32 -0.69 0 O-C-N 123.718 0.636 . . . . 0.0 109.402 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.74 -0.7 89.17 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.276 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.0 mt -106.97 131.32 21.79 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.66 0.267 . . . . 0.0 110.324 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.62 39.87 0.45 Allowed 'Trans proline' 0 CA--C 1.531 0.34 0 C-N-CA 122.827 2.351 . . . . 0.0 112.439 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.326 -0.423 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.967 -179.495 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 81.1 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.884 0.373 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.5 37.92 94.23 Favored Glycine 0 C--N 1.333 0.361 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.749 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.12 142.42 24.23 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.537 HG22 HG12 ' A' ' 21' ' ' ILE . 21.2 p -111.07 143.87 41.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.04 0.448 . . . . 0.0 110.759 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.557 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -112.08 60.45 0.63 Allowed 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.827 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -56.98 -32.24 65.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.63 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.79 14.76 58.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.631 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.33 44.16 66.76 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.875 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.405 ' H ' ' HB2' ' A' ' 5' ' ' CYS . 12.8 t -150.53 142.42 23.84 Favored 'General case' 0 N--CA 1.447 -0.582 0 O-C-N 122.845 -0.209 . . . . 0.0 110.544 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.557 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -135.64 131.78 36.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.179 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -82.88 -32.96 27.12 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.186 0.517 . . . . 0.0 109.706 178.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.418 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 4.6 m -66.31 120.35 69.44 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.812 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.0 Cg_exo -65.08 141.19 68.87 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.929 2.42 . . . . 0.0 113.071 -179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.03 26.1 73.21 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.272 -0.876 . . . . 0.0 113.161 179.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.8 m -116.8 121.84 42.7 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.078 0.466 . . . . 0.0 110.632 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -81.32 135.0 35.67 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.364 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.2 t -77.35 88.71 3.75 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.232 0.539 . . . . 0.0 111.832 -179.254 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.8 m -87.6 67.42 9.28 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -28.26 124.05 0.25 Allowed Pre-proline 0 N--CA 1.461 0.12 0 CA-C-N 113.772 -1.558 . . . . 0.0 113.144 -176.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.7 Cg_endo -101.1 34.37 7.7 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.53 -1.446 . . . . 0.0 113.997 0.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.537 HG12 HG22 ' A' ' 4' ' ' THR . 61.9 mt -130.33 133.08 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 O-C-N 121.935 -0.478 . . . . 0.0 111.754 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.494 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 35.0 m -78.05 127.75 32.8 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.149 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.1 p -119.46 146.49 45.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.582 0.706 . . . . 0.0 112.416 -178.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.1 tpp85 -92.44 81.35 4.88 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.8 t70 64.49 49.84 2.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.766 -177.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.81 -26.72 19.09 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.774 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 91.0 mt -91.1 118.8 68.77 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 117.404 0.602 . . . . 0.0 111.47 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.15 39.74 0.41 Allowed 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 122.882 2.388 . . . . 0.0 112.431 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.894 -179.611 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.582 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.0 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 120.869 0.366 . . . . 0.0 110.153 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.05 35.04 90.06 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.604 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -150.14 143.18 24.89 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.557 HG22 HG12 ' A' ' 21' ' ' ILE . 21.1 p -111.67 144.5 40.83 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.106 0.479 . . . . 0.0 110.86 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.517 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.0 p -113.27 62.19 0.64 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.849 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -56.93 -34.61 68.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.256 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -101.42 18.1 54.24 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.625 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.44 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 66.82 43.45 91.58 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.808 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.86 136.67 27.29 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.49 0.186 . . . . 0.0 111.047 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.517 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 59.7 m -133.17 129.58 38.01 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.945 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -84.9 -32.26 23.24 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.303 0.573 . . . . 0.0 109.567 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.9 m -66.44 122.55 82.29 Favored Pre-proline 0 N--CA 1.452 -0.354 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.948 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.51 141.12 59.87 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.783 2.322 . . . . 0.0 112.933 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.445 ' O ' ' HD3' ' A' ' 24' ' ' ARG . . . 72.83 27.83 68.19 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.887 179.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.462 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 85.6 m -118.5 116.99 27.82 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 121.113 0.482 . . . . 0.0 111.239 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.1 p -80.34 131.89 35.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 178.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.44 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.8 t -74.22 95.01 2.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.322 0.582 . . . . 0.0 112.076 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.4 m -91.95 67.22 5.16 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 176.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.0 t90 -27.19 122.68 0.24 Allowed Pre-proline 0 C--O 1.231 0.11 0 CA-C-N 113.703 -1.589 . . . . 0.0 113.213 -176.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 93.3 Cg_endo -101.78 35.74 6.52 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.024 0.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 4' ' ' THR . 64.4 mt -130.74 133.19 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.952 -0.468 . . . . 0.0 111.695 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.4 m -78.2 131.6 37.23 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.41 HG22 ' HA ' ' A' ' 28' ' ' PRO . 80.7 p -129.28 154.69 46.58 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.586 0.588 . . . . 0.0 112.586 -178.438 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.582 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 22.7 mmt85 -89.59 69.63 7.84 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 177.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 26.4 t70 65.98 53.34 1.12 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.926 0.869 . . . . 0.0 109.257 -177.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.48 -30.29 10.24 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.309 -0.859 . . . . 0.0 113.004 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 85.4 mt -81.92 113.43 42.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 117.006 0.403 . . . . 0.0 111.483 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.4 Cg_exo -73.77 39.36 0.5 Allowed 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 123.139 2.559 . . . . 0.0 112.422 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 111.929 -179.64 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 58.5 m . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 59.44 37.78 92.55 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -139.28 144.76 38.51 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 115.314 -0.443 . . . . 0.0 110.346 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.43 HG22 HD13 ' A' ' 21' ' ' ILE . 82.0 p -108.41 151.16 26.4 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.077 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.939 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -131.99 58.8 1.73 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.152 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -52.88 -31.92 42.21 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.19 0.519 . . . . 0.0 109.873 178.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -137.81 37.31 1.84 Allowed Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 177.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.545 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.59 42.06 99.69 Favored Glycine 0 C--N 1.337 0.619 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.3 p -108.41 44.5 1.11 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.939 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.8 m -81.85 123.43 28.81 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.104 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.416 ' N ' HD22 ' A' ' 11' ' ' ASN . 1.6 m120 -70.79 -36.28 72.94 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.6 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.7 m -73.44 118.56 69.94 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.981 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -74.56 142.16 28.98 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.932 2.421 . . . . 0.0 112.698 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.96 -22.42 40.96 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.325 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.739 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 96.4 m -69.69 125.26 26.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 0.0 111.063 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -79.31 128.57 33.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.2 t -76.31 94.41 3.58 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.574 0.583 . . . . 0.0 112.574 -178.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.2 m -91.38 65.45 5.32 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -23.2 120.68 0.17 Allowed Pre-proline 0 N--CA 1.462 0.169 0 CA-C-N 113.389 -1.732 . . . . 0.0 113.75 -176.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.9 Cg_endo -101.8 29.04 11.66 Favored 'Cis proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.876 -1.302 . . . . 0.0 113.699 0.287 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.43 HD13 HG22 ' A' ' 4' ' ' THR . 35.0 mm -123.02 128.39 75.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 O-C-N 122.218 -0.302 . . . . 0.0 111.459 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.739 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.65 131.81 36.07 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.434 0.635 . . . . 0.0 111.607 178.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.5 p -117.87 140.06 50.24 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.863 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.479 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 17.9 tpt85 -93.11 103.08 15.4 Favored 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 59.46 36.31 23.06 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 124.032 0.832 . . . . 0.0 110.159 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.23 -15.78 62.62 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.345 179.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.1 mt -92.8 121.1 66.66 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 117.205 0.502 . . . . 0.0 111.148 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.473 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.9 Cg_exo -71.94 39.32 0.39 Allowed 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 123.118 2.545 . . . . 0.0 112.215 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--N 1.326 -0.436 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.748 -179.528 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.596 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 87.5 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.469 0.176 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.67 36.96 94.01 Favored Glycine 0 N--CA 1.449 -0.435 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.477 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -141.59 145.65 35.31 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 115.125 -0.537 . . . . 0.0 109.812 -178.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.4 p -118.02 144.48 45.53 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -117.97 55.65 0.87 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.045 0.45 . . . . 0.0 111.006 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -56.38 -34.16 66.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.309 178.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.85 20.09 42.27 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.885 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.49 43.88 75.44 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.352 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.9 t -150.41 143.67 24.96 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.9 m -135.15 129.23 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.208 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 59.3 m-80 -70.51 -39.57 74.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.896 0.379 . . . . 0.0 110.36 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.9 m -71.8 117.22 55.76 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.562 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -68.84 138.96 42.22 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 123.122 2.548 . . . . 0.0 112.846 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.78 -20.05 51.57 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.765 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 71.4 m -77.18 126.24 30.62 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.073 0.463 . . . . 0.0 111.353 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -81.07 135.94 35.88 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.0 t -77.78 94.84 4.55 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.291 0.567 . . . . 0.0 112.227 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 15.9 m -93.81 67.7 3.83 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 107.089 -1.449 . . . . 0.0 107.089 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.554 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.3 t90 -27.18 122.47 0.24 Allowed Pre-proline 0 N--CA 1.463 0.184 0 CA-C-N 113.75 -1.568 . . . . 0.0 113.219 -176.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.554 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.84 30.28 10.5 Favored 'Cis proline' 0 N--CA 1.455 -0.774 0 C-N-CA 123.564 -1.432 . . . . 0.0 114.01 0.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.57 132.6 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 O-C-N 122.051 -0.405 . . . . 0.0 111.682 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.477 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.4 m -79.72 128.41 33.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.764 0.316 . . . . 0.0 110.552 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.447 ' HB ' ' N ' ' A' ' 27' ' ' LEU . 47.0 p -117.43 137.41 52.52 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.078 0.466 . . . . 0.0 112.043 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.596 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.1 tpt85 -90.58 101.3 14.04 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 177.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 59.6 38.56 22.1 Favored 'General case' 0 C--N 1.328 -0.345 0 O-C-N 123.891 0.744 . . . . 0.0 111.207 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.5 32.54 24.7 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.156 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.597 HD12 ' HD2' ' A' ' 28' ' ' PRO . 24.3 tp -144.83 117.77 5.48 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.068 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.597 ' HD2' HD12 ' A' ' 27' ' ' LEU . 56.3 Cg_endo -70.8 44.49 0.51 Allowed 'Trans proline' 0 N--CA 1.475 0.396 0 C-N-CA 123.25 2.633 . . . . 0.0 114.059 -178.277 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.591 HG13 ' HG ' ' A' ' 27' ' ' LEU . 18.6 m . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 120.933 0.397 . . . . 0.0 111.082 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.597 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 94.4 m . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 120.427 0.156 . . . . 0.0 111.077 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.72 40.72 98.82 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -150.31 147.63 27.87 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.0 p -117.61 143.24 46.33 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.979 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.544 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -114.67 56.14 0.73 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.011 0.434 . . . . 0.0 111.4 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.65 -34.47 67.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.214 178.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.48 20.93 38.39 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.866 179.148 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.26 42.91 81.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.468 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 13.4 t -150.53 143.4 24.67 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 58.1 m -132.83 128.82 37.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.687 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -68.82 -44.87 72.6 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.8 m -64.91 117.5 39.51 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.732 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -71.1 142.57 42.38 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.84 2.36 . . . . 0.0 113.067 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.41 33.65 38.61 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.161 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.4 m -124.31 133.74 53.38 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.868 0.366 . . . . 0.0 110.797 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -84.06 135.14 34.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.458 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 14.5 t -81.43 95.28 7.01 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.258 0.552 . . . . 0.0 111.759 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 12.5 m -93.66 67.91 3.94 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.5 t90 -27.95 122.79 0.25 Allowed Pre-proline 0 C--O 1.232 0.138 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.176 -176.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.7 Cg_endo -101.61 30.26 10.72 Favored 'Cis proline' 0 N--CA 1.455 -0.759 0 C-N-CA 123.59 -1.421 . . . . 0.0 114.083 0.635 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.0 mt -125.94 132.64 70.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 O-C-N 122.007 -0.433 . . . . 0.0 111.511 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.431 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 29.7 m -80.64 127.67 32.74 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.876 0.37 . . . . 0.0 110.768 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.7 p -119.48 142.48 48.24 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.233 0.539 . . . . 0.0 111.56 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.597 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 31.3 ttt85 -99.47 106.28 18.3 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 58.96 34.96 23.91 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 123.89 0.744 . . . . 0.0 110.14 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.31 -17.01 60.13 Favored Glycine 0 CA--C 1.52 0.403 0 CA-C-N 115.712 -0.676 . . . . 0.0 113.489 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.4 mt -93.84 122.59 61.84 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.213 0.507 . . . . 0.0 111.32 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.8 Cg_exo -72.16 39.09 0.39 Allowed 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 123.074 2.516 . . . . 0.0 112.343 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.667 -179.731 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.487 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.6 m . . . . . 0 N--CA 1.448 -0.534 0 CA-C-O 120.527 0.203 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.55 37.96 95.57 Favored Glycine 0 C--N 1.333 0.378 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 -178.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.546 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.6 tp10 -144.56 142.88 30.5 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.167 -0.516 . . . . 0.0 109.678 -178.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.9 p -116.17 144.49 44.11 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.915 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.4 p -118.48 56.7 0.87 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -55.79 -35.18 66.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.474 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.17 20.87 36.96 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.966 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.07 44.54 66.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.202 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.6 m -147.63 135.75 21.36 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 62.8 m -127.95 126.18 40.94 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.181 0.3 . . . . 0.0 110.355 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -66.4 -43.62 85.32 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.2 m -71.63 117.18 55.1 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.487 179.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_exo -70.13 139.16 38.31 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.978 2.452 . . . . 0.0 112.825 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.89 -23.53 35.62 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.655 179.54 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.5 m -73.7 127.68 33.44 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.071 0.462 . . . . 0.0 111.462 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.8 t -79.93 134.77 36.3 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.5 t -77.86 93.88 4.44 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.301 0.572 . . . . 0.0 112.274 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.8 m -92.38 67.98 4.89 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 176.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.2 t90 -27.4 122.82 0.24 Allowed Pre-proline 0 N--CA 1.463 0.175 0 CA-C-N 113.861 -1.518 . . . . 0.0 113.305 -176.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 87.3 Cg_endo -101.69 30.55 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.516 -1.452 . . . . 0.0 114.047 0.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.6 mt -126.53 132.57 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 120.973 0.416 . . . . 0.0 111.487 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.546 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.5 m -79.62 128.79 33.83 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.805 0.336 . . . . 0.0 110.389 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -122.96 146.36 47.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.978 0.418 . . . . 0.0 112.003 -178.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.487 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 3.4 mmm-85 -91.25 95.54 10.09 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 177.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.97 37.35 21.44 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 123.928 0.768 . . . . 0.0 110.104 -178.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.15 -18.81 56.12 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.721 -0.672 . . . . 0.0 113.338 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.573 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.5 tp -89.53 113.82 58.13 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.157 0.478 . . . . 0.0 110.559 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 8.0 Cg_exo -73.14 46.74 1.18 Allowed 'Trans proline' 0 CA--C 1.531 0.36 0 C-N-CA 123.431 2.754 . . . . 0.0 113.59 -178.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.573 HG13 ' HG ' ' A' ' 27' ' ' LEU . 24.5 m . . . . . 0 C--N 1.325 -0.466 0 CA-C-O 121.085 0.469 . . . . 0.0 111.199 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.8 m . . . . . 0 N--CA 1.45 -0.434 0 CA-C-O 121.012 0.434 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 36.77 92.29 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.373 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -150.31 151.38 32.84 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.935 0.398 . . . . 0.0 110.129 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 38.7 p -110.3 146.69 35.27 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.952 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.549 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 28.2 p -115.12 54.82 0.78 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.135 0.493 . . . . 0.0 110.64 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -55.22 -35.42 64.9 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.68 179.287 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.11 19.56 45.88 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.91 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.1 46.16 67.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.975 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -149.78 142.36 24.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.629 0.252 . . . . 0.0 110.524 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 65.6 m -136.02 128.34 30.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.182 -179.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.5 p30 -77.61 -28.26 51.45 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.864 0.364 . . . . 0.0 110.404 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.41 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -70.99 123.42 89.29 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.497 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -69.51 136.12 32.83 Favored 'Trans proline' 0 N--CA 1.464 -0.221 0 C-N-CA 122.614 2.209 . . . . 0.0 113.114 -179.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.38 66.42 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.878 179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.41 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 66.1 m -112.71 128.05 56.3 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.065 0.459 . . . . 0.0 111.09 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.3 t -84.44 141.59 30.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.229 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.5 t -83.29 95.28 8.13 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.199 0.523 . . . . 0.0 111.995 -179.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.9 m -92.67 66.71 4.47 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.9 t90 -27.71 123.0 0.24 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.177 -176.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.8 Cg_endo -101.55 31.89 9.35 Favored 'Cis proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.497 -1.46 . . . . 0.0 114.039 0.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.6 mt -126.45 134.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 O-C-N 121.994 -0.441 . . . . 0.0 111.648 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.489 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -79.3 132.58 36.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.712 0.291 . . . . 0.0 110.85 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.5 p -128.31 136.61 51.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 111.37 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.5 ttt-85 -95.3 107.01 19.1 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 60.28 34.89 20.86 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 123.731 0.644 . . . . 0.0 110.067 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.62 -13.39 67.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.183 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.689 ' HB3' HG23 ' A' ' 29' ' ' VAL . 90.9 mt -94.11 118.68 67.19 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 117.159 0.479 . . . . 0.0 111.097 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -72.82 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.066 2.511 . . . . 0.0 112.512 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.689 HG23 ' HB3' ' A' ' 27' ' ' LEU . 3.2 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-O 121.348 0.595 . . . . 0.0 110.732 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 80.8 m . . . . . 0 N--CA 1.449 -0.522 0 CA-C-O 120.73 0.3 . . . . 0.0 110.593 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 41.13 97.21 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.406 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -146.87 145.19 29.76 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.958 0.409 . . . . 0.0 110.13 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -114.02 144.35 43.25 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.767 178.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.493 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.6 p -118.38 55.36 0.9 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.052 0.453 . . . . 0.0 111.289 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -56.62 -33.74 66.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.313 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.77 20.48 38.84 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.889 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.16 44.85 74.6 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.386 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.0 t -150.19 142.79 24.52 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.586 0.231 . . . . 0.0 110.541 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.493 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 56.0 m -134.52 131.01 37.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.254 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -66.7 -35.02 79.14 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.93 0.395 . . . . 0.0 110.382 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -80.89 117.23 67.1 Favored Pre-proline 0 N--CA 1.45 -0.442 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.977 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.69 136.87 28.91 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.71 2.274 . . . . 0.0 112.157 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.07 -27.23 21.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.655 -0.783 . . . . 0.0 111.999 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.3 m -72.54 127.81 33.68 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.989 0.423 . . . . 0.0 110.952 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -79.93 134.84 36.3 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.403 179.366 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.6 t -77.85 93.47 4.37 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.268 0.556 . . . . 0.0 111.727 -179.292 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.5 m -90.97 68.05 6.13 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.5 t90 -27.75 122.98 0.25 Allowed Pre-proline 0 N--CA 1.463 0.194 0 CA-C-N 113.932 -1.485 . . . . 0.0 113.268 -176.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.67 30.57 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.589 -1.421 . . . . 0.0 113.972 0.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.5 mt -126.86 132.52 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 O-C-N 122.058 -0.401 . . . . 0.0 111.567 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.492 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 28.6 m -79.35 128.96 33.98 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.823 0.344 . . . . 0.0 110.689 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -121.28 144.05 48.84 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.277 0.56 . . . . 0.0 111.393 -179.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.49 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 59.9 ttp180 -95.59 84.1 3.9 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.1 t70 67.27 49.95 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 O-C-N 124.248 0.968 . . . . 0.0 109.631 -177.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.29 -24.9 20.13 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.925 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -92.14 116.02 65.72 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 117.378 0.589 . . . . 0.0 111.547 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -73.21 39.02 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.005 2.47 . . . . 0.0 112.196 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 C--N 1.324 -0.503 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.61 -179.505 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.401 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 82.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 120.67 0.271 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 34.32 87.86 Favored Glycine 0 N--CA 1.451 -0.33 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -178.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.478 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -134.0 145.16 49.23 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.9 -0.65 . . . . 0.0 109.959 -179.034 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.427 HG22 HD13 ' A' ' 21' ' ' ILE . 65.0 p -114.17 146.03 40.88 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.614 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.578 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 27.9 p -124.21 54.07 1.38 Allowed 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.15 0.5 . . . . 0.0 110.854 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -56.43 -33.3 65.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.387 179.078 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.53 19.87 41.05 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.807 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.42 45.03 70.86 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.324 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.9 t -150.11 142.8 24.6 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.542 0.21 . . . . 0.0 110.591 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.482 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 46.4 m -134.34 127.75 32.32 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.025 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -72.04 -34.55 68.86 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.931 0.396 . . . . 0.0 110.232 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.5 m -72.47 118.24 65.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.483 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.85 135.45 32.7 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.638 2.225 . . . . 0.0 112.864 -179.472 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.66 -22.5 39.98 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 76.9 m -78.12 121.59 24.5 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.085 0.469 . . . . 0.0 111.014 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.5 t -82.59 138.16 34.31 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.29 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 26.6 t -74.49 113.81 12.16 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.469 0.652 . . . . 0.0 111.941 -179.219 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.0 m -113.13 66.12 0.65 Allowed 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 177.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.1 t90 -23.55 120.36 0.18 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 113.489 -1.687 . . . . 0.0 113.665 -176.584 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.518 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 76.0 Cg_endo -101.96 25.62 14.53 Favored 'Cis proline' 0 N--CA 1.456 -0.729 0 C-N-CA 123.668 -1.388 . . . . 0.0 113.784 0.432 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.427 HD13 HG22 ' A' ' 4' ' ' THR . 41.4 mm -119.74 132.77 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-O 120.729 0.299 . . . . 0.0 111.628 -179.063 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.0 m -81.4 128.28 33.69 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.3 p -115.79 145.78 42.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.222 0.534 . . . . 0.0 111.532 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.402 ' HD2' ' HA ' ' A' ' 24' ' ' ARG . 16.9 tpt85 -89.7 85.24 6.4 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.294 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 62.58 43.14 7.86 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.2 -177.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.99 -23.68 34.71 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.702 -0.761 . . . . 0.0 113.616 179.301 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.57 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.3 tp -92.6 111.6 51.66 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 117.355 0.578 . . . . 0.0 110.617 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.454 ' HD2' HD12 ' A' ' 27' ' ' LEU . 60.4 Cg_endo -72.86 47.38 1.22 Allowed 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 123.184 2.589 . . . . 0.0 113.817 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.57 HG13 ' HG ' ' A' ' 27' ' ' LEU . 30.3 m . . . . . 0 C--N 1.324 -0.511 0 CA-C-O 120.87 0.367 . . . . 0.0 111.416 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.617 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 52.5 m . . . . . 0 N--CA 1.448 -0.573 0 CA-C-O 120.402 0.144 . . . . 0.0 111.148 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.32 37.74 94.24 Favored Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -178.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.484 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.1 tp10 -140.91 145.85 36.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.142 -0.529 . . . . 0.0 109.858 -179.032 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.403 HG22 HD13 ' A' ' 21' ' ' ILE . 64.4 p -115.6 146.73 41.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.784 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.1 p -125.02 55.58 1.36 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.239 0.543 . . . . 0.0 110.715 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -57.05 -33.0 66.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.271 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.98 18.89 48.35 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.73 -0.747 . . . . 0.0 111.657 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.57 42.77 79.69 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.045 -0.597 . . . . 0.0 112.298 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.6 t -150.62 143.77 24.82 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 110.452 -0.203 . . . . 0.0 110.452 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.482 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 39.6 m -132.1 129.5 40.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -70.69 -35.45 72.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.978 0.418 . . . . 0.0 110.344 179.72 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 10.6 m -76.66 116.6 58.07 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.792 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.17 139.6 46.79 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.948 2.432 . . . . 0.0 112.489 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.05 -27.37 20.33 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.015 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.0 m -76.34 125.63 29.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.094 0.473 . . . . 0.0 110.967 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.8 m -85.99 134.81 33.84 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.71 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 27.2 t -73.49 116.18 13.75 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.339 0.59 . . . . 0.0 111.873 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.8 m -115.96 66.87 0.71 Allowed 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.57 -1.641 . . . . 0.0 106.57 177.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.8 t90 -23.51 119.48 0.18 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.518 -1.674 . . . . 0.0 113.643 -176.555 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 75.5 Cg_endo -102.7 26.7 12.49 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.855 0.544 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.403 HD13 HG22 ' A' ' 4' ' ' THR . 38.6 mm -120.33 133.73 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 111.624 -179.07 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 40.6 m -82.31 126.06 31.7 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 178.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -113.19 150.84 31.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.529 0.68 . . . . 0.0 111.71 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.617 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.5 ttm180 -103.72 86.65 2.65 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.118 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.7 t0 66.52 49.51 1.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 O-C-N 124.245 0.965 . . . . 0.0 109.509 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.82 -25.01 12.51 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.773 179.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.8 mt -88.92 117.9 68.73 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 117.316 0.558 . . . . 0.0 111.547 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -73.96 38.71 0.48 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.027 2.485 . . . . 0.0 112.269 179.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.325 -0.491 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.617 -179.476 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.0 m . . . . . 0 N--CA 1.45 -0.468 0 CA-C-O 120.644 0.259 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.75 38.71 94.72 Favored Glycine 0 N--CA 1.451 -0.345 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -178.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.482 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -141.88 147.18 36.71 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.797 -178.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.2 p -118.46 145.66 45.08 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.973 0.416 . . . . 0.0 110.752 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.2 p -120.69 56.49 1.0 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.006 0.431 . . . . 0.0 111.028 -179.691 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.61 -34.02 66.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.29 179.018 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.49 20.23 40.19 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.82 179.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.5 43.61 76.63 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.339 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.7 t -150.22 142.88 24.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.461 0.172 . . . . 0.0 110.565 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.49 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.6 m -132.71 128.74 37.58 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.037 -179.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.3 m-80 -69.67 -34.58 74.17 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.021 0.439 . . . . 0.0 110.021 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.1 m -75.27 115.66 47.21 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.362 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -70.3 136.18 30.94 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.92 2.413 . . . . 0.0 112.472 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.45 -24.23 32.84 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.454 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -77.72 130.47 36.8 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.151 0.5 . . . . 0.0 111.219 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.1 t -84.77 137.52 33.15 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.468 179.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 25.0 t -77.16 112.62 14.02 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.301 0.572 . . . . 0.0 111.739 -179.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.7 m -111.25 67.6 0.65 Allowed 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 177.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.0 t90 -26.33 122.53 0.22 Allowed Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 113.776 -1.556 . . . . 0.0 113.344 -176.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.5 Cg_endo -101.36 28.84 12.35 Favored 'Cis proline' 0 N--CA 1.454 -0.804 0 C-N-CA 123.6 -1.417 . . . . 0.0 114.086 0.534 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 61.3 mt -127.55 134.71 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 O-C-N 121.997 -0.439 . . . . 0.0 111.538 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 31.4 m -79.87 130.41 35.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.908 0.385 . . . . 0.0 110.43 179.442 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 54.4 p -121.48 157.95 29.49 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.215 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.434 ' HA ' ' HD2' ' A' ' 24' ' ' ARG . 13.9 tpt85 -87.99 58.33 4.76 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.264 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 64.45 45.88 3.56 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.955 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 142.43 -47.94 0.8 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.385 -0.912 . . . . 0.0 113.479 178.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 99.0 mt -108.93 127.87 26.52 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 122.553 -0.38 . . . . 0.0 111.777 -179.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.8 Cg_endo -75.6 39.03 0.6 Allowed 'Trans proline' 0 CA--C 1.528 0.22 0 C-N-CA 123.209 2.606 . . . . 0.0 112.47 179.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 -179.642 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 60.9 m . . . . . 0 N--CA 1.448 -0.542 0 CA-C-O 120.695 0.283 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.52 45.01 96.76 Favored Glycine 0 C--N 1.335 0.479 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.437 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.414 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -150.16 149.86 30.83 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.958 0.408 . . . . 0.0 110.698 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.472 HG22 HD13 ' A' ' 21' ' ' ILE . 42.4 p -123.41 142.85 50.56 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.61 178.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 29.3 p -105.34 57.32 0.68 Allowed 'General case' 0 C--N 1.315 -0.923 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.688 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -56.59 -33.54 66.32 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -106.02 23.36 29.34 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.61 178.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 66.92 37.33 92.11 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 121.197 -0.525 . . . . 0.0 113.082 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.4 t -151.06 142.61 23.55 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.717 0.294 . . . . 0.0 111.371 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.743 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.8 m -122.54 132.44 54.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.634 179.371 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -64.68 -34.56 78.59 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.921 0.391 . . . . 0.0 110.394 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.4 m -79.71 115.74 55.89 Favored Pre-proline 0 N--CA 1.45 -0.465 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.717 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.97 135.8 26.1 Favored 'Trans proline' 0 N--CA 1.462 -0.349 0 C-N-CA 122.516 2.144 . . . . 0.0 112.37 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.03 -26.65 23.89 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.071 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.8 m -71.65 125.82 28.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.974 0.416 . . . . 0.0 111.234 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -89.58 121.21 31.56 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.827 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 19.6 t -86.86 116.95 25.28 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 113.464 0.912 . . . . 0.0 113.464 -177.17 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.9 m -88.72 72.64 8.62 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 174.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.509 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 12.7 t90 -21.56 122.25 0.12 Allowed Pre-proline 0 N--CA 1.468 0.433 0 CA-C-N 113.889 -1.505 . . . . 0.0 113.834 -175.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 88.8 Cg_endo -101.78 31.31 9.65 Favored 'Cis proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.228 0.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.472 HD13 HG22 ' A' ' 4' ' ' THR . 43.8 mm -116.52 120.54 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.236 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.827 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 28.8 m -74.67 130.2 39.09 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.413 HG22 ' CA ' ' A' ' 28' ' ' PRO . 37.2 p -131.04 139.67 49.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.124 0.488 . . . . 0.0 111.876 -178.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 5.6 tmm_? -96.7 102.22 13.97 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 59.41 40.4 20.9 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 123.807 0.692 . . . . 0.0 110.302 -177.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.25 -15.68 60.58 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.557 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.5 mt -91.61 118.93 68.63 Favored Pre-proline 0 C--N 1.327 -0.396 0 CA-C-N 117.232 0.516 . . . . 0.0 111.5 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.413 ' CA ' HG22 ' A' ' 23' ' ' THR . 71.5 Cg_endo -74.82 38.82 0.54 Allowed 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 123.081 2.521 . . . . 0.0 112.049 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--N 1.324 -0.525 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.818 -179.452 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.451 -0.402 0 CA-C-O 120.664 0.269 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.65 37.67 95.16 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -143.29 141.48 31.03 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.47 HG22 HG12 ' A' ' 21' ' ' ILE . 37.7 p -111.88 146.86 36.99 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.036 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.805 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 23.2 p -122.69 57.94 1.09 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -56.09 -36.05 67.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.127 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.56 20.56 43.91 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.684 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.08 40.22 88.45 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.351 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.2 t -151.19 142.92 23.74 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.555 -0.165 . . . . 0.0 110.555 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.805 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -139.06 137.5 36.29 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.8 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -67.24 -41.29 85.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.518 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.2 m -70.67 114.41 26.36 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.409 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.89 137.93 27.73 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.058 2.505 . . . . 0.0 112.449 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.8 -25.25 28.62 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.301 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.703 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 91.2 m -71.04 127.79 33.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.022 0.439 . . . . 0.0 111.272 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -79.64 126.7 31.25 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.8 t -73.88 96.89 2.67 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.488 0.661 . . . . 0.0 112.191 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.7 m -94.11 68.15 3.69 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.2 t90 -25.7 122.26 0.22 Allowed Pre-proline 0 N--CA 1.463 0.22 0 CA-C-N 113.918 -1.492 . . . . 0.0 113.313 -176.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.7 Cg_endo -101.55 30.31 10.72 Favored 'Cis proline' 0 N--CA 1.456 -0.71 0 C-N-CA 123.606 -1.414 . . . . 0.0 114.159 0.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.47 HG12 HG22 ' A' ' 4' ' ' THR . 67.6 mt -131.26 131.83 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.954 -0.466 . . . . 0.0 111.341 -179.482 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.703 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -79.4 134.97 36.57 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.306 0.574 . . . . 0.0 111.982 179.587 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 70.6 p -120.9 149.51 42.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.076 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.511 ' HG2' ' OD1' ' A' ' 25' ' ' ASP . 17.0 ttt-85 -88.17 94.86 9.95 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.672 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.511 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 1.1 p-10 46.38 42.78 11.03 Favored 'General case' 0 N--CA 1.469 0.483 0 O-C-N 124.334 1.022 . . . . 0.0 111.434 -177.163 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.57 -22.18 29.0 Favored Glycine 0 C--N 1.335 0.49 0 CA-C-N 115.52 -0.763 . . . . 0.0 113.865 178.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.522 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.6 tp -93.45 113.82 61.22 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 117.256 0.528 . . . . 0.0 111.015 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 11.2 Cg_exo -71.59 48.26 1.0 Allowed 'Trans proline' 0 CA--C 1.533 0.431 0 C-N-CA 123.498 2.799 . . . . 0.0 113.772 -179.236 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.522 HG13 ' HG ' ' A' ' 27' ' ' LEU . 31.1 m . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 121.004 0.431 . . . . 0.0 111.257 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.1 m . . . . . 0 N--CA 1.449 -0.492 0 CA-C-O 120.786 0.327 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.51 37.8 94.74 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.543 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -144.25 143.88 31.24 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.126 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 45.2 p -105.75 153.63 21.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.701 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.903 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 22.2 p -131.67 56.97 1.79 Allowed 'General case' 0 C--N 1.321 -0.643 0 O-C-N 122.269 -0.27 . . . . 0.0 110.95 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -52.01 -35.99 48.58 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.215 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.23 31.65 3.98 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 178.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.517 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.99 48.36 83.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.143 -0.551 . . . . 0.0 111.823 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.6 m -130.7 69.27 1.46 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 111.975 0.361 . . . . 0.0 111.975 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.903 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 92.6 m -90.88 130.98 36.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.763 0.316 . . . . 0.0 111.18 179.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.8 p-10 -64.51 -35.12 79.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.935 -179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 18.1 m -85.01 114.68 57.27 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.196 -179.127 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 8.0 Cg_exo -71.94 139.73 33.65 Favored 'Trans proline' 0 N--CA 1.462 -0.341 0 C-N-CA 123.111 2.541 . . . . 0.0 111.932 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.02 -25.93 26.11 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.079 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.709 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 97.6 m -67.05 128.34 35.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.839 0.352 . . . . 0.0 110.744 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.7 m -78.87 123.5 27.3 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.6 t -72.6 98.83 2.41 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.362 0.601 . . . . 0.0 112.232 -178.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 9.0 m -94.49 68.38 3.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.536 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.6 t90 -25.18 121.06 0.21 Allowed Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.355 -176.464 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.536 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.5 Cg_endo -102.76 33.6 7.5 Favored 'Cis proline' 0 N--CA 1.455 -0.764 0 C-N-CA 123.69 -1.379 . . . . 0.0 114.153 0.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.421 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 67.9 mt -132.23 132.99 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 O-C-N 121.992 -0.442 . . . . 0.0 111.576 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.709 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.58 134.93 36.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.34 0.59 . . . . 0.0 112.474 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 42.5 p -123.0 143.82 49.67 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.651 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.453 ' HD2' ' HA ' ' A' ' 24' ' ' ARG . 2.3 mmm-85 -95.25 101.9 13.67 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 60.03 36.14 21.42 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 123.944 0.778 . . . . 0.0 110.006 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.56 -14.49 65.16 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.623 -0.717 . . . . 0.0 113.192 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.629 ' HG ' HG13 ' A' ' 29' ' ' VAL . 21.6 tp -92.96 116.35 66.37 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 117.067 0.433 . . . . 0.0 110.273 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.563 ' HD2' HD12 ' A' ' 27' ' ' LEU . 58.4 Cg_endo -71.7 45.61 0.73 Allowed 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 123.122 2.548 . . . . 0.0 113.83 -178.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.629 HG13 ' HG ' ' A' ' 27' ' ' LEU . 16.0 m . . . . . 0 C--N 1.326 -0.421 0 CA-C-O 120.928 0.394 . . . . 0.0 111.465 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 N--CA 1.448 -0.538 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.11 34.32 87.56 Favored Glycine 0 C--N 1.333 0.387 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.791 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -140.53 134.21 30.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.468 HG22 HD13 ' A' ' 21' ' ' ILE . 77.8 p -96.21 146.19 24.91 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.429 -178.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.638 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -120.65 58.48 0.94 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.204 179.217 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -55.92 -34.66 65.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.48 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.77 17.33 56.6 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.485 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.458 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 67.81 41.57 88.32 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 121.144 -0.55 . . . . 0.0 111.946 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.3 t -151.47 144.92 24.84 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.077 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.638 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 30.2 m -146.62 140.8 26.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.9 m-80 -73.23 -35.24 66.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.569 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.4 m -66.78 115.24 22.76 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.842 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.86 134.48 27.87 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.654 2.236 . . . . 0.0 112.837 -179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.61 -18.53 57.16 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.69 -0.767 . . . . 0.0 113.001 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.584 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 94.9 m -77.41 120.63 22.67 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.179 0.514 . . . . 0.0 111.016 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -79.41 131.27 36.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.458 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 32.9 t -75.52 92.73 2.91 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.338 0.59 . . . . 0.0 112.24 -178.466 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.0 m -89.58 66.74 7.35 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -25.22 121.33 0.21 Allowed Pre-proline 0 C--O 1.232 0.168 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.68 -176.543 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 85.4 Cg_endo -101.75 26.31 14.26 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.59 -1.421 . . . . 0.0 113.787 0.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.468 HD13 HG22 ' A' ' 4' ' ' THR . 35.9 mm -120.56 127.87 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 O-C-N 122.257 -0.277 . . . . 0.0 111.424 -179.208 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.584 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 13.0 m -79.78 130.36 35.26 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.254 0.55 . . . . 0.0 111.35 179.062 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 69.0 p -118.59 140.6 49.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.723 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 35.8 tpt85 -89.66 92.14 8.95 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 61.04 40.61 14.92 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 124.028 0.83 . . . . 0.0 110.48 -178.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.75 -22.89 35.63 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 113.841 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.9 mt -93.86 117.45 67.23 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 117.381 0.59 . . . . 0.0 111.589 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.85 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.924 2.416 . . . . 0.0 112.266 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 C--N 1.326 -0.451 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.875 -179.581 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 N--CA 1.45 -0.47 0 CA-C-O 120.86 0.362 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.42 40.38 97.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.887 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -147.44 142.09 26.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.976 0.417 . . . . 0.0 110.19 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.619 HG22 HG12 ' A' ' 21' ' ' ILE . 41.7 p -107.36 146.79 31.16 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.694 179.581 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.787 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 21.4 p -122.38 56.82 1.1 Allowed 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.989 0.423 . . . . 0.0 110.757 179.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -55.99 -36.77 68.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.252 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.91 21.31 40.71 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.516 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.7 40.71 90.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.183 -0.532 . . . . 0.0 112.408 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.2 t -150.78 142.92 24.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.787 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 89.4 m -137.49 137.58 38.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.744 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -64.44 -35.67 81.66 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.1 m -76.89 113.77 33.18 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.709 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.52 136.02 27.6 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.539 2.159 . . . . 0.0 112.376 -179.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.64 -19.32 54.83 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.502 -0.856 . . . . 0.0 113.037 179.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.512 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 68.6 m -74.65 131.7 41.11 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 117.287 0.543 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.1 m -81.96 119.36 23.86 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.743 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 10.4 t -68.76 112.41 5.47 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.433 0.635 . . . . 0.0 111.775 -178.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.8 m -109.06 69.61 0.71 Allowed 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -25.19 122.1 0.21 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.352 -176.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 83.7 Cg_endo -101.57 31.22 9.88 Favored 'Cis proline' 0 N--CA 1.455 -0.739 0 C-N-CA 123.541 -1.441 . . . . 0.0 114.277 0.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.619 HG12 HG22 ' A' ' 4' ' ' THR . 64.4 mt -135.7 134.19 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 O-C-N 121.97 -0.456 . . . . 0.0 111.436 -179.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.512 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -76.77 137.02 39.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.14 0.495 . . . . 0.0 111.491 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.4 p -128.99 158.84 37.74 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.939 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.01 55.0 3.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 178.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 65.12 43.1 3.8 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.872 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 148.63 -45.77 0.71 Allowed Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.325 -0.941 . . . . 0.0 113.263 179.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 98.1 mt -114.96 129.86 24.69 Favored Pre-proline 0 C--N 1.327 -0.383 0 O-C-N 122.509 -0.407 . . . . 0.0 111.686 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.6 Cg_endo -75.39 39.92 0.65 Allowed 'Trans proline' 0 CA--C 1.53 0.279 0 C-N-CA 123.247 2.631 . . . . 0.0 112.506 179.606 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.6 m . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.034 -179.656 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.9 m . . . . . 0 N--CA 1.448 -0.546 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.98 39.1 96.57 Favored Glycine 0 C--N 1.335 0.495 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.864 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -147.74 152.29 37.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.769 0.318 . . . . 0.0 110.388 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.414 HG22 HG12 ' A' ' 21' ' ' ILE . 22.7 p -122.45 146.0 47.78 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.506 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.513 ' HB2' ' N ' ' A' ' 9' ' ' THR . 21.6 p -107.63 60.35 0.62 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.135 0.493 . . . . 0.0 111.028 -179.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -56.17 -30.24 61.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.101 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.55 17.38 46.66 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.789 -0.719 . . . . 0.0 111.564 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 39.82 86.93 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.558 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.513 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.2 m -150.92 137.27 18.57 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 122.581 -0.364 . . . . 0.0 111.087 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.723 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 57.8 m -125.15 129.95 51.19 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 178.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -77.0 -34.11 57.53 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.041 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -63.96 119.18 52.82 Favored Pre-proline 0 C--O 1.236 0.361 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.599 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.88 135.89 36.69 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.952 2.435 . . . . 0.0 113.801 -178.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.22 17.07 78.74 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.465 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 55.9 m -105.33 121.36 43.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 117.141 0.471 . . . . 0.0 111.078 179.282 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.7 m -90.23 117.71 29.19 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 107.305 -1.368 . . . . 0.0 107.305 178.089 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.838 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 17.9 t -81.6 118.34 22.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 113.491 0.922 . . . . 0.0 113.491 -176.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.8 m -92.34 73.35 5.3 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 104.964 -2.235 . . . . 0.0 104.964 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -23.04 125.59 0.12 Allowed Pre-proline 0 N--CA 1.467 0.42 0 CA-C-N 113.767 -1.561 . . . . 0.0 113.661 -175.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.495 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 94.6 Cg_endo -100.52 33.53 8.56 Favored 'Cis proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.332 -1.528 . . . . 0.0 114.449 0.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.414 HG12 HG22 ' A' ' 4' ' ' THR . 66.4 mt -124.58 125.83 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 O-C-N 121.865 -0.522 . . . . 0.0 112.097 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.838 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 14.0 m -72.1 129.11 37.73 Favored 'General case' 0 C--O 1.233 0.212 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.439 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.0 p -128.79 138.11 51.9 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.127 0.489 . . . . 0.0 111.844 -178.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.99 104.97 16.85 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.24 37.38 23.76 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.434 0.635 . . . . 0.0 110.043 -178.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.65 -11.45 70.18 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.522 -0.763 . . . . 0.0 113.447 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.1 mt -94.44 123.58 58.05 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 117.2 0.5 . . . . 0.0 111.202 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -73.39 39.99 0.51 Allowed 'Trans proline' 0 CA--C 1.53 0.302 0 C-N-CA 123.072 2.515 . . . . 0.0 112.038 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.326 -0.425 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.895 -179.327 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 68.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 121.135 0.493 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.26 34.63 90.42 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.511 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -145.34 136.83 25.18 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-O 120.934 0.397 . . . . 0.0 110.026 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.582 HG22 HG12 ' A' ' 21' ' ' ILE . 36.7 p -99.41 143.57 29.51 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.164 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.61 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -115.36 60.45 0.7 Allowed 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.412 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -55.97 -34.91 66.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.494 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.52 16.95 57.36 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.597 -0.811 . . . . 0.0 111.593 178.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.422 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 68.13 40.82 88.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.877 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.6 t -151.55 146.46 25.89 Favored 'General case' 0 C--N 1.324 -0.539 0 C-N-CA 121.272 -0.171 . . . . 0.0 110.685 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.61 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 18.8 m -145.69 138.74 26.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.015 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -74.01 -42.58 60.15 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.311 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.1 m -62.15 118.15 36.83 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.723 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -68.43 147.55 71.47 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 123.056 2.504 . . . . 0.0 113.528 -178.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.6 25.78 71.44 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.133 -0.939 . . . . 0.0 113.53 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.753 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 89.5 m -114.2 122.49 46.96 Favored 'General case' 0 N--CA 1.444 -0.765 0 O-C-N 122.288 -0.536 . . . . 0.0 110.665 179.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -79.44 127.55 32.25 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.422 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.6 t -74.93 90.22 2.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.333 0.587 . . . . 0.0 112.107 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.1 m -88.5 68.06 8.69 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 177.007 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -26.44 123.54 0.22 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.896 -1.502 . . . . 0.0 113.317 -176.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.439 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 80.4 Cg_endo -101.04 30.76 10.71 Favored 'Cis proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.51 -1.454 . . . . 0.0 114.092 0.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.582 HG12 HG22 ' A' ' 4' ' ' THR . 65.5 mt -131.12 131.31 63.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 O-C-N 122.029 -0.419 . . . . 0.0 111.358 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.753 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 37.9 m -79.08 132.45 36.61 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.312 0.577 . . . . 0.0 111.709 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -116.22 147.14 41.76 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.842 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.7 tpp85 -94.39 83.38 4.17 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.7 t70 64.74 49.32 2.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.866 -177.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.01 -26.56 18.29 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.724 -0.75 . . . . 0.0 113.956 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.467 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.9 mt -91.98 119.93 68.09 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 117.51 0.655 . . . . 0.0 111.388 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 9.2 Cg_exo -71.28 39.01 0.34 Allowed 'Trans proline' 0 CA--C 1.531 0.334 0 C-N-CA 123.137 2.558 . . . . 0.0 112.447 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.901 -179.665 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.647 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 96.7 m . . . . . 0 N--CA 1.451 -0.409 0 CA-C-O 120.7 0.286 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.87 36.19 92.81 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.398 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.546 ' HG2' ' H ' ' A' ' 11' ' ' ASN . 6.9 tp10 -150.5 143.64 24.85 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.056 0.455 . . . . 0.0 110.326 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -101.1 148.88 24.56 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.122 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.765 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -124.82 56.08 1.32 Allowed 'General case' 0 C--N 1.318 -0.78 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.478 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -53.83 -32.32 52.45 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.177 0.513 . . . . 0.0 109.802 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.32 42.42 1.36 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 178.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.6 34.39 89.78 Favored Glycine 0 C--N 1.336 0.537 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.014 -179.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 p -89.58 50.58 1.93 Allowed 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.469 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -81.92 95.0 7.23 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.946 179.346 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.546 ' H ' ' HG2' ' A' ' 3' ' ' GLU . 40.8 m-80 -68.31 -37.1 80.26 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.235 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.804 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.9 m -69.02 124.93 91.45 Favored Pre-proline 0 N--CA 1.451 -0.423 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.732 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 29.4 Cg_exo -63.04 135.61 52.12 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 123.163 2.575 . . . . 0.0 114.601 -178.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.74 21.48 79.65 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.675 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.804 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 63.8 m -91.89 127.09 37.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 117.008 0.404 . . . . 0.0 111.202 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.2 t -79.47 130.83 35.78 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 40.8 t -78.26 87.65 4.32 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.153 0.502 . . . . 0.0 112.064 -178.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -86.03 66.84 9.77 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 176.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -27.49 124.01 0.24 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.537 -1.665 . . . . 0.0 113.267 -176.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 91.4 Cg_endo -101.36 33.25 8.36 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.507 -1.456 . . . . 0.0 114.067 0.574 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 68.0 mt -129.34 134.22 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.983 -0.448 . . . . 0.0 111.585 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.765 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.5 m -77.91 133.8 38.02 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.6 p -122.05 139.97 53.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.351 0.596 . . . . 0.0 112.474 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.647 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 1.3 mmm180 -91.71 106.08 18.21 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 176.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 55.41 34.26 22.6 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 123.917 0.761 . . . . 0.0 110.443 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.24 -16.65 58.94 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.946 -0.645 . . . . 0.0 113.782 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.0 mt -95.52 125.44 49.51 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 117.497 0.648 . . . . 0.0 111.104 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.09 37.42 0.26 Allowed 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 122.943 2.429 . . . . 0.0 113.231 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.617 179.96 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.514 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 38.2 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 121.051 0.453 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.21 37.38 94.46 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -149.89 150.2 31.56 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-O 121.018 0.437 . . . . 0.0 110.26 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.421 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 43.2 p -105.92 148.3 27.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.538 179.654 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.635 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -117.8 53.0 0.96 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.236 0.541 . . . . 0.0 110.696 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.421 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 6.7 m-85 -55.18 -35.42 64.79 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.598 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.58 20.31 42.3 Favored Glycine 0 N--CA 1.445 -0.71 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.94 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.84 46.84 64.45 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.947 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -148.71 141.28 24.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.67 0.271 . . . . 0.0 110.546 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.9 m -130.57 131.94 45.28 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.532 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.9 p-10 -72.85 -32.55 65.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.906 0.384 . . . . 0.0 110.541 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.643 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.0 m -80.3 124.77 82.32 Favored Pre-proline 0 N--CA 1.451 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.742 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.2 Cg_exo -67.26 136.1 39.19 Favored 'Trans proline' 0 N--CA 1.464 -0.214 0 C-N-CA 122.877 2.385 . . . . 0.0 112.582 -179.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 87.01 -6.85 82.53 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.046 -0.597 . . . . 0.0 113.503 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.643 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 72.8 m -79.74 130.05 35.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.144 0.497 . . . . 0.0 111.703 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -83.31 139.53 33.0 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 18.6 t -83.51 91.56 7.43 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.154 0.502 . . . . 0.0 111.908 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.5 m -89.28 67.09 7.76 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.0 t90 -28.01 122.95 0.25 Allowed Pre-proline 0 C--O 1.231 0.117 0 CA-C-N 113.807 -1.542 . . . . 0.0 113.143 -176.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 90.4 Cg_endo -102.0 30.68 10.01 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.511 -1.454 . . . . 0.0 113.916 0.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.8 mt -125.29 133.25 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 O-C-N 121.955 -0.465 . . . . 0.0 111.517 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.635 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.0 m -79.29 134.61 36.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.687 0.279 . . . . 0.0 111.516 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 23.9 p -126.18 133.54 51.53 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.219 0.533 . . . . 0.0 112.142 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.514 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 10.0 ttp180 -106.93 122.0 45.54 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 64.56 24.57 13.07 Favored 'General case' 0 C--N 1.32 -0.69 0 O-C-N 123.718 0.636 . . . . 0.0 109.402 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.74 -0.7 89.17 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.276 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.0 mt -106.97 131.32 21.79 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 120.66 0.267 . . . . 0.0 110.324 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.62 39.87 0.45 Allowed 'Trans proline' 0 CA--C 1.531 0.34 0 C-N-CA 122.827 2.351 . . . . 0.0 112.439 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.326 -0.423 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.967 -179.495 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 81.1 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.884 0.373 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.5 37.92 94.23 Favored Glycine 0 C--N 1.333 0.361 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.749 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.12 142.42 24.23 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.537 HG22 HG12 ' A' ' 21' ' ' ILE . 21.2 p -111.07 143.87 41.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.04 0.448 . . . . 0.0 110.759 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.557 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -112.08 60.45 0.63 Allowed 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.827 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -56.98 -32.24 65.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.63 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.79 14.76 58.78 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.631 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.33 44.16 66.76 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.944 -0.646 . . . . 0.0 111.875 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.405 ' H ' ' HB2' ' A' ' 5' ' ' CYS . 12.8 t -150.53 142.42 23.84 Favored 'General case' 0 N--CA 1.447 -0.582 0 O-C-N 122.845 -0.209 . . . . 0.0 110.544 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.557 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -135.64 131.78 36.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.179 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.1 t30 -82.88 -32.96 27.12 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.186 0.517 . . . . 0.0 109.706 178.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.418 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 4.6 m -66.31 120.35 69.44 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.812 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.0 Cg_exo -65.08 141.19 68.87 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 122.929 2.42 . . . . 0.0 113.071 -179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.03 26.1 73.21 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.272 -0.876 . . . . 0.0 113.161 179.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.8 m -116.8 121.84 42.7 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.078 0.466 . . . . 0.0 110.632 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -81.32 135.0 35.67 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.364 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.2 t -77.35 88.71 3.75 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.232 0.539 . . . . 0.0 111.832 -179.254 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 16.8 m -87.6 67.42 9.28 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -28.26 124.05 0.25 Allowed Pre-proline 0 N--CA 1.461 0.12 0 CA-C-N 113.772 -1.558 . . . . 0.0 113.144 -176.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.7 Cg_endo -101.1 34.37 7.7 Favored 'Cis proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.53 -1.446 . . . . 0.0 113.997 0.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.537 HG12 HG22 ' A' ' 4' ' ' THR . 61.9 mt -130.33 133.08 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 O-C-N 121.935 -0.478 . . . . 0.0 111.754 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.494 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 35.0 m -78.05 127.75 32.8 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.149 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.1 p -119.46 146.49 45.36 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.582 0.706 . . . . 0.0 112.416 -178.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.1 tpp85 -92.44 81.35 4.88 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 23.8 t70 64.49 49.84 2.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.196 -0.911 . . . . 0.0 109.766 -177.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.81 -26.72 19.09 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.774 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 91.0 mt -91.1 118.8 68.77 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 117.404 0.602 . . . . 0.0 111.47 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.15 39.74 0.41 Allowed 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 122.882 2.388 . . . . 0.0 112.431 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.894 -179.611 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.582 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.0 m . . . . . 0 N--CA 1.45 -0.444 0 CA-C-O 120.869 0.366 . . . . 0.0 110.153 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.05 35.04 90.06 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.604 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -150.14 143.18 24.89 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.557 HG22 HG12 ' A' ' 21' ' ' ILE . 21.1 p -111.67 144.5 40.83 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.106 0.479 . . . . 0.0 110.86 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.517 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.0 p -113.27 62.19 0.64 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.849 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -56.93 -34.61 68.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.256 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -101.42 18.1 54.24 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.625 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.44 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 66.82 43.45 91.58 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.808 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.86 136.67 27.29 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.49 0.186 . . . . 0.0 111.047 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.517 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 59.7 m -133.17 129.58 38.01 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.945 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -84.9 -32.26 23.24 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.303 0.573 . . . . 0.0 109.567 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.9 m -66.44 122.55 82.29 Favored Pre-proline 0 N--CA 1.452 -0.354 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.948 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.51 141.12 59.87 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.783 2.322 . . . . 0.0 112.933 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.445 ' O ' ' HD3' ' A' ' 24' ' ' ARG . . . 72.83 27.83 68.19 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.329 -0.851 . . . . 0.0 112.887 179.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.462 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 85.6 m -118.5 116.99 27.82 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-O 121.113 0.482 . . . . 0.0 111.239 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.1 p -80.34 131.89 35.7 Favored 'General case' 0 N--CA 1.446 -0.635 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 178.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.44 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 30.8 t -74.22 95.01 2.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.322 0.582 . . . . 0.0 112.076 -178.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.4 m -91.95 67.22 5.16 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 176.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.0 t90 -27.19 122.68 0.24 Allowed Pre-proline 0 C--O 1.231 0.11 0 CA-C-N 113.703 -1.589 . . . . 0.0 113.213 -176.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 93.3 Cg_endo -101.78 35.74 6.52 Favored 'Cis proline' 0 N--CA 1.454 -0.826 0 C-N-CA 123.553 -1.436 . . . . 0.0 114.024 0.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 4' ' ' THR . 64.4 mt -130.74 133.19 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 121.952 -0.468 . . . . 0.0 111.695 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.4 m -78.2 131.6 37.23 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.41 HG22 ' HA ' ' A' ' 28' ' ' PRO . 80.7 p -129.28 154.69 46.58 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.586 0.588 . . . . 0.0 112.586 -178.438 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.582 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 22.7 mmt85 -89.59 69.63 7.84 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 177.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 26.4 t70 65.98 53.34 1.12 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.926 0.869 . . . . 0.0 109.257 -177.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.48 -30.29 10.24 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.309 -0.859 . . . . 0.0 113.004 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 85.4 mt -81.92 113.43 42.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 117.006 0.403 . . . . 0.0 111.483 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.4 Cg_exo -73.77 39.36 0.5 Allowed 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 123.139 2.559 . . . . 0.0 112.422 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 111.929 -179.64 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 58.5 m . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 110.127 -0.323 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 59.44 37.78 92.55 Favored Glycine 0 C--N 1.335 0.527 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -139.28 144.76 38.51 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 115.314 -0.443 . . . . 0.0 110.346 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.43 HG22 HD13 ' A' ' 21' ' ' ILE . 82.0 p -108.41 151.16 26.4 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.077 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.939 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 25.7 p -131.99 58.8 1.73 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.152 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -52.88 -31.92 42.21 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.19 0.519 . . . . 0.0 109.873 178.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -137.81 37.31 1.84 Allowed Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 177.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.545 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.59 42.06 99.69 Favored Glycine 0 C--N 1.337 0.619 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.3 p -108.41 44.5 1.11 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.14 0.792 . . . . 0.0 113.14 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.939 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.8 m -81.85 123.43 28.81 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.104 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.416 ' N ' HD22 ' A' ' 11' ' ' ASN . 1.6 m120 -70.79 -36.28 72.94 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.6 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.7 m -73.44 118.56 69.94 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.981 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -74.56 142.16 28.98 Favored 'Trans proline' 0 C--O 1.234 0.316 0 C-N-CA 122.932 2.421 . . . . 0.0 112.698 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.96 -22.42 40.96 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.325 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.739 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 96.4 m -69.69 125.26 26.2 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 0.0 111.063 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -79.31 128.57 33.49 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 38.2 t -76.31 94.41 3.58 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.574 0.583 . . . . 0.0 112.574 -178.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.2 m -91.38 65.45 5.32 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 176.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.3 t90 -23.2 120.68 0.17 Allowed Pre-proline 0 N--CA 1.462 0.169 0 CA-C-N 113.389 -1.732 . . . . 0.0 113.75 -176.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.9 Cg_endo -101.8 29.04 11.66 Favored 'Cis proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.876 -1.302 . . . . 0.0 113.699 0.287 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.43 HD13 HG22 ' A' ' 4' ' ' THR . 35.0 mm -123.02 128.39 75.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 O-C-N 122.218 -0.302 . . . . 0.0 111.459 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.739 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.65 131.81 36.07 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.434 0.635 . . . . 0.0 111.607 178.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 44.5 p -117.87 140.06 50.24 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.863 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.479 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 17.9 tpt85 -93.11 103.08 15.4 Favored 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 177.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 59.46 36.31 23.06 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 124.032 0.832 . . . . 0.0 110.159 -178.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.23 -15.78 62.62 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.345 179.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 92.1 mt -92.8 121.1 66.66 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 117.205 0.502 . . . . 0.0 111.148 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.473 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.9 Cg_exo -71.94 39.32 0.39 Allowed 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 123.118 2.545 . . . . 0.0 112.215 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--N 1.326 -0.436 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.748 -179.528 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.596 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 87.5 m . . . . . 0 N--CA 1.45 -0.456 0 CA-C-O 120.469 0.176 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.67 36.96 94.01 Favored Glycine 0 N--CA 1.449 -0.435 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.477 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -141.59 145.65 35.31 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-N 115.125 -0.537 . . . . 0.0 109.812 -178.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.4 p -118.02 144.48 45.53 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.597 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -117.97 55.65 0.87 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.045 0.45 . . . . 0.0 111.006 -179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -56.38 -34.16 66.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.309 178.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.85 20.09 42.27 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.885 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.49 43.88 75.44 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.352 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.9 t -150.41 143.67 24.96 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 57.9 m -135.15 129.23 33.51 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.208 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 59.3 m-80 -70.51 -39.57 74.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.896 0.379 . . . . 0.0 110.36 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.9 m -71.8 117.22 55.76 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.562 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -68.84 138.96 42.22 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 123.122 2.548 . . . . 0.0 112.846 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.78 -20.05 51.57 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.765 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 71.4 m -77.18 126.24 30.62 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.073 0.463 . . . . 0.0 111.353 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -81.07 135.94 35.88 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 23.0 t -77.78 94.84 4.55 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.291 0.567 . . . . 0.0 112.227 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 15.9 m -93.81 67.7 3.83 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 107.089 -1.449 . . . . 0.0 107.089 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.554 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.3 t90 -27.18 122.47 0.24 Allowed Pre-proline 0 N--CA 1.463 0.184 0 CA-C-N 113.75 -1.568 . . . . 0.0 113.219 -176.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.554 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.84 30.28 10.5 Favored 'Cis proline' 0 N--CA 1.455 -0.774 0 C-N-CA 123.564 -1.432 . . . . 0.0 114.01 0.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 65.5 mt -125.57 132.6 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 O-C-N 122.051 -0.405 . . . . 0.0 111.682 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.477 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.4 m -79.72 128.41 33.39 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.764 0.316 . . . . 0.0 110.552 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.447 ' HB ' ' N ' ' A' ' 27' ' ' LEU . 47.0 p -117.43 137.41 52.52 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.078 0.466 . . . . 0.0 112.043 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.596 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.1 tpt85 -90.58 101.3 14.04 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 177.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 59.6 38.56 22.1 Favored 'General case' 0 C--N 1.328 -0.345 0 O-C-N 123.891 0.744 . . . . 0.0 111.207 -178.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.5 32.54 24.7 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.156 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.597 HD12 ' HD2' ' A' ' 28' ' ' PRO . 24.3 tp -144.83 117.77 5.48 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.068 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.597 ' HD2' HD12 ' A' ' 27' ' ' LEU . 56.3 Cg_endo -70.8 44.49 0.51 Allowed 'Trans proline' 0 N--CA 1.475 0.396 0 C-N-CA 123.25 2.633 . . . . 0.0 114.059 -178.277 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.591 HG13 ' HG ' ' A' ' 27' ' ' LEU . 18.6 m . . . . . 0 C--N 1.323 -0.583 0 CA-C-O 120.933 0.397 . . . . 0.0 111.082 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.597 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 94.4 m . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 120.427 0.156 . . . . 0.0 111.077 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.72 40.72 98.82 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -150.31 147.63 27.87 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.0 p -117.61 143.24 46.33 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.979 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.544 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -114.67 56.14 0.73 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.011 0.434 . . . . 0.0 111.4 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.65 -34.47 67.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.214 178.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.48 20.93 38.39 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.734 -0.746 . . . . 0.0 111.866 179.148 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.26 42.91 81.8 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.468 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 13.4 t -150.53 143.4 24.67 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 58.1 m -132.83 128.82 37.52 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.687 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -68.82 -44.87 72.6 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.8 m -64.91 117.5 39.51 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.732 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -71.1 142.57 42.38 Favored 'Trans proline' 0 C--O 1.235 0.345 0 C-N-CA 122.84 2.36 . . . . 0.0 113.067 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.41 33.65 38.61 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.161 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.4 m -124.31 133.74 53.38 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.868 0.366 . . . . 0.0 110.797 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.9 t -84.06 135.14 34.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.458 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 14.5 t -81.43 95.28 7.01 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.258 0.552 . . . . 0.0 111.759 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 12.5 m -93.66 67.91 3.94 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.5 t90 -27.95 122.79 0.25 Allowed Pre-proline 0 C--O 1.232 0.138 0 CA-C-N 114.062 -1.426 . . . . 0.0 113.176 -176.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.7 Cg_endo -101.61 30.26 10.72 Favored 'Cis proline' 0 N--CA 1.455 -0.759 0 C-N-CA 123.59 -1.421 . . . . 0.0 114.083 0.635 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.0 mt -125.94 132.64 70.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 O-C-N 122.007 -0.433 . . . . 0.0 111.511 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.431 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 29.7 m -80.64 127.67 32.74 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.876 0.37 . . . . 0.0 110.768 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.7 p -119.48 142.48 48.24 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.233 0.539 . . . . 0.0 111.56 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.597 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 31.3 ttt85 -99.47 106.28 18.3 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 177.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 58.96 34.96 23.91 Favored 'General case' 0 C--N 1.323 -0.569 0 O-C-N 123.89 0.744 . . . . 0.0 110.14 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.31 -17.01 60.13 Favored Glycine 0 CA--C 1.52 0.403 0 CA-C-N 115.712 -0.676 . . . . 0.0 113.489 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.4 mt -93.84 122.59 61.84 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.213 0.507 . . . . 0.0 111.32 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.8 Cg_exo -72.16 39.09 0.39 Allowed 'Trans proline' 0 CA--C 1.532 0.413 0 C-N-CA 123.074 2.516 . . . . 0.0 112.343 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.667 -179.731 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.487 ' SG ' ' HG2' ' A' ' 24' ' ' ARG . 99.6 m . . . . . 0 N--CA 1.448 -0.534 0 CA-C-O 120.527 0.203 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.55 37.96 95.57 Favored Glycine 0 C--N 1.333 0.378 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 -178.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.546 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.6 tp10 -144.56 142.88 30.5 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.167 -0.516 . . . . 0.0 109.678 -178.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.9 p -116.17 144.49 44.11 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.915 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.4 p -118.48 56.7 0.87 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -55.79 -35.18 66.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.474 179.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.17 20.87 36.96 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.966 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.07 44.54 66.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.202 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.6 m -147.63 135.75 21.36 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 62.8 m -127.95 126.18 40.94 Favored 'General case' 0 C--N 1.327 -0.405 0 O-C-N 123.181 0.3 . . . . 0.0 110.355 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -66.4 -43.62 85.32 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.2 m -71.63 117.18 55.1 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.487 179.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_exo -70.13 139.16 38.31 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.978 2.452 . . . . 0.0 112.825 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.89 -23.53 35.62 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.655 179.54 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.5 m -73.7 127.68 33.44 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.071 0.462 . . . . 0.0 111.462 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.8 t -79.93 134.77 36.3 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.5 t -77.86 93.88 4.44 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.301 0.572 . . . . 0.0 112.274 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.8 m -92.38 67.98 4.89 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 176.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 6.2 t90 -27.4 122.82 0.24 Allowed Pre-proline 0 N--CA 1.463 0.175 0 CA-C-N 113.861 -1.518 . . . . 0.0 113.305 -176.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 87.3 Cg_endo -101.69 30.55 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.516 -1.452 . . . . 0.0 114.047 0.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.6 mt -126.53 132.57 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.344 0 CA-C-O 120.973 0.416 . . . . 0.0 111.487 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.546 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 29.5 m -79.62 128.79 33.83 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.805 0.336 . . . . 0.0 110.389 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -122.96 146.36 47.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.978 0.418 . . . . 0.0 112.003 -178.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.487 ' HG2' ' SG ' ' A' ' 1' ' ' CYS . 3.4 mmm-85 -91.25 95.54 10.09 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 177.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.97 37.35 21.44 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 123.928 0.768 . . . . 0.0 110.104 -178.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.15 -18.81 56.12 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.721 -0.672 . . . . 0.0 113.338 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.573 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.5 tp -89.53 113.82 58.13 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 117.157 0.478 . . . . 0.0 110.559 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 8.0 Cg_exo -73.14 46.74 1.18 Allowed 'Trans proline' 0 CA--C 1.531 0.36 0 C-N-CA 123.431 2.754 . . . . 0.0 113.59 -178.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.573 HG13 ' HG ' ' A' ' 27' ' ' LEU . 24.5 m . . . . . 0 C--N 1.325 -0.466 0 CA-C-O 121.085 0.469 . . . . 0.0 111.199 179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.8 m . . . . . 0 N--CA 1.45 -0.434 0 CA-C-O 121.012 0.434 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 36.77 92.29 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.625 -0.716 . . . . 0.0 112.373 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -150.31 151.38 32.84 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.935 0.398 . . . . 0.0 110.129 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 38.7 p -110.3 146.69 35.27 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.952 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.549 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 28.2 p -115.12 54.82 0.78 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.135 0.493 . . . . 0.0 110.64 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -55.22 -35.42 64.9 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.68 179.287 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.11 19.56 45.88 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.91 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.1 46.16 67.29 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.975 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.8 t -149.78 142.36 24.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.629 0.252 . . . . 0.0 110.524 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 65.6 m -136.02 128.34 30.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.182 -179.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.5 p30 -77.61 -28.26 51.45 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.864 0.364 . . . . 0.0 110.404 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.41 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -70.99 123.42 89.29 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.497 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -69.51 136.12 32.83 Favored 'Trans proline' 0 N--CA 1.464 -0.221 0 C-N-CA 122.614 2.209 . . . . 0.0 113.114 -179.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.18 25.38 66.42 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.878 179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.41 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 66.1 m -112.71 128.05 56.3 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.065 0.459 . . . . 0.0 111.09 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.3 t -84.44 141.59 30.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.229 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.5 t -83.29 95.28 8.13 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.199 0.523 . . . . 0.0 111.995 -179.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.9 m -92.67 66.71 4.47 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 176.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.9 t90 -27.71 123.0 0.24 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.177 -176.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.8 Cg_endo -101.55 31.89 9.35 Favored 'Cis proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.497 -1.46 . . . . 0.0 114.039 0.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.6 mt -126.45 134.04 67.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 O-C-N 121.994 -0.441 . . . . 0.0 111.648 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.489 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.8 m -79.3 132.58 36.5 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.712 0.291 . . . . 0.0 110.85 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.5 p -128.31 136.61 51.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 111.37 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.5 ttt-85 -95.3 107.01 19.1 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 60.28 34.89 20.86 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 123.731 0.644 . . . . 0.0 110.067 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.62 -13.39 67.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.183 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.689 ' HB3' HG23 ' A' ' 29' ' ' VAL . 90.9 mt -94.11 118.68 67.19 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 117.159 0.479 . . . . 0.0 111.097 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -72.82 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.066 2.511 . . . . 0.0 112.512 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.689 HG23 ' HB3' ' A' ' 27' ' ' LEU . 3.2 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-O 121.348 0.595 . . . . 0.0 110.732 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 80.8 m . . . . . 0 N--CA 1.449 -0.522 0 CA-C-O 120.73 0.3 . . . . 0.0 110.593 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 41.13 97.21 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.406 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -146.87 145.19 29.76 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.958 0.409 . . . . 0.0 110.13 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.2 p -114.02 144.35 43.25 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.767 178.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.493 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.6 p -118.38 55.36 0.9 Allowed 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.052 0.453 . . . . 0.0 111.289 -179.414 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -56.62 -33.74 66.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.313 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.77 20.48 38.84 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.889 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.16 44.85 74.6 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 121.003 -0.617 . . . . 0.0 112.386 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.0 t -150.19 142.79 24.52 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.586 0.231 . . . . 0.0 110.541 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.493 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 56.0 m -134.52 131.01 37.48 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.254 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -66.7 -35.02 79.14 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.93 0.395 . . . . 0.0 110.382 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -80.89 117.23 67.1 Favored Pre-proline 0 N--CA 1.45 -0.442 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.977 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.69 136.87 28.91 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.71 2.274 . . . . 0.0 112.157 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.07 -27.23 21.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.655 -0.783 . . . . 0.0 111.999 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.3 m -72.54 127.81 33.68 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.989 0.423 . . . . 0.0 110.952 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.0 t -79.93 134.84 36.3 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.403 179.366 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.6 t -77.85 93.47 4.37 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.268 0.556 . . . . 0.0 111.727 -179.292 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.5 m -90.97 68.05 6.13 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.5 t90 -27.75 122.98 0.25 Allowed Pre-proline 0 N--CA 1.463 0.194 0 CA-C-N 113.932 -1.485 . . . . 0.0 113.268 -176.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 84.9 Cg_endo -101.67 30.57 10.37 Favored 'Cis proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.589 -1.421 . . . . 0.0 113.972 0.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 64.5 mt -126.86 132.52 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 O-C-N 122.058 -0.401 . . . . 0.0 111.567 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.492 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 28.6 m -79.35 128.96 33.98 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.823 0.344 . . . . 0.0 110.689 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 81.5 p -121.28 144.05 48.84 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.277 0.56 . . . . 0.0 111.393 -179.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.49 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 59.9 ttp180 -95.59 84.1 3.9 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.1 t70 67.27 49.95 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 O-C-N 124.248 0.968 . . . . 0.0 109.631 -177.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.29 -24.9 20.13 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.925 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -92.14 116.02 65.72 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 117.378 0.589 . . . . 0.0 111.547 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -73.21 39.02 0.44 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.005 2.47 . . . . 0.0 112.196 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 C--N 1.324 -0.503 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.61 -179.505 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.401 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 82.1 m . . . . . 0 N--CA 1.45 -0.469 0 CA-C-O 120.67 0.271 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.17 34.32 87.86 Favored Glycine 0 N--CA 1.451 -0.33 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -178.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.478 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -134.0 145.16 49.23 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.9 -0.65 . . . . 0.0 109.959 -179.034 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.427 HG22 HD13 ' A' ' 21' ' ' ILE . 65.0 p -114.17 146.03 40.88 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.614 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.578 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 27.9 p -124.21 54.07 1.38 Allowed 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.15 0.5 . . . . 0.0 110.854 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -56.43 -33.3 65.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.387 179.078 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.53 19.87 41.05 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.807 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.42 45.03 70.86 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.324 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.9 t -150.11 142.8 24.6 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.542 0.21 . . . . 0.0 110.591 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.482 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 46.4 m -134.34 127.75 32.32 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.025 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -72.04 -34.55 68.86 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.931 0.396 . . . . 0.0 110.232 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.5 m -72.47 118.24 65.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.483 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.85 135.45 32.7 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 122.638 2.225 . . . . 0.0 112.864 -179.472 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.66 -22.5 39.98 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.576 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 76.9 m -78.12 121.59 24.5 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.085 0.469 . . . . 0.0 111.014 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.5 t -82.59 138.16 34.31 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.29 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 26.6 t -74.49 113.81 12.16 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.469 0.652 . . . . 0.0 111.941 -179.219 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.0 m -113.13 66.12 0.65 Allowed 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 106.611 -1.625 . . . . 0.0 106.611 177.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.1 t90 -23.55 120.36 0.18 Allowed Pre-proline 0 N--CA 1.463 0.202 0 CA-C-N 113.489 -1.687 . . . . 0.0 113.665 -176.584 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.518 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 76.0 Cg_endo -101.96 25.62 14.53 Favored 'Cis proline' 0 N--CA 1.456 -0.729 0 C-N-CA 123.668 -1.388 . . . . 0.0 113.784 0.432 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.427 HD13 HG22 ' A' ' 4' ' ' THR . 41.4 mm -119.74 132.77 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-O 120.729 0.299 . . . . 0.0 111.628 -179.063 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 55.0 m -81.4 128.28 33.69 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.3 p -115.79 145.78 42.52 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.222 0.534 . . . . 0.0 111.532 -179.15 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.402 ' HD2' ' HA ' ' A' ' 24' ' ' ARG . 16.9 tpt85 -89.7 85.24 6.4 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.294 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 62.58 43.14 7.86 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.2 -177.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.99 -23.68 34.71 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.702 -0.761 . . . . 0.0 113.616 179.301 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.57 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.3 tp -92.6 111.6 51.66 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 117.355 0.578 . . . . 0.0 110.617 -179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.454 ' HD2' HD12 ' A' ' 27' ' ' LEU . 60.4 Cg_endo -72.86 47.38 1.22 Allowed 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 123.184 2.589 . . . . 0.0 113.817 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.57 HG13 ' HG ' ' A' ' 27' ' ' LEU . 30.3 m . . . . . 0 C--N 1.324 -0.511 0 CA-C-O 120.87 0.367 . . . . 0.0 111.416 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.617 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 52.5 m . . . . . 0 N--CA 1.448 -0.573 0 CA-C-O 120.402 0.144 . . . . 0.0 111.148 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.32 37.74 94.24 Favored Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -178.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.484 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.1 tp10 -140.91 145.85 36.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.142 -0.529 . . . . 0.0 109.858 -179.032 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.403 HG22 HD13 ' A' ' 21' ' ' ILE . 64.4 p -115.6 146.73 41.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.784 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.1 p -125.02 55.58 1.36 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.239 0.543 . . . . 0.0 110.715 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -57.05 -33.0 66.79 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.271 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.98 18.89 48.35 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.73 -0.747 . . . . 0.0 111.657 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.57 42.77 79.69 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.045 -0.597 . . . . 0.0 112.298 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.6 t -150.62 143.77 24.82 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 110.452 -0.203 . . . . 0.0 110.452 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.482 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 39.6 m -132.1 129.5 40.01 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -70.69 -35.45 72.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.978 0.418 . . . . 0.0 110.344 179.72 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 10.6 m -76.66 116.6 58.07 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.792 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.17 139.6 46.79 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.948 2.432 . . . . 0.0 112.489 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.05 -27.37 20.33 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.015 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.0 m -76.34 125.63 29.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.094 0.473 . . . . 0.0 110.967 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.8 m -85.99 134.81 33.84 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.71 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 27.2 t -73.49 116.18 13.75 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.339 0.59 . . . . 0.0 111.873 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.8 m -115.96 66.87 0.71 Allowed 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.57 -1.641 . . . . 0.0 106.57 177.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 3.8 t90 -23.51 119.48 0.18 Allowed Pre-proline 0 N--CA 1.463 0.204 0 CA-C-N 113.518 -1.674 . . . . 0.0 113.643 -176.555 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 75.5 Cg_endo -102.7 26.7 12.49 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.855 0.544 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.403 HD13 HG22 ' A' ' 4' ' ' THR . 38.6 mm -120.33 133.73 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 111.624 -179.07 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 40.6 m -82.31 126.06 31.7 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 178.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 74.4 p -113.19 150.84 31.72 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.529 0.68 . . . . 0.0 111.71 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.617 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 29.5 ttm180 -103.72 86.65 2.65 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.118 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 33.7 t0 66.52 49.51 1.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 O-C-N 124.245 0.965 . . . . 0.0 109.509 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.82 -25.01 12.51 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.773 179.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.8 mt -88.92 117.9 68.73 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 117.316 0.558 . . . . 0.0 111.547 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -73.96 38.71 0.48 Allowed 'Trans proline' 0 CA--C 1.53 0.3 0 C-N-CA 123.027 2.485 . . . . 0.0 112.269 179.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.325 -0.491 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.617 -179.476 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.0 m . . . . . 0 N--CA 1.45 -0.468 0 CA-C-O 120.644 0.259 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.75 38.71 94.72 Favored Glycine 0 N--CA 1.451 -0.345 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -178.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.482 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 4.9 tp10 -141.88 147.18 36.71 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.797 -178.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 35.2 p -118.46 145.66 45.08 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.973 0.416 . . . . 0.0 110.752 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.526 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.2 p -120.69 56.49 1.0 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.006 0.431 . . . . 0.0 111.028 -179.691 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.61 -34.02 66.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.29 179.018 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.49 20.23 40.19 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.82 179.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.5 43.61 76.63 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.339 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.7 t -150.22 142.88 24.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.461 0.172 . . . . 0.0 110.565 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.49 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 37.6 m -132.71 128.74 37.58 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.037 -179.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.3 m-80 -69.67 -34.58 74.17 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.021 0.439 . . . . 0.0 110.021 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.1 m -75.27 115.66 47.21 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.362 179.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_exo -70.3 136.18 30.94 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.92 2.413 . . . . 0.0 112.472 -179.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.45 -24.23 32.84 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.454 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -77.72 130.47 36.8 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.151 0.5 . . . . 0.0 111.219 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.1 t -84.77 137.52 33.15 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.468 179.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 25.0 t -77.16 112.62 14.02 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.301 0.572 . . . . 0.0 111.739 -179.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.7 m -111.25 67.6 0.65 Allowed 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 177.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.0 t90 -26.33 122.53 0.22 Allowed Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 113.776 -1.556 . . . . 0.0 113.344 -176.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.5 Cg_endo -101.36 28.84 12.35 Favored 'Cis proline' 0 N--CA 1.454 -0.804 0 C-N-CA 123.6 -1.417 . . . . 0.0 114.086 0.534 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 61.3 mt -127.55 134.71 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 O-C-N 121.997 -0.439 . . . . 0.0 111.538 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 31.4 m -79.87 130.41 35.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.908 0.385 . . . . 0.0 110.43 179.442 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 54.4 p -121.48 157.95 29.49 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.215 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.434 ' HA ' ' HD2' ' A' ' 24' ' ' ARG . 13.9 tpt85 -87.99 58.33 4.76 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.264 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 64.45 45.88 3.56 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.955 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 142.43 -47.94 0.8 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.385 -0.912 . . . . 0.0 113.479 178.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 99.0 mt -108.93 127.87 26.52 Favored Pre-proline 0 C--N 1.326 -0.456 0 O-C-N 122.553 -0.38 . . . . 0.0 111.777 -179.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.8 Cg_endo -75.6 39.03 0.6 Allowed 'Trans proline' 0 CA--C 1.528 0.22 0 C-N-CA 123.209 2.606 . . . . 0.0 112.47 179.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 C--N 1.327 -0.394 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.86 -179.642 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 60.9 m . . . . . 0 N--CA 1.448 -0.542 0 CA-C-O 120.695 0.283 . . . . 0.0 110.527 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.52 45.01 96.76 Favored Glycine 0 C--N 1.335 0.479 0 C-N-CA 120.711 -0.757 . . . . 0.0 111.437 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.414 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 5.0 tp10 -150.16 149.86 30.83 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.958 0.408 . . . . 0.0 110.698 -178.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.472 HG22 HD13 ' A' ' 21' ' ' ILE . 42.4 p -123.41 142.85 50.56 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.61 178.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 29.3 p -105.34 57.32 0.68 Allowed 'General case' 0 C--N 1.315 -0.923 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.688 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -56.59 -33.54 66.32 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -106.02 23.36 29.34 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.61 178.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 66.92 37.33 92.11 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 121.197 -0.525 . . . . 0.0 113.082 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.4 t -151.06 142.61 23.55 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.717 0.294 . . . . 0.0 111.371 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.743 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.8 m -122.54 132.44 54.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.634 179.371 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -64.68 -34.56 78.59 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.921 0.391 . . . . 0.0 110.394 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.4 m -79.71 115.74 55.89 Favored Pre-proline 0 N--CA 1.45 -0.465 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.717 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.97 135.8 26.1 Favored 'Trans proline' 0 N--CA 1.462 -0.349 0 C-N-CA 122.516 2.144 . . . . 0.0 112.37 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.03 -26.65 23.89 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.071 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.8 m -71.65 125.82 28.09 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.974 0.416 . . . . 0.0 111.234 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -89.58 121.21 31.56 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.827 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 19.6 t -86.86 116.95 25.28 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 113.464 0.912 . . . . 0.0 113.464 -177.17 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.9 m -88.72 72.64 8.62 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 174.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.509 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 12.7 t90 -21.56 122.25 0.12 Allowed Pre-proline 0 N--CA 1.468 0.433 0 CA-C-N 113.889 -1.505 . . . . 0.0 113.834 -175.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 88.8 Cg_endo -101.78 31.31 9.65 Favored 'Cis proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.475 -1.469 . . . . 0.0 114.228 0.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.472 HD13 HG22 ' A' ' 4' ' ' THR . 43.8 mm -116.52 120.54 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.236 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.827 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 28.8 m -74.67 130.2 39.09 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.413 HG22 ' CA ' ' A' ' 28' ' ' PRO . 37.2 p -131.04 139.67 49.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.124 0.488 . . . . 0.0 111.876 -178.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 5.6 tmm_? -96.7 102.22 13.97 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 177.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 59.41 40.4 20.9 Favored 'General case' 0 C--N 1.328 -0.367 0 O-C-N 123.807 0.692 . . . . 0.0 110.302 -177.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.25 -15.68 60.58 Favored Glycine 0 CA--C 1.519 0.301 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.557 179.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.5 mt -91.61 118.93 68.63 Favored Pre-proline 0 C--N 1.327 -0.396 0 CA-C-N 117.232 0.516 . . . . 0.0 111.5 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.413 ' CA ' HG22 ' A' ' 23' ' ' THR . 71.5 Cg_endo -74.82 38.82 0.54 Allowed 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 123.081 2.521 . . . . 0.0 112.049 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--N 1.324 -0.525 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.818 -179.452 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.451 -0.402 0 CA-C-O 120.664 0.269 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.65 37.67 95.16 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -143.29 141.48 31.03 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.47 HG22 HG12 ' A' ' 21' ' ' ILE . 37.7 p -111.88 146.86 36.99 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.036 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.805 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 23.2 p -122.69 57.94 1.09 Allowed 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -56.09 -36.05 67.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.127 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.56 20.56 43.91 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.684 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.08 40.22 88.45 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.351 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.2 t -151.19 142.92 23.74 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.555 -0.165 . . . . 0.0 110.555 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.805 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -139.06 137.5 36.29 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.8 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -67.24 -41.29 85.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.518 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.2 m -70.67 114.41 26.36 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.409 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.89 137.93 27.73 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 123.058 2.505 . . . . 0.0 112.449 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.8 -25.25 28.62 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.301 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.703 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 91.2 m -71.04 127.79 33.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.022 0.439 . . . . 0.0 111.272 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 t -79.64 126.7 31.25 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 13.8 t -73.88 96.89 2.67 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.488 0.661 . . . . 0.0 112.191 -178.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.7 m -94.11 68.15 3.69 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 5.2 t90 -25.7 122.26 0.22 Allowed Pre-proline 0 N--CA 1.463 0.22 0 CA-C-N 113.918 -1.492 . . . . 0.0 113.313 -176.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 86.7 Cg_endo -101.55 30.31 10.72 Favored 'Cis proline' 0 N--CA 1.456 -0.71 0 C-N-CA 123.606 -1.414 . . . . 0.0 114.159 0.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.47 HG12 HG22 ' A' ' 4' ' ' THR . 67.6 mt -131.26 131.83 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 O-C-N 121.954 -0.466 . . . . 0.0 111.341 -179.482 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.703 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -79.4 134.97 36.57 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.306 0.574 . . . . 0.0 111.982 179.587 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 70.6 p -120.9 149.51 42.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.076 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.511 ' HG2' ' OD1' ' A' ' 25' ' ' ASP . 17.0 ttt-85 -88.17 94.86 9.95 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 177.672 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.511 ' OD1' ' HG2' ' A' ' 24' ' ' ARG . 1.1 p-10 46.38 42.78 11.03 Favored 'General case' 0 N--CA 1.469 0.483 0 O-C-N 124.334 1.022 . . . . 0.0 111.434 -177.163 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.57 -22.18 29.0 Favored Glycine 0 C--N 1.335 0.49 0 CA-C-N 115.52 -0.763 . . . . 0.0 113.865 178.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.522 ' HG ' HG13 ' A' ' 29' ' ' VAL . 20.6 tp -93.45 113.82 61.22 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 117.256 0.528 . . . . 0.0 111.015 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 11.2 Cg_exo -71.59 48.26 1.0 Allowed 'Trans proline' 0 CA--C 1.533 0.431 0 C-N-CA 123.498 2.799 . . . . 0.0 113.772 -179.236 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.522 HG13 ' HG ' ' A' ' 27' ' ' LEU . 31.1 m . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 121.004 0.431 . . . . 0.0 111.257 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.1 m . . . . . 0 N--CA 1.449 -0.492 0 CA-C-O 120.786 0.327 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.51 37.8 94.74 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.543 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -144.25 143.88 31.24 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 120.95 0.405 . . . . 0.0 110.502 -179.126 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 45.2 p -105.75 153.63 21.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.701 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.903 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 22.2 p -131.67 56.97 1.79 Allowed 'General case' 0 C--N 1.321 -0.643 0 O-C-N 122.269 -0.27 . . . . 0.0 110.95 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -52.01 -35.99 48.58 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.215 179.235 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.23 31.65 3.98 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 178.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.517 ' HA2' ' HB2' ' A' ' 5' ' ' CYS . . . 61.99 48.36 83.93 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.143 -0.551 . . . . 0.0 111.823 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.6 m -130.7 69.27 1.46 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 111.975 0.361 . . . . 0.0 111.975 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.903 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 92.6 m -90.88 130.98 36.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.763 0.316 . . . . 0.0 111.18 179.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.8 p-10 -64.51 -35.12 79.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.935 -179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 18.1 m -85.01 114.68 57.27 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.196 -179.127 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 8.0 Cg_exo -71.94 139.73 33.65 Favored 'Trans proline' 0 N--CA 1.462 -0.341 0 C-N-CA 123.111 2.541 . . . . 0.0 111.932 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.02 -25.93 26.11 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.079 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.709 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 97.6 m -67.05 128.34 35.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.839 0.352 . . . . 0.0 110.744 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.7 m -78.87 123.5 27.3 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 31.6 t -72.6 98.83 2.41 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.362 0.601 . . . . 0.0 112.232 -178.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 9.0 m -94.49 68.38 3.48 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.536 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.6 t90 -25.18 121.06 0.21 Allowed Pre-proline 0 C--O 1.232 0.156 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.355 -176.464 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.536 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 81.5 Cg_endo -102.76 33.6 7.5 Favored 'Cis proline' 0 N--CA 1.455 -0.764 0 C-N-CA 123.69 -1.379 . . . . 0.0 114.153 0.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.421 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 67.9 mt -132.23 132.99 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 O-C-N 121.992 -0.442 . . . . 0.0 111.576 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.709 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.6 m -79.58 134.93 36.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.34 0.59 . . . . 0.0 112.474 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 42.5 p -123.0 143.82 49.67 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.651 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.453 ' HD2' ' HA ' ' A' ' 24' ' ' ARG . 2.3 mmm-85 -95.25 101.9 13.67 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 177.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 60.03 36.14 21.42 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 123.944 0.778 . . . . 0.0 110.006 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.56 -14.49 65.16 Favored Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.623 -0.717 . . . . 0.0 113.192 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.629 ' HG ' HG13 ' A' ' 29' ' ' VAL . 21.6 tp -92.96 116.35 66.37 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 117.067 0.433 . . . . 0.0 110.273 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.563 ' HD2' HD12 ' A' ' 27' ' ' LEU . 58.4 Cg_endo -71.7 45.61 0.73 Allowed 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 123.122 2.548 . . . . 0.0 113.83 -178.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.629 HG13 ' HG ' ' A' ' 27' ' ' LEU . 16.0 m . . . . . 0 C--N 1.326 -0.421 0 CA-C-O 120.928 0.394 . . . . 0.0 111.465 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 N--CA 1.448 -0.538 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.11 34.32 87.56 Favored Glycine 0 C--N 1.333 0.387 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.791 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -140.53 134.21 30.27 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.468 HG22 HD13 ' A' ' 21' ' ' ILE . 77.8 p -96.21 146.19 24.91 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.429 -178.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.638 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 27.2 p -120.65 58.48 0.94 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.204 179.217 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -55.92 -34.66 65.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.48 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.77 17.33 56.6 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.485 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.458 ' HA2' ' SG ' ' A' ' 17' ' ' CYS . . . 67.81 41.57 88.32 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 121.144 -0.55 . . . . 0.0 111.946 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.3 t -151.47 144.92 24.84 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.077 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.638 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 30.2 m -146.62 140.8 26.3 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.9 m-80 -73.23 -35.24 66.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.569 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.4 m -66.78 115.24 22.76 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.842 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.86 134.48 27.87 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.654 2.236 . . . . 0.0 112.837 -179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.61 -18.53 57.16 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.69 -0.767 . . . . 0.0 113.001 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.584 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 94.9 m -77.41 120.63 22.67 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.179 0.514 . . . . 0.0 111.016 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.7 t -79.41 131.27 36.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.458 ' SG ' ' HA2' ' A' ' 8' ' ' GLY . 32.9 t -75.52 92.73 2.91 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.338 0.59 . . . . 0.0 112.24 -178.466 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.0 m -89.58 66.74 7.35 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.2 t90 -25.22 121.33 0.21 Allowed Pre-proline 0 C--O 1.232 0.168 0 CA-C-N 113.728 -1.578 . . . . 0.0 113.68 -176.543 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 85.4 Cg_endo -101.75 26.31 14.26 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.59 -1.421 . . . . 0.0 113.787 0.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.468 HD13 HG22 ' A' ' 4' ' ' THR . 35.9 mm -120.56 127.87 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 O-C-N 122.257 -0.277 . . . . 0.0 111.424 -179.208 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.584 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 13.0 m -79.78 130.36 35.26 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.254 0.55 . . . . 0.0 111.35 179.062 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 69.0 p -118.59 140.6 49.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.723 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 35.8 tpt85 -89.66 92.14 8.95 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 61.04 40.61 14.92 Favored 'General case' 0 C--N 1.327 -0.382 0 O-C-N 124.028 0.83 . . . . 0.0 110.48 -178.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.75 -22.89 35.63 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 113.841 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.9 mt -93.86 117.45 67.23 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 117.381 0.59 . . . . 0.0 111.589 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.85 38.72 0.41 Allowed 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.924 2.416 . . . . 0.0 112.266 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 C--N 1.326 -0.451 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.875 -179.581 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.0 m . . . . . 0 N--CA 1.45 -0.47 0 CA-C-O 120.86 0.362 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.42 40.38 97.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.887 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -147.44 142.09 26.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.976 0.417 . . . . 0.0 110.19 -179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.619 HG22 HG12 ' A' ' 21' ' ' ILE . 41.7 p -107.36 146.79 31.16 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.694 179.581 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.787 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 21.4 p -122.38 56.82 1.1 Allowed 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.989 0.423 . . . . 0.0 110.757 179.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -55.99 -36.77 68.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.252 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -102.91 21.31 40.71 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.516 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.7 40.71 90.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.183 -0.532 . . . . 0.0 112.408 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.2 t -150.78 142.92 24.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.787 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 89.4 m -137.49 137.58 38.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.744 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -64.44 -35.67 81.66 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.1 m -76.89 113.77 33.18 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.709 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.52 136.02 27.6 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.539 2.159 . . . . 0.0 112.376 -179.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.64 -19.32 54.83 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 120.502 -0.856 . . . . 0.0 113.037 179.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.512 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 68.6 m -74.65 131.7 41.11 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 117.287 0.543 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.1 m -81.96 119.36 23.86 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.743 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 10.4 t -68.76 112.41 5.47 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.433 0.635 . . . . 0.0 111.775 -178.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.8 m -109.06 69.61 0.71 Allowed 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 4.3 t90 -25.19 122.1 0.21 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.352 -176.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 83.7 Cg_endo -101.57 31.22 9.88 Favored 'Cis proline' 0 N--CA 1.455 -0.739 0 C-N-CA 123.541 -1.441 . . . . 0.0 114.277 0.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.619 HG12 HG22 ' A' ' 4' ' ' THR . 64.4 mt -135.7 134.19 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 O-C-N 121.97 -0.456 . . . . 0.0 111.436 -179.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.512 ' HB3' ' HB3' ' A' ' 15' ' ' CYS . 1.7 m -76.77 137.02 39.04 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.14 0.495 . . . . 0.0 111.491 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 44.4 p -128.99 158.84 37.74 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.939 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.01 55.0 3.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 178.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 65.12 43.1 3.8 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.872 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 148.63 -45.77 0.71 Allowed Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.325 -0.941 . . . . 0.0 113.263 179.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 98.1 mt -114.96 129.86 24.69 Favored Pre-proline 0 C--N 1.327 -0.383 0 O-C-N 122.509 -0.407 . . . . 0.0 111.686 -179.081 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 73.6 Cg_endo -75.39 39.92 0.65 Allowed 'Trans proline' 0 CA--C 1.53 0.279 0 C-N-CA 123.247 2.631 . . . . 0.0 112.506 179.606 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.6 m . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.241 -0.436 . . . . 0.0 112.034 -179.656 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 57.9 m . . . . . 0 N--CA 1.448 -0.546 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.98 39.1 96.57 Favored Glycine 0 C--N 1.335 0.495 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.864 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -147.74 152.29 37.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.769 0.318 . . . . 0.0 110.388 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.414 HG22 HG12 ' A' ' 21' ' ' ILE . 22.7 p -122.45 146.0 47.78 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.506 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.513 ' HB2' ' N ' ' A' ' 9' ' ' THR . 21.6 p -107.63 60.35 0.62 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.135 0.493 . . . . 0.0 111.028 -179.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -56.17 -30.24 61.95 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.101 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.55 17.38 46.66 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.789 -0.719 . . . . 0.0 111.564 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.46 39.82 86.93 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.558 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.513 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.2 m -150.92 137.27 18.57 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 122.581 -0.364 . . . . 0.0 111.087 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.723 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 57.8 m -125.15 129.95 51.19 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 178.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -77.0 -34.11 57.53 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.041 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -63.96 119.18 52.82 Favored Pre-proline 0 C--O 1.236 0.361 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.599 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.88 135.89 36.69 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.952 2.435 . . . . 0.0 113.801 -178.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.22 17.07 78.74 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.465 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 55.9 m -105.33 121.36 43.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 117.141 0.471 . . . . 0.0 111.078 179.282 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.7 m -90.23 117.71 29.19 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 107.305 -1.368 . . . . 0.0 107.305 178.089 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.838 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 17.9 t -81.6 118.34 22.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 113.491 0.922 . . . . 0.0 113.491 -176.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.8 m -92.34 73.35 5.3 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 104.964 -2.235 . . . . 0.0 104.964 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -23.04 125.59 0.12 Allowed Pre-proline 0 N--CA 1.467 0.42 0 CA-C-N 113.767 -1.561 . . . . 0.0 113.661 -175.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.495 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 94.6 Cg_endo -100.52 33.53 8.56 Favored 'Cis proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.332 -1.528 . . . . 0.0 114.449 0.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.414 HG12 HG22 ' A' ' 4' ' ' THR . 66.4 mt -124.58 125.83 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 O-C-N 121.865 -0.522 . . . . 0.0 112.097 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.838 ' HA ' ' HA ' ' A' ' 17' ' ' CYS . 14.0 m -72.1 129.11 37.73 Favored 'General case' 0 C--O 1.233 0.212 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.439 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.0 p -128.79 138.11 51.9 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.127 0.489 . . . . 0.0 111.844 -178.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.99 104.97 16.85 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 59.24 37.38 23.76 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.434 0.635 . . . . 0.0 110.043 -178.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.65 -11.45 70.18 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.522 -0.763 . . . . 0.0 113.447 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.1 mt -94.44 123.58 58.05 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 117.2 0.5 . . . . 0.0 111.202 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -73.39 39.99 0.51 Allowed 'Trans proline' 0 CA--C 1.53 0.302 0 C-N-CA 123.072 2.515 . . . . 0.0 112.038 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--N 1.326 -0.425 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.895 -179.327 . . . . . . . . 0 0 . 1 stop_ save_